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Intratumoral B and T cell receptors: reconstruction
and analysis
Meltem Gürel
When cells divide, mistakes happen. However, an intricate surveillance system has
evolved to detect and eliminate anomalous cells before they become detrimental to the
host organism. In cancer, abnormal cells manage to escape the immune system and grow
uncontrollably. In this sense, cancer can be considered as an oversight of the immune
system, as immune escape is a defining feature of clinically detectable cancers. The role
of the immune system in fighting cancer is becoming increasingly indisputable as our
understanding of its underlying mechanisms expand owing to technological advances in
genomics, cancer biology, and computational sciences. In particular, significant research
effort is undertaken in the field of cancer immunotherapy, where the immune system is
stimulated to recognize and attack cancerous cells. In this thesis, I investigate certain
aspects of the immune system in the context of cancer by computationally reconstructing
and analyzing intratumoral B and T cell receptors.
Applying a novel immune cell receptor profiling protocol to original single-cell RNA
sequencing (scRNA-seq) data obtained from melanoma patients, I present a complete
computational reconstruction of intratumoral immune receptors in this cancer type. The
scRNA-seq results are consistent with the presence of an ongoing intratumoral immune
response, likely involving tertiary lymphoid structures and the cooperation between B
and T cells.
Additionally, using a dataset of paired tumor biopsies collected pre- and post-
treatment, I show that B cell infiltration increases after immunotherapy in pancreatic
and colorectal cancer. This thesis includes the sequences of the most clonally expanded
intratumoral antibodies expressed in these biopsies which I computationally reconstructed
from bulk RNA sequencing reads.
Furthermore, by combining scRNA-seq and immune cell receptor profiling of samples
collected from a novel mouse model, I present a comprehensive statistical analysis of gene
expression in clonal tumor-reactive T cells. I also show the distribution of tumor-reactive
clones across the tumor and spleen. This study forms a first proof-of-principle effort for
the in-depth assessment of tumor-reactive T and B cell clones, in-vivo, and paves the
way for further, more extensive experiments.
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1.1 The adaptive immune system and cancer
Mutations such as copy number alterations, point mutations, and chromosome rear-
rangements, occur frequently during the life of a cell, and can sometimes have serious
consequences for the host. Cancer is a group of diseases where the host organism’s
self cells behave abnormally and divide rapidly, and possibly invade healthy tissue and
organs. The immune system constantly monitors for such deleterious cells and normally
eliminates them before they become life-threatening. It is widely accepted that the
main reason behind the evolution of the immune system is to defend the host against
pathogens, i.e., any microorganism that can cause disease in the host. In order to respond
to a vast array of pathogens, the immune system utilizes a range of white blood cells,
known as leukocytes, which can be at various stages of differentiation. These immune
cells are examined in two major clusters: cells of the innate and of the adaptive immune
system [117, Chapter 1, p. 5-17].
Innate immune cells are the first line of defense, and they are non-specific; they target
anything that is non-self and potentially harmful, such as bacteria, viruses, or pollen.
Macrophages, which are a particular type of phagocytic cells - the “eating” or “devouring
cells” - that engulf bacteria and viruses in order to destroy them, are examples of innate
immune cells. Another example is Natural Killer (NK) cells. NK cells are cytotoxic; they
can release toxic granules containing perforin and granzymes to kill the target cell [238].
The innate immune cells are rapid in response, but in comparison to the adaptive immune
cells, they are static; the host has an absolute arsenal - inherited from ancestors - with
no memory that can accumulate on their own during the lifetime of the host organism
[155]. Some innate immune cells also play a role in the adaptive immune system. The
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dendritic cells, for example, present antigens on their surfaces in order to trigger the
adaptive immune system [126, Chapter 6, p. 186-188].
The adaptive immune system, or acquired immunity, is generated in response to
a specific type of antigen and has an immunological memory that learns and stores
information to provide increased immune response against repeating pathogens caused
by the same pathogen. Compared to the innate immune response, the adaptive immune
response is much slower; however, its effects are highly specific and sustained long-term
[155]. The adaptive immune system relies on two major cell types: B cells and T
cells. Both cell types are derived from the same type of stem cell, namely multipotent
hematopoietic stem cells, in the bone marrow. However, after they are generated in the
bone marrow, they mature and become activated following different paths [117, Chapter
2, p. 24-38].
1.1.1 B cells
In birds, B cells mature in the bursa of Fabricius, a lymphoid organ that acts as a
lymph gland and gives these cells their name [79]. In mammals, they mature in the
bone marrow, becoming what is called a naive B cell, and move into the lymphatic
system to circulate throughout the host organism. B cells produce protein molecules
called immunoglobulins (Ig) to bind to pathogens and neutralize them. Immunoglobulins
produced by an individual B cell, have the same amino acid sequence and the same
binding-site, which are both unique to that specific cell. These sequences are inherent
to the organism’s DNA and are generated via genetic recombination with a theoretical
diversity greater than 1018 [62]. Initial Igs produced by newly formed B cells are inserted
into the cell’s plasma membrane. These distinct antigen-specific surface receptors, called
B cell receptors (BCRs), recognize and bind to antigens [162, Chapter 4, p. 141-152].
Naive B cells are activated when they encounter an antigen. The B cell which
recognizes a specific antigen via its BCR proliferates and differentiates into either
memory B cells or antibody-secreting effector cells. Memory B cells are record keepers
for the specific antigens which activated them. Upon a possible immune response recall,
they can quickly reactivate and proliferate, and differentiate in order to secrete antibodies.
An antibody is a soluble form of Ig which is not membrane-bound [126, Chapter 6,
p. 198-200].
Antibody-secreting effector cells produce large amounts of antibodies in response
to a particular antigen. Antibodies can either label pathogens and unwanted cells to
signal destruction to other components of the immune system or can directly neutralize
them themselves. Secreted in large amounts, antibodies are normally one of the most
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Fig. 1.1 Reactive lymphoid follicle in a lymph node, showing the classical distri-
bution of T and B lymphocytes. B cells (CD20, texas red) are abundant in the germinal
center, where activated B cells proliferate, mutate, and undergo clonal selection. B cells either
differentiate into plasma cells that produce high-affinity antibodies against target antigens; or
memory B cells, which then migrate out of the germinal center into the marginal zone [126,
Chapter 6, p. 189-195]. T cells (CD3, FITC) are located in the peripheral zone, surrounding the
germinal center. Naive B cells are also usually present in the peripheral zone (immunofluorescent
stain, CD20:texas red, CD3:FITC, 200X). Image courtesy of Dr. Bora Gürel.
abundant protein components in plasma [34, Chapter 24, p. 1315]. The end-stage of an
antibody-secreting effector B cell’s differentiation is called a plasma cell. Plasma cells
are much larger and dedicate most of their protein-synthesizing capacity to continuously
secreting antibodies. Secreted antibodies circulate throughout the host organism to
recognize free pathogens and other threats.
Proliferation and differentiation take place in the germinal centers (GCs), which are
microenvironments formed within the B cell follicles of secondary lymphoid tissues upon
an immune response. Some of the activated B cells migrate to lymphoid follicles and
proliferate to form germinal centers [127]. We can think of germinal centers as specialized
factories that are built upon an attack to produce fighters. Although activated B cells can
immediately start secreting antibodies for an initial response, in germinal centers, B cells
go through various changes to provide a more effective response. These modifications are
crucial to finely tune the antibody for the antigen that it needs to fight. The selected
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memory or plasma B cells exiting the germinal centers will have higher-affinity antibodies
[117, Chapter 11, p. 267-272].
1.1.2 T cells
T progenitor cells that leave the bone marrow migrate to the thymus in order to mature
and become T cells (T from thymus). Similar to B cells, T cells also express distinct
antigen-specific surface receptors, namely T cell receptors (TCRs). In addition, T cells
express various surface markers, including CD3, CD4, and CD8, which distinguish their
functionality. Thymic selection ensures that mature T cells express either one of the
surface markers CD4 or CD81. While BCRs can bind to antigens directly, TCRs can
only recognize antigens that are bound to specific receptor molecules, namely Major
Histocompatibility Complex class I (MHCI) and class II (MHCII). While MHCI molecules
are expressed on the surface of all nucleated cells, MHCII expression is generally restricted
to a few cell types, including antigen-presenting cells (APCs), such as dendritic cells and
macrophages. During development, T cells undergo two selection processes. Positive and
negative selection, in combination, ensure that only the self-tolerant T lymphocytes that
recognize self-MHC molecules survive, while the majority are destined for programmed
cell death - apoptosis [117, Chapter 10, p. 221-244]. It is important to note that T cell
self-recognition is not restricted to thymic self-peptides, as surviving T cells of thymic
selection would then assume cells of other tissues to be non-self and create an immune
response towards them. The protein AIRE is responsible for the negative selection of
organ-specific T cells which are not typically expressed in thymic cells [145].
Surface markers help distinguish T cells in three main types with different functions:
Helper T cells (Th) express CD4, and help in the recruitment and activation of other
immune cells. Cytotoxic T cells (Tc) express CD8, and are, in essence, the killer cells
responsible for eliminating unwanted cells. T regulatory cells (Treg) co-express CD4,
CD25, and the transcription factor FOXP3, and help distinguish between self and non-self
molecules, hence monitor and control immunity. Once a threat is eliminated during
a primary immune response, most effector T cells die, leaving behind some long-lived
memory T cells at standby for a possible secondary immune response. These cells can
circulate between blood, secondary lymphoid organs, non-lymphoid tissues, or reside in
tissues without circulation [166].
The adaptive immune system provides humoral and cell-mediated immunity, which are
dependent essentially on the functions of B and T cells, respectively. Humoral immunity
1Sections 4.2.1 and 4.5.2 describe the thymic selection and provide cases of possible mature CD4+CD8+
T cells.
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refers to the bodily fluids where the secreted antibodies bind to antigens. B cells are
the key players of the humoral immune system and, as mentioned, are responsible for
producing antigen-specific antibodies. With cell-mediated immunity, the response is
carried out by different T cell populations [117, Chapter 1, p. 9-17].
1.1.3 Immune system interactions with cancer
It is estimated that more than 20,000 DNA repair events take place per cell every day by
specific DNA repair pathways [143]. Cells that are not repaired might acquire malignant
changes. Given that it is the role of the immune system to monitor for and protect
against such damaged cells, it is surprising that cancer is the second leading cause of
death globally, responsible for over nine million deaths in 2018 [250].
The immune system recognizes and attacks cancerous cells continuously via im-
munosurveillance which is thought to be based on a cell’s expression of tumor-specific
neoantigens or tumor-associated antigens [229]. Mutated proteins from oncogenes or
other genes expressed and presented on the cell surface, and abnormal over-expression of
self-proteins found on tumors are targets for immunosurveillance. Both the innate and
adaptive immune effector cells play a role in controlling cancer [153]. NK cells of the
innate immune system can detect and kill the initial, altered self-cells via direct tumor cell
lysis. Later, macrophages and dendritic cells can engulf the fragments spread from this
destruction and present them to T cells, thus triggering an adaptive immune response.
The adaptive immune system eliminates the remaining tumor cells and generates a
long-lasting immune memory specific to the recognized tumor components. According to
the immunoediting theory [205], [159], this initial stage is called the eliminating phase.
However, some tumor cells can escape the host immune response and survive into the
next stage, called the equilibrium phase. During this phase, the tumor is present but
does not grow or further metastasize, and the immune system is keeping it under control
via immunosurveillance. This stage can be long-lasting, imitating elimination. Again,
however, this equilibrium can be compromised with tumor cells that can resist, avoid, or
suppress the anti-tumor immune response, resulting in tumor escape. These three phases,
elimination, equilibrium, and escape, represent a high level, but a broadly accepted
interpretation of the interplay between cancer and immune cells [169].
1.1.4 Cancer immunotherapy
Cancer cells can bypass immune cells by avoiding immune recognition, developing
resistance to attack by immune cells, or instigating an immunosuppressive tumor mi-
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Fig. 1.2 PD-1/PD-L1 immune checkpoint inhibitors. PD-L1 binds to PD-1 and inhibits
T cell killing of tumor cell. Blocking PD-L1 or PD-1 allows T cell killing of tumor cell. This
illustration was drawn based on Figure 1 in [170]. Image courtesy of Ms. Güliz Yazan.
croenvironment (TME) [159], [169]. According to the cancer immunotherapy theory, it
should be possible to slow or arrest tumor growth and prevent it from metastasizing by
strengthening and restoring the host organism’s immune system. There is a growing range
of cancer immunotherapies which aim to provide long-term tumor control or complete
elimination: therapeutic cancer vaccines which for the moment only prolong survival for
cancer patients [157], Chimeric Antigen Receptor (CAR) T-cell therapy where a patient’s
T cells are modified to bind to a specific antigen on the patient’s tumor cells and kill
them [112], stimulating the immune system by exploiting cytokine signaling networks
[133], and checkpoint blockade therapies, which have sparked the most interest [189], are
all rapidly evolving treatment strategies in oncology.
Immune checkpoint inhibitor therapy
Immune checkpoint molecules are receptors found on the surface of several immune cell
types, including B, T, and NK cells [232], [236], [178]. CTLA-4 (Cytotoxic T-Lymphocyte
Associated Protein 4) and PD-1 (Programmed cell death-1) are the most studied immune
checkpoint molecules [189]. Through such immune checkpoints, the immune cell functions
are regulated, ensuring that the immune response is directed to the right cells while
limiting the extent and duration of response. However, tumor cells can also exploit these
immune checkpoints in order to suppress anti-tumor immune responses [52].
Immune checkpoint inhibitors (ICI) such as PD-1 inhibitors, PD-L1 inhibitors, and
CTLA-4 inhibitors are drugs that block the targeted checkpoint proteins in order to stop
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them from binding and therefore promote immune-mediated elimination of tumor cells.
Figure 1.2 illustrates the blocking of the PD-1 or PD-L1 checkpoint molecules. Immune
checkpoint therapies using such blocking monoclonal antibodies have demonstrated
positive clinical outcome in several cancers including non–small-cell lung cancer (NSCLC),
renal cell cancer, and has been particularly successful in melanoma [189]. Ipilimumab, an
anti-CTLA-4 monoclonal antibody therapy, was the first drug to show long-term survival
in patients with advanced melanoma [98]. It has been shown that among 1,861 melanoma
patients treated with ipilimumab, the median overall survival was 11.4 months, with
possible continued response up to 10 years after starting therapy [203]. Nivolumab, an
anti-PD-1 monoclonal antibody, improved the overall survival of patients with melanoma
and NSCLC [237], and pembrolizumab, another anti-PD-1 monoclonal antibody, increased
progression-free survival and overall survival in patients with advanced melanoma and
had less toxicity than ipilimumab [191]. Dual immune checkpoint blockade of anti-PD-1
and anti-CTLA-4 has demonstrated an overall survival rate of 58% at three years in the
nivolumab-plus-ipilimumab group and 52% in the nivolumab only group, and 34% in the
ipilimumab only group [252]. However, 59% of patients administered the combination
immunotherapy experienced toxicity, compared to 21% of those in the nivolumab only
group, and 28% in the ipilimumab only group. With the recent publication of the five-year
follow-up [130], it has been reported that the overall survival at five years is 52% in
the nivolumab-plus-ipilimumab group, 44% in the nivolumab group, and 26% in the
ipilimumab group.
Owing to such drugs, immunotherapy has become a powerful clinical strategy for
cancer treatment. Numerous other treatments are in clinical and preclinical developmental
stages [81]. However, the outcome is not the same for every patient; not every patient
responds the same to therapy. Checkpoint blockade therapy so far only helps a minority
of patients, and its effects are not long-lived [140], [169]. In a study, it was observed
that the type, density, and location of immune cells within the tumor site could predict
clinical outcome in colorectal cancer [73]. A scoring system, namely Immunoscore, based
on the quantification of CD3+ and CD8+ cell populations both at the tumor site and
the invasive margin was devised following this finding. With this scoring system, tumors
are classified based on their immune infiltration. This led to the concept of hot (highly
infiltrated) and cold (non-infiltrated) tumors. Furthermore, studies analyzing the TME
have observed that response to immune checkpoint blockade favors pre-existing T cell
infiltration in tumors [26]. Effective immune response post-anti-PD-1 therapy requires the
reactivation and clonal-proliferation of antigen-experienced immune cells to be present in
the TME [214].
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It is thus essential to analyze the TME prior to therapy as well as post-therapy, in
order to identify patients for whom immune checkpoint therapies could result in positive
outcomes. Methods that can expose clonally expanded immune cells and fully characterize
the TME could help transform immunotherapy into a more broadly applicable treatment
for cancer [188], [266].
1.1.5 Tertiary lymphoid structures
The cell-mediated and humoral immune responses against cancer are thought to be
primarily initiated in the secondary lymphoid organs (SLOs) such as the lymph nodes
and the spleen [48]. APCs that have processed antigens from the tumor site travel to
the SLOs where they present these peptides to B and T cells, initiating their activation.
Following proliferation and differentiation, immune cells migrate into the tumor in order
to eliminate the tumor cells [80]. Hence, SLOs are considered crucial in initiating and
regulating an adaptive immune response to cancer as they provide the grounds for
interaction between immune cells and tumor antigens.
However, recent studies have shown that SLOs are not the only sites where the
anti-tumor immune response is generated [201]. Tertiary lymphoid structures (TLSs)
are ectopic lymphoid-like structures that develop in non-lymphoid tissues at sites of
infection or chronic inflammation, including tumors. TLSs have been observed in the
stroma, invasive margin, and within the center of many solid tumors, including breast,
pancreatic, NSCLC, and melanoma [48]. TLSs organizationally resemble lymph nodes.
In primary cancers, TLSs have been reported to comprise a T cell zone, a B cell zone with
characteristics of a germinal center mainly containing B cells, and antigen-presenting
cells such as DCs, and macrophages [80]. TLSs provide a local setting for T and B cell
activation, proliferation, and differentiation through the presentation of antigens from
the neighboring tumor [201]. A dense population of plasma cells has been observed
surrounding TLSs in various tumors [123], [132], [231] and for example, in ovarian cancer,
the presence of tumor-infiltrating antibody-producing plasma cells has been reported to
strengthen the prognostically favorable cytolytic T cell responses [123]. Studies suggest
that tumor-infiltrating B cells could be presenting tumor antigens to T cells [35], [261].
Moreover, it has been hypothesized that TLSs enable the local production of antibodies
[103]. Although it is accepted that CD8+ T cells drive anti-tumor immunity, observations
suggest that TLSs may be facilitating an effective anti-tumor immune response achieved
via the coordination of T and B cells.
Furthermore, an association between the presence of TLS and a favorable prognosis
has been reported for many solid tumors, although the outcome depends on parameters
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including cancer type and disease stage. An extensive review is presented in [201]. Besides
established biomarkers such as the quantification of pre-existing anti-tumor T cells, PDL1
expression at the tumor site, or tumor mutational burden, the presence of TLSs is being
regarded as a prognostic and predictive factor in patient response to immunotherapies,
as well as a criterion for patient selection for immunotherapy [48].
1.2 B and T cell antigen receptors guide the adap-
tive immune response
B and T adaptive immune cells utilize their antigen-specific surface receptors to recognize
a vast array of threats against the host organism. This highly specific recognition is
achieved via the considerable diversity of BCRs and TCRs and decides the fate of a cell;
the cell’s development, survival, and activation are heavily influenced by signals received
via its BCR or TCR.
BCRs are composed of two identical heavy chains encoded by the IGH gene locus
and two identical light chains encoded by the IGK or IGL genes, respectively. TCRs are
composed of either α and β or γ and δ chains where each chain is encoded by a different
germline TRA, TRB, TRG, or TRD gene locus, respectively (see Figure 1.3). Each of
these chains is made up of one of the many possible germline variable (V), diversity (D),
joining (J), and constant (C) gene segments. One of each V, D (only in BCR heavy and
TCRβ chains), J, and C segment are combined through somatic DNA rearrangements
during B and T cell development. This process is known as V(D)J recombination and
is the major driver of the receptor diversity. Additional diversity between receptors is
generated by random insertion and deletion of nucleotides at the V-(D)-J junction sites.
The pairing of heavy and light, and α and β or γ and δ chains is also a factor of diversity
[117, Chapters 4, 5, and 9].
BCR and TCR chains contain three complementarity determining regions: CDR1
and CDR2 are encoded solely by V genes in the germline DNA segments, whereas CDR3
is encoded by the terminal of V genes, the D genes in the case of BCR heavy and TCRβ
chains, the beginning of J genes, and the junctional sites between those genes, making it
the most variable region in a chain (see Figure 1.4) [117, Chapter 5, p. 115], [117, Chapter
9, p. 207]. CDR3 regions are also the primary antigen-binding site of the receptors [74].
Due to these characteristics, antigen receptors (AgRs) are, in general, identified by their
CDR3 regions [137].
When an adaptive immune cell recognizes a specific antigen, it might proliferate,




















Fig. 1.3 B and T cell receptor structure. Figure adapted from [174].
same clone and their AgRs of the same clonotype [137]. A clone can be defined by
the set of unique CDR3 regions its receptors encode, meaning that cells with receptors
that have identical sequences in their CDR3 region are considered to be of the same
clone. With some exceptions [239], it is highly unlikely that two cells with no common
predecessor express the same receptor, hence cells of the same clone are considered to
have proliferated from the same ancestor cell. When a B or T cell is antigen challenged,
it divides and undergoes clonal expansion. Thus the AgR sequences serve as a unique
“clonal index” which decodes antigen specificity and cell lineage.
In theory, the number of unique BCR and TCR sequences can surpass 1018 [62].
However, there are only 3.72 ×1013 non-bacterial cells in the human body [20], and some
BCR and TCR tend to be more frequent than others due to antigen specificity and
other factors, hence the full possible collection cannot be realized in a single host. The
adaptive immune repertoire refers to the collection of B and T cell receptors within an
individual host, and is formed throughout a lifetime, shaped adaptively in response to
antigen challenge. The clonal diversity and distribution, and abundance of BCRs and
TCRs are used to characterize this dynamic repertoire.
1.2.1 BCRs
In addition to the combinatorial, junctional, and coupling diversity, BCRs achieve
increased functional diversity through isotype/class switching their constant regions
(C-region), somatic hypermutation, and affinity maturation.
Mammals have five classes of antibodies: IgA, IgD, IgE, IgG, and IgM, where each has
a distinct heavy chain C-region α, δ, ϵ, γ, and µ, respectively. In humans, IgG and IgA
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Fig. 1.4 The V(D)J recombination process, in which individual V, D, and J genes are
randomly selected (selection). These genes are then joined together after a process that deletes
random nucleotides on the boundaries (deletion) and inserts random nucleotides in the light
blue N-region (insertion). The diversity and specificity of an antigen receptor are, to a large
extent, determined by the recombination site CDR3. I have illustrated this process based on
details provided in [152, Chapter 4, p. 85-110].
have further subclasses IgG1, IgG2, IgG3, and IgG4, having γ1, γ2, γ3, and γ4 heavy chain
C-regions, respectively, and IgA1 and IgA2 with α1 and α2 heavy chain C-regions. Each
class has different functional properties and determines what follows antigen binding.
Naive B cells express IgD and IgM, either as BCRs or secreted antibodies. IgM is secreted
into the blood during a primary antibody response, upon initial exposure to an antigen.
IgG is secreted in large quantities during secondary immune responses and makes up the
majority of immunoglobulin in the blood. As an immune response evolves, a BCR can
“switch” its “class” to alter its functional role. Following antigen binding, by excising
unwanted isotypes, active B cells may express IgG, IgA, and IgE, or continue expressing
IgM [34, Chapter 24, p. 1315-1318]. While the exact process behind class-switching is
unknown, it has been observed that cytokines play a major role in determining which
isotype a B cell will express [117, Chapter 5, p. 121-122].
Antibodies produced during the early stages of an immune response usually have
much lower binding strength compared to those produced later on. This is achieved
overtime via fine-tuning their ability to bind an antigen through a process called somatic
hypermutation (SHM). Point mutations accumulate in the V-regions of both the heavy
and light chains, with the overall goal of producing diversity, but not affinity. Antibodies
12 Introduction
undergoing SHMs can end up with higher, lower, or fixed strength antigen binding. SHMs
can also produce non-productive antibodies. In order to increase a B cell’s affinity for
a specific antigen, it undergoes affinity maturation, which is the repeated process of
SHMs and subsequent selective survival of high-affinity antibodies. Mutations tend to
accumulate in the CDRs. As affinity maturation is guided via antigen binding, it is the
CDRs that end up with the most mutations after affinity maturation [117, Chapter 5,
p. 117-122].
Clonal expansion, class switching, SHMs, and affinity maturation all take place in
intratumoral TLSs and GCs [231]. Naive B cells entering a GC clonally expand and
accumulate SHMs. Cells that generate antigen affinity increasing mutations in their
antibodies are selected for class switching. They then differentiate into plasma or memory
B cells and exit the GCs (see Figure 1.5). Cells which, after SHM, produce antibodies
with a decreased antigen affinity are signaled for apoptosis. Similarly, in GC found in
TLSs, B cells undergo terminal differentiation into effector cells and migrate from the
TLS B-cell follicle to the tumor stroma [76].
In this thesis, when describing BCR reconstruction, the terms BCR and antibody are
used interchangeably if not specified otherwise since their sequences are identical. I focus
on BCRs in Chapters 2 and 3 in which I present complete computational reconstructions




























Fig. 1.5 B cell affinity maturation in GC. Naive B cells entering the GC are fine tuned
for a given antigen. B cells with decreased affinity are signalled for apoptosis while ones with
increased affinity differentiate into memory and plasma B cells. Figure adapted from [127].
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1.2.2 TCRs
TCRs are always membrane-bound, and they guide cell-to-cell adaptive immunity [162,
Chapter 4, p. 153-155]. In humans and mice, the TCRαβ+ lineage makes up more
than 90% of the T cells in the peripheral immune system [126, Chapter 6, p. 190]. In
general, TCRs do not undergo SHMs when a T cell is exposed to antigen. Thus, the
antigen affinity of a given T cell clone and their TCR clonotype remain static after
V(D)J recombination. However, SHM was observed in the TCRα of mice and TCRβ of
HIV-infected patients, as well as the variable domain of TCR in camel and shark [21].
In Chapter 4 of this thesis, I give a detailed description of T cells and TCRs and
present a comprehensive statistical analysis of gene expression of clonal tumor-reactive T
cells coupled with their TCR repertoire profiles.
1.3 Strategies for antigen receptor reconstruction
In the past, immune cell receptor studies would only recover a tiny fraction of the
complete repertoire [11]. Early studies characterizing the TCR repertoire were conducted
at the protein level using flow cytometry and monoclonal antibodies [64]. Experiments at
the genomic level were initially based on CDR3 sequence length rather than the actual
nucleotide sequences [83]. Characterization of the TCR repertoire at the nucleotide
sequence level was achieved via molecular cloning techniques coupled with Sanger se-
quencing [200]. Although Sanger sequencing provides specificity, it is not reasonable
to assume capture of the immense diversity using a method with such low capacity -
studies were only able to sequence receptors in the 102–103 range [11]. [222] provides an
extensive review of methods developed to recover AgRs and assess repertoire diversity
prior to high throughput sequencing (HTS).
With the advent of HTS, research focusing on AgR repertoires gained significant
momentum. Cost-effective massively parallel sequencing of millions of DNA molecules
offered a comprehensive view of receptor sequences, including V(D)J regions and the
complete CDR3 sequence. In 2009, using the HTS platform Roche 454 - which can
provide, on average 500 bp length reads - for immune repertoire analysis for the first
time, [248] described the diversity of the antigen-binding domain of the Ig heavy chain
recovered from 14 zebrafish to analyze V(D)J usage and antibody sequences. Their work
was followed by others using the 454 sequencing platform to cover the entire V(D)J region
of the human BCR and TCR repertoires [29], [247]. Studies next utilized the Illumina
HiSeq platform, which offers shorter read length but much higher read throughput at
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a lower cost, allowing for deep sequencing of repertoires [70], [192]. Since then, HTS
profiling of immune receptors has been used extensively to study adaptive immunity [39].
However, the alignment of AgRs has to go beyond those developed for genome se-
quencing as their intrinsic nature, especially of BCRs, present particular challenges in
recovering V(D)J sequences. First, as receptors are a product of V(D)J recombination,
junctional insertions and deletions (indels), and possible SHMs, there are no reference
sequences for CDR3s in the genome. Second, the edit distances between two different
V(D)J sequences can be less than the acceptable sequencing error rate, i.e., sequencing
reads may result in erroneous sequence variants with mismatches, and it may be chal-
lenging to decide whether the sequence represents the same CDR3 with technical errors
or a completely different V(D)J sequence.
1.3.1 Targeted repertoire sequencing
Currently, there are two main approaches taken to reconstruct AgRs: targeted repertoire
sequencing and computational reconstruction of unselected RNA-seq reads. Targeted
repertoire sequencing methods selectively target TCR/BCR molecules; using polymerase
chain reaction (PCR) and HTS, they generate a large number of short to mid-length
DNA/RNA sequences covering regions of interest of AgRs. They employ a target
enrichment step to increase the sensitivity, using either genomic DNA or cDNA as
starting material. Multiplex PCR, targeted in-solution enrichment, and 5′RACE-switch-
oligo nested PCR are the most commonly used enrichment methods [17]. Multiplex
PCR uses a multiplex pool of forward PCR primers complementary to V segments,
and depending on whether the starting material is gDNA or cDNA, either a pool of
reverse primers designed for the J segments, or for the constant regions, respectively
[59], [242]. Using quantitative multiplex immunofluorescence, and HTS of TCRs, [242]
analyzed samples from 46 patients with metastatic melanoma obtained before and during
anti-PD-1 therapy (pembrolizumab). Pre-treatment samples obtained from responding
patients showed a more clonally expanded TCR repertoire, suggesting these patients had
already mounted an adaptive immune response prior to therapy. They also concluded
that successful anti-PD-1 outcome requires pre-existing CD8+ T cells that are negatively
regulated by PD-1/PD-L1-mediated adaptive immune resistance. Targeted/bait-based
enrichment uses RNA baits which are complementary to the sequences of interest and
tolerate a few mismatches. 5′ rapid amplification of cDNA ends (RACE) technologies
decrease the amount of PCR bias that may result from using multiple primers for different
V and J genes. This method adds only a single universal oligo at the 5′ end of the
transcript, and a reverse primer to the C region of the transcript [70]. 5′RACE-switch-
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oligo method uses transcript RNA as input material while the two others can use genomic
DNA or transcript RNA.
low high
Sequence Similarity
IGHV alleles TRBV alleles
Fig. 1.6 Levenshtein distance matrix of human IGHV and TRBV alleles. Each cell
is colored by the sequence similarity between any two alleles of a BCR heavy (left) and TCRβ
(right) variable group, where high corresponds to a Levenshtein distance of 0, and low to 250
and above. The median length of human IGHV allele sequences is 353 bp, and human TRBV
allele sequences is 344 bp.
Apart from the amplification technique, the choice of input material is also important
and depends on the research question. Genomic DNA offers better stability and allows
for better quantification of AgR clones as each cell contains a single DNA copy of the
gene encoding each receptor chain, however, it does not provide any information on the
gene expression level and may lead to sequencing errors because of introns or possible
residuals of V(D)J recombinations [222]. With RNA, we can obtain the final BCR and
TCR products along with dynamic expression level information, while excluding the
non-productive sequences that are functionally irrelevant. However, when using RNA,
quantification can be challenging as an immune cell will contain more than one immune
receptor transcript, and BCR and TCR representation in plasma B cells and activated
T cells will be quite high. RNA-based methods can utilize unique molecular identifiers
(UMIs), which are a sequence of 8–12 random nucleotides attached to each initial cDNA,
in order to detect and quantify unique mRNA transcripts after PCRs and sequencing
[120]. These unique molecular barcodes allow for BCR/TCR transcript quantification
and error correction during data analysis. As mentioned before, AgRs may differ by
single nucleotides. Therefore it is imperative to distinguish between PCR or sequencing
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errors, and low-frequency clonotypes. UMIs provide a reliable technique to distinguish
technical errors from distinct AgRs or daughter AgRs with SHMs.
Once AgRs have been sequenced, the raw HTS platform sequence data files are
converted to FASTQ format [47] and are then processed to match the obtained sequence
to the known germline gene sections. However, unlike standard alignment where short
reads are mapped to the most similar regions of the reference, this gene matching process
is a bit tricky. The BCR and TCR loci are made up of many similar V, D, and J
genes, which need to be distinguished accurately. As an example, Figure 1.6 shows this
similarity with a heatmap of all the human BCR heavy and TCRβ V allele edit distances.
Also, these BCR/TCR variable regions accumulate insertions and deletions and possible
SHMs during recombination and affinity maturation, diverging them from the actual
gene sequences. Table 1 in [96] lists the current receptor gene assignment and profiling
tools that were developed specifically for targeted AgR sequencing datasets.
1.3.2 Computational reconstruction and repertoire profiling of
antigen receptors from bulk RNA-seq reads
The alternative to targeted AgR sequencing is computationally reconstructing AgRs from
RNA-seq reads obtained from any sample containing immune cells. The downside of this
method is that a small fraction of such sequencing reads will come from BCRs and TCRs,
and a high sequencing depth will be required to pick up the AgR signal in the RNA-seq
read pool [33]. However, as new computational methods develop, this is becoming less of
a challenge. [33] extracted TCR sequence information from the RNA-seq data of 6,738
tumor samples taken from The Cancer Genome Atlas (TCGA) [164], with a typical yield
of one unique TCR per 10 million reads. However, their poor detection rate is dependent
on using computational methods that are not explicitly designed for unselected RNA-seq
data. In comparison, [137], with a specialized method, detected an order of magnitude
more distinct CDR3 sequences in the same dataset.
The fraction of BCR and TCR reads covering CDR3s in RNA-seq data varies from
sample to sample depending on the degree of immune cell infiltration, and can range
from 10−4 to 10−7 for BCRs and 10−5 to 10−7 for TCRs [24]. Moreover, as the length
of RNA-seq paired-end reads is typically in the 50-100 bp range, successful detection of
target V(D)J junctions requires alignment with very short fragments of germline V and
J genes (12-15 bp). Another challenge in the evaluation of such short sequences is the
high probability of false-positive alignments. Efficient reconstruction of antigen receptors
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from raw RNA-seq reads thus requires the extraction of as many true CDR3 sequences
as possible while ensuring nearly zero CDR3-like false-positives.
Targeted amplicon sequencing based methods cannot evaluate AgR variation in the
context of genetic diversity. RNA-seq based transcriptome analysis is now quite affordable
and routine in biological research and clinical studies. Extracting AgRs directly from the
readily available RNA-seq data provides the ability to assess receptor clones within the
gene expression space. Furthermore, the quantity of starting material is a factor that
can make targeted amplicon sequencing based methods unfavorable. Especially in cancer
studies, tumor tissue samples taken during ongoing treatment can be quite limited as they
are often from needle biopsies. If only low quantities of starting material are available, it
is beneficial to extract the BCR/TCR information directly from RNA-seq data along
with other -omics data, rather than having to separate the sample for transcriptome,
BCR, and TCR profiling.
Moreover, with the ongoing “fight against cancer”, cancer researchers have been
amassing data in centralized repositories such as TCGA [164] and the International
Cancer Genome Consortium (ICGC) [104]. AgR reconstruction methods can employ
such readily available databases for immune receptor profiling, providing an additional
layer of information to pre-existing research without extra wet-lab time and cost. In
this regard, [137] demonstrated their computational algorithm named TRUST [138] on
unselected tumor RNA-seq data taken from the TCGA cohort to characterize the TCR
repertoire of tumor-infiltrating T cells. One of their findings is that the diversity of
T cell clonotypes positively associates with cancer somatic mutation load. Similarly,
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Fig. 1.7 Simplified representation of
targeted AgR sequencing vs RNA-seq.
Each horizontal line represents an mRNA
transcript where each color denotes a unique
gene sequence. (a) The mixed pool of all
possible mRNA in a given sample includ-
ing the recombined AgR transcripts (multi-
colored) and the non-AgR sequences (blue,
brown, red). (b) Targeted sequencing am-
plifies the selected CDR3 region of receptor
transcripts (displayed as a color gradient). (c)
RNA-seq generates fragments from all tran-
scripts present in the mixed pool, including
fragments of the CDR3 encoding sequence.
Figure adapted from [33].
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(SKCM) patients from 48+48- bp paired-end RNA-seq data taken from TCGA. They
associated a combination of high intratumoral IGH expression levels and high levels of
IGH clonality with more prolonged survival. Patients with abundance and high clonality
of IGH showed better prognosis compared to patients with a similar abundance of IGH
but diverse repertoires.
1.3.3 Reconstructing antigen receptors from single cell RNA-
seq data
The immune system is a complex network of cells that vary in type, state, and differentia-
tion stage. In order to grasp the full heterogeneity of the immune system and understand
the intricate underlying mechanism, studies need to be conducted at single-cell reso-
lution. In the past 50 years, flow cytometry has provided significant developments in
high-throughput quantitative analysis of cells and other particles [177]. In immunology,
microscopy and flow cytometry are used to classify and quantify populations of immune
cells based on the specific surface marker and intracellular protein expression. Recent
computational flow cytometry tools and software have also begun providing reproducible
and unbiased results that manual analysis could not [198]. However, such methods are
still limited by the number of parameters for cell-type classification and the reliance on
prior knowledge of known markers [44].
Single-cell RNA-seq (scRNA-seq) is an ideal method to reveal cellular heterogeneity.
scRNA-seq measures the gene expression levels within a single cell, allowing for the
classification of individual cells by transcriptome analysis rather than surface markers.
In immunology, with scRNA-seq, cellular complexity can be investigated in far greater
detail than conventional methods, exposing new cell types and functionally diverse
subpopulations of known cell types [246], [22]. scRNA-seq has also allowed for the
in-depth study of the adaptive immunity against cancer. [235] analyzed a total of 4,645
malignant and tumor cells from 19 human melanoma samples. They examined CD8+ T
cells to identify dysfunction programs. Similarly, [140] analyzed the tumor-infiltrating
immune cells in human melanoma to reveal the trajectories of CD8+ T cell dysfunction.
Profiling immune cells from melanoma patients using scRNA-seq, [197] determined that
TCF7 (TCF1 in mice) expression can predict positive clinical response. Many other
studies have dissected tumor tissues using scRNA-seq to characterize the TME [175],
[221], [184], [13], [202], [66].
The usual scRNA-seq workflow consists of single-cell capture, mRNA reverse tran-
scription, cDNA amplification, library preparation, high-throughput sequencing, and
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data analysis [44]. In some protocols, to eliminate the amplification bias, UMIs are
attached to each transcript within a cell during reverse transcription [107]. The absolute
copy number of a transcript in a single cell can be found by counting the number of
distinct UMIs. The count of sequenced UMI reads that align to a specific gene represents
the expression level of that gene. Each cell is presented as a vector of gene expression
levels, and the cell vectors merged on genes make up the digital (gene x cell) expression
matrix of the captured cells.
scRNA-seq is an ideal method to study the vast diversity of AgRs, along with their
relation to their cells’ type and state. Similar to bulk data, the sequences of BCRs
and TCRs can be assembled from scRNA-seq reads or reconstructed using targeted
AgR sequencing. With “bulk” approaches, information about the pairing of heavy and
light chains in the case of Ig, and the α and β chain for TCR, cannot be obtained with
certainty. In clonal repertoires, one may think to pair the most clonal heavy and light
clonotypes together. However, the most frequent heavy or light chains may be expressed
by several clones. They would be the most common chain, but not necessarily the most
clonally expanded clonotype. Furthermore, in the case of allelic inclusion [227], [30],
chains cannot be assumed to pair up. In this regard, scRNA-seq is superior to bulk
RNA-seq in reconstructing AgR repertoires.
scRNA-seq also allows for the incorporation of single-cell gene expression profiles
with BCR/TCR information at the cellular level in order to uncover the links and
transitions between transcriptional states. [197], via single-cell gene expression and
TCR analysis, showed that T cells can transition from one state to the other. This
was later confirmed by [140], where again combining scRNA-seq and TCR-seq, they
showed that the dysfunctional CD8+ T cell state rather than being a discrete pool
constituted a gradient spectrum going from transitional state to early dysfunction, and
highly dysfunctional.
1.3.4 Ontology for immunogenetics
The International Immunogenetics Information System (IMGT), created in 1989 by Pro-
fessor Emeritus Marie-Paule Lefranc, is the most widely used reference in immunogenetics
and immunoinformatics [135]. It is a centralized repository for immunogenetics-related
data, specializing in AgRs and MHCs of all vertebrate species. The IMGT/GENE-DB
database [134] contains a well-annotated set of genomic V, D, J, and C genes. This
database provides the reference for most AgR gene assignment tools, as well as for tools
that can directly extract immune repertoires from whole-transcriptome RNA-seq data
sets. These tools are reviewed in Section 1.3.5. IMGT/GENE-DB statistics [106] of
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IGH, IGK, IGL, TRA, and TRB genes for homo sapiens and mus musculus species are
provided below in Tables 1.1 and 1.2. The tables below also present the median allele
lengths of each IMGT group. Note how short D and J genes are; often, the D segment
remains unidentified due to its short length. Also, as shown previously with Figure 1.6,
V gene segments are very homologous. Considering that it is the V(D)J region which
has indels and SHMs the most, it becomes apparent that AgR reconstruction is more
tedious than standard alignment. Differentiating between allelic differences and V(D)J
recombination sequence alterations require extra care.
Locus IGH IGK IGL
Species IMGT group IGHV IGHD IGHJ IGHC IGKV IGKJ IGKC IGLV IGLJ IGLC
Homo
sapiens
Number of genes 185 37 9 12 109 5 1 79 11 14
Number of alleles 524 44 19 93 148 9 5 133 14 29
Median length (bp) 353 23 52 1131 353 38 321 353 38 318
Mus
musculus
Number of genes 352 31 4 9 177 5 1 8 5 4
Number of alleles 508 38 9 26 208 10 3 14 5 5
Median length (bp) 351 17 48 1032 351 38 321 351 38 315
Table 1.1 Number and median length in basepairs of IMGT IG genes and alleles of homo
sapiens and mus musculus species per IMGT group.
Locus TRA TRB
Species IMGT group TRAV TRAJ TRAC TRBV TRBD TRBJ TRBC
Homo
sapiens
Number of genes 57 61 1 77 2 14 2
Number of alleles 115 71 1 168 3 16 6
Median length (bp) 338 61 422 344 16 50 537
Mus
musculus
Number of genes 132 60 1 35 2 14 2
Number of alleles 279 71 2 61 2 19 4
Median length (bp) 340 61 408 344 13 49 518
Table 1.2 Number and median length in basepairs of IMGT TRA and TRB genes and alleles
of homo sapiens and mus musculus species per IMGT group.
1.3.5 Software tools and pipelines reconstructing antigen re-
ceptors from unselected RNA-seq data
Before discussing state of the art, it is necessary to mention that to date, there is no gold
standard method, and that it is difficult to define one given our limited knowledge of
immunogenomics. Certain dogmas such as each BCR has one heavy and one light chain, or
that a lymphocyte can have either a BCR or a TCR but not both, are being proven wrong
as our knowledge expands [7], [227], [30]. The tools developed need to be more flexible
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in their assumptions. Benchmarking on real data sets is not straightforward, as it is not
possible to know the actual repertoire of a sample before measuring it. Benchmarking
is often carried out in silico; however, the simulated data may not be reflective of the
actual sample space as it is far cleaner and incorporates possible false assumptions. That
being said, every available method has its advantages and disadvantages, and it is up to
the researcher to decide which tool, and which configuration will most accurately answer
their research question.
IgBlast is one of the earliest BCR and TCR variable domain sequence V(D)J mapping
tools [259]. IgBlast carries out read-mapping via BLAST [27] with an optimized set of
parameters. However, IgBlast does not extract the sequence of CDR3 region directly
from HTS data, meaning it is a mapping tool and not a complete reconstruction tool.
Also, IgBlast is designed to analyze the V domain sequence. If the query sequence only
contains D or J gene and not the V gene, it will not be analyzed adequately by IgBlast.
Many reconstruction pipelines such as TraCeR [227] and BraCeR [144], use IgBlast in
their workflow to analyze the assembled contigs.
A variety of software tools have been developed to reconstruct AgRs from unselected
bulk and single-cell RNA-seq data directly. As mentioned before, the V(D)J recombination
and possible SHMs renders the RNA-seq reads from AgRs unmappable to the reference
sequence. TRUST [138], V’DJer [161], and MiXCR [25] reconstruct antigen receptors
from RNA-seq data using different underlying algorithms to map the short RNA-seq
reads to germline genes. TRUST first maps all reads to the reference genome and
finds read pairs where one of the pairs properly maps to a TCR gene and the other
read pair is unmappable, assuming so due to V(D)J recombination. Then taking the
unmapped reads, it constructs an overlap matrix, represented by an undirected graph,
where nodes correspond to reads and edges indicate partial sequence overlap. Disjoint
subgraphs (cliques) represent potentially distinct CDR3 sequences. All reads in a clique
are assembled de novo to obtain contigs, which are then annotated with amino-acid
sequences, and the associated V and J genes using IMGT. Contigs not annotated as CDR3
regions are discarded to reduce false-positive rates. TRUST is developed specifically for
TCR reconstruction, although recent updates include BCR CDR3 calling function as
well [102]. V’DJer similarly reconstructs AgR sequences by extracting fully or partially
Ig gene mapped and unmappable RNA-seq reads and with them constructs a De Bruijn
graph [180]. The graph is traversed, producing possible contigs that are filtered for
homology with V and J segments. The final set of assembled contigs spanning most
of the V(D)J region and a portion of the constant region is returned with annotation
from IMGT. V’DJer returns the most abundant portions of the BCR repertoire. MiXCR
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enables assembly of both BCR and TCR clonotypes from various raw sequencing data
such as whole-genome sequencing, RNA-seq, and paired-end sequenced cDNA library
of IGH gene prepared using 5′RACE-based protocols. The MiXCR workflow consists
of three main steps: (i) building alignments of sequencing reads to reference V, D, J
and C genes, (ii) assembling clonotypes using the alignments, and (iii) exporting filtered
alignments. The alignment step is an implementation of the k-mer chaining algorithm
proposed by [142] and can handle short alignments and alignments with mismatches,
indels, and big gaps. Identical sequences are clustered into clonotypes and corrected for
PCR and sequencing errors. The clustering algorithm looks for fuzzy matches between
clonotypes and organizes the matched clonotypes in a tree, where each daughter node is
highly similar to its parent but has a significantly smaller abundance. Only parent nodes
are considered as clonotypes. Lastly, clonotype sequences are aligned to reference V, D,
J, and C genes using the Smith-Waterman algorithm [224]. Benchmarking with in silico
generated data demonstrated MiXCR to have an order of magnitude higher efficiency in
terms of reconstructing true clonotypes and filtering for false-positives when compared
to TRUST [24]. Comparing the number of TCR-seq-confirmed RNA-seq-extracted high-
frequency clonotypes of lymph node metastasis, MiXCR demonstrated better accuracy
than that of TRUST. However, since the MiXCR-conducted-benchmarking, TRUST has
been updated, clarifying the claimed performance gaps [101]. MiXCR, when compared
with V’DJer, demonstrated significantly better computing performance [24]. Average
analysis time of 108 RNA-seq reads, took 28 hours with V’DJer, and 4 hours with MiXCR.
To analyze all IGH, IGK, and IGL chains, V’DJer needs to be run three times for each
chain [24].
There are also pipelines specific to the reconstruction of AgRs from scRNA-seq
data. TraCeR [227] and BraCeR [144] are two pipelines that reconstruct TCR and BCR
sequences from raw scRNA-seq data making use of various available bioinformatics tools.
They use Bowtie2 [129] to align the scRNA-seq reads to custom in silico combinations of
all known chosen reference V and J gene alleles taken from IMGT. Using Trinity [84],
they assemble reads into BCR/TCR contigs. Next, IgBLAST is used for the analysis
of assembled contigs. For BCR/TCR expression quantification, they use Kallisto [32],
or Salmon [176]. BraCeR additionally uses BLAST to determine the BCR isotype.
VDJPuzzle [190] is a similar pipeline that reconstructs productive, full-length BCRs of
both heavy and light chains and can extract SHMs on the V(D)J region. It makes use of
multiple rounds of alignment and assembly; first to the reference genome to filter reads for
initial contig assembly, another to re-align all reads to the assembled contigs in order to
retrieve any possible misses followed by a second assembly and a third alignment for error
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correction. In the VDJPuzzle pipeline, paired-end reads are trimmed using Trimmomatic
[23] and aligned to the reference genome using Tophat [115]. Paired reads with at least
one pair aligned to any of the V, D, J, or C genes are extracted using BEDtools [186],
and de novo assembled using Trinity [84]. Resulting contigs are matched to IMGT to
find complete, productive, and in-frame BCRs. Reads are re-aligned against the primary
repertoire using Bowtie2, and aligned reads are used for assembly of a second round of
contigs with Trinity. Contigs corresponding to a BCR from the primary repertoire are
merged. For error correction, paired-end reads are re-aligned a third time, to the merged
repertoire using BWA [139]. A semi de novo pipeline called BASIC reconstructs a BCR
sequence by anchoring reads to the V and the C genes and then extends the sequence by
progressively concatenating overlapping reads to the anchored sequence [42].
BALDR [243] is another BCR reconstruction pipeline, and similar to BraCeR makes
use of seven different bioinformatics tools and performs de novo assembly of RNA-seq
reads. The one tool that is the workhorse of all these pipelines is the Trinity assembler
[84]. Trinity constructs and traverses a set of de Bruijn graphs 2 where each graph
represents the transcriptional complexity at a given gene or locus and then processes
each graph independently to fully reconstruct a significant fraction of the transcripts.
TRAPeS is a TCR reconstruction tool which (i) for each chain, identifies the V and J
segments by searching for paired reads with one read mapping to the V segment and its
mate mapping to the J segment, (ii) identifies a set of putative CDR3-originating reads
as the set of unmapped reads whose mates map to the V, J, and C segments, and (iii)
constructs the CDR3 region with the putative CDR3 reads [5]. BRAPeS is an extension
of TRAPeS which reconstructs a BCR in two extra steps: in addition to TRAPeS (i)-(iii)
steps, BRAPeS determines the BCR isotype by running RSEM [136] on the reconstructed
sequence with all possible constant segments added to it and then corrects for SHMs [4].
2De Bruijn graphs, named after Nicolaas Govert de Bruijn, are directed graphs that represent overlaps
between sequences of symbols [54]. Every possible (k − 1) − mer of the given symbol sequence is assigned
to a node and edges connect any two nodes that have a consecutive perfect overlap of (k − 2) − mer,
which means that the two nodes are the prefix and the suffix of a k-mer from the input sequence. The
edges correspond to this k-mer. De Bruijn graphs can be used for the de novo assembly of sequencing
reads by determining which reads should be concatenated to form sequence contigs. Possible contigs
are produced by traversing a graph of sub-reads (sequences of nucleotides) of length L that overlap
consecutively by L − 1 bases. For example, in transcriptomics, each path in a de Bruijn graph would
represent a possible transcript.
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1.4 Aims of this thesis
The overall aim of this thesis is to investigate the anti-tumor immune response to better
understand adaptive immunity in cancer. I focused on B and T cell antigen receptors as
they guide the adaptive immune response.
In the scRNA-seq human melanoma study presented in Chapter 2, I aimed to
incorporate AgR detection with scRNA-seq in order to investigate the clonal adaptive
immune response in melanoma. By extracting both gene expression and AgR clonotype
data at the single-cell level, I aimed to find the possible subpopulations of immune cells
driving the intratumoral immune response.
By analyzing the bulk RNA-seq colorectal cancer (CRC) and pancreatic ductal ade-
nocarcinoma (PDAC) dataset presented in Chapter 3, I focused on the tumor infiltration
of B cells, specifically in CRC and PDAC. I aimed to study the effect of a particular
immunotherapy drug on the B cell responses towards these cancers. Using paired data
from a clinical trial, I aimed to find immune receptors expanded after therapy.
In the scRNA-seq mouse melanoma study presented in Chapter 4, I aimed to link
the TCR repertoire with whole-transcriptome scRNA-seq data. Combining the two at
a single cell level allowed me to investigate the relationship between T cell phenotypes
and TCR repertoires. By using a novel transgenic mouse model that can help track the
clonal T cell response to tumor antigens, I investigated the clonality and diversity of
tumor-reactive TCRs.
1.5 Overview of work done
In this thesis, I investigate certain aspects of the immune system in the context of cancer
by computationally reconstructing and analyzing intratumoral B and T cell receptors
from both bulk and single-cell RNA-seq data. In the remainder of this thesis, RNA-seq
will refer to bulk RNA-seq unless otherwise noted.
1.5.1 Chapter overviews
In Chapter 2, applying a novel single-cell immune profiling protocol on original data
obtained from melanoma patients, I present a complete computational reconstruction of
immune receptors. Patient biopsies were collected prior to immunotherapy, and their
repertoire analysis depicts the baseline immunological status of patients. With the
abundance of plasma cells and the fully class-switched antibodies in these biopsies, I
show the presence of an ongoing integrated immune response which involves B and T
1.5 Overview of work done 25
cell cooperation. In this dataset, single-cell RNA-sequencing results are consistent with
the presence of tertiary lymphoid structures.
In Chapter 3, using a clinical trial dataset of paired biopsies, I show that B cell infiltra-
tion increases after immunotherapy in pancreatic and colorectal cancers. I then present
the sequences of post-therapy clonal antibodies which I computationally reconstructed
from RNA-seq data.
In Chapter 4, I focus on T cells and TCRs. I describe our approach that combines
single-cell gene expression profiles with TCR information at the cellular level in order to
uncover the links and transitions between transcriptional states. By linking T cells via
their TCRs, I show the differentiation of tumor-infiltrating T cells caused by the interplay
between the tumor and immune response. I present a novel transgenic mouse model that
can help track the clonal CD8+ T cell response to tumor antigens. I describe how, using
this mouse model, we were able to harvest and sequence tumor-reactive T cells, and how
we obtained their gene expression profile and TCR repertoires. I give a detailed account
of my analysis on the obtained dataset from the single-cell RNA sequencing of the mouse
model, focusing on investigating the clonality and diversity of T cells.
1.5.2 Original contribution
In Chapter 2, I processed a novel, linked single-cell RNA-seq and AgR repertoire dataset
of two melanoma patients and identified paired heavy and light antibody chains which
could be further analyzed for antigen binding. The paired nucleotide sequences are
presented in Appendix A.
In Chapter 3, I performed a complete BCR repertoire analysis of 37 PDAC and CRC
patient samples taken before and after a new type of immune treatment [65]. To the
best of my knowledge, BCRs have not been reconstructed and analyzed from tumor
tissue of PDAC, which is one of the most aggressive and lethal forms of cancer. With
this clinical trial data, I showed a snapshot of the adaptive immune response pre and
post immunotherapy, and showed increased BCR clonality and expansion post-treatment.
I further identified clonal BCRs which could potentially be used to identify antigens
that drive PDAC and CRC intratumoral immune responses. The possible pairings of
nucleotide sequences are presented in Appendix A.
In Chapter 4, I presented a combined TCR and gene expression analysis of tumor-
reactive T cells at an unprecedented level of detail. This work also confirms the usability
of the presented novel mouse model in AgR signaling experiments.
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1.5.3 Other PhD work
I began my PhD in September 2015. Between October 2015 and December 2017, I worked
on developing a method, namely CamSeq, to sequence concatenated amplicons on the
Oxford Nanopore’s MinION sequencer. I worked with Dr. James Hadfield and Dr. Sarah
Field to design and implement an amplicon sequencing method to detect low-frequency
alleles in cancer samples using the MinION sequencer. For this purpose, I wrote a pipeline
that takes in Nanopore MinION sequencing reads and outputs possible mutations. I also
developed a signal detection tool using time-point change detection algorithms to call
mutations directly within the signal space rather than on the base-called sequences. This
work was in collaboration with AstraZeneca and has been handed over to their labs to
improve further.
Between December 2016 and September 2018, together with Dr. Daniele Biasci, I
worked on standardizing the application of existing methods in liquid biopsy data analysis
[91]. I developed Varbench [92], a suite of tools that compare somatic variant callers
for targeted deep sequencing data, run the best performing one, and report the allele
frequencies of the called variants using estimate intervals. Varbench comprises four
pipelines, namely varbench:simulate, varbench:compare, varbench:estimate and
varbench:validate. varbench:simulate and varbench:compare pipelines allow users
to systematically asses, compare, and choose the best combination of tools for the data
at hand. The varbench:estimate pipeline is designed to robustly estimate and quantify
uncertainty for allele frequencies, with particular attention to low-frequency mutations.
Importantly, the estimates obtained can be used to detect changes during longitudinal
ctDNA monitoring in patients. Finally, varbench:validate assists the user in selecting
mutations for downstream validation.
Chapter 2
Characterization of the melanoma
TME and antibody repertoire
2.1 Introduction
Although melanoma accounts for only 1% of skin cancers, it makes up the majority of skin
cancer-related deaths [8]. Immune checkpoint blockade (ICB) therapies have drastically
increased life expectancy in melanoma patients [130], however still a considerable number
of patients do not show a positive outcome post-treatment. Melanomas are considered
as immunologically “hot” tumors, meaning they harbor high levels of tumor-infiltrating
T cells, resulting in an inflamed TME, which increases the effectiveness of checkpoint
blockade immunotherapies [72]. Hence it is essential to study the TME of melanoma
at baseline at single-cell level in order to understand the mechanisms of anti-tumor
immunity prior to immunotherapy.
Majority of theories on inflamed TMEs focus on T cell responses. In this study, I
investigated the presence of tumor-infiltrating B cells (TIL-Bs) in melanomas, charac-
terizing them based on both functional phenotypes and clonality. I achieved this by
linking the whole-transcriptome scRNA-seq data with the BCR repertoire at a single-cell
level. In Section 2.2, I review the role of B cells in tumor immunity and immunotherapy,
and explain the mechanisms via which diverse BCR repertoires are generated. I further
describe how a novel protocol, The Chromium Single Cell Immune Profiling Solution,
allows the gene expression profile, and full-length, paired, BCR and TCR clonotypes
to be obtained from the same input sample [269]. In Section 2.3, I present the two
melanoma samples that I used for this study, and in Section 2.4 describe how they were
pre-processed with the aforementioned protocol. Here, I also point out the shortcomings
of the protocol’s analysis pipelines and how they can be further improved. In Section 2.5,
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I give a detailed account of my analysis on the obtained scRNA-seq datasets, while in
Section 2.6, I present the antigen receptor repertoires obtained again from the same
datasets. In Section 2.7, I present my findings which include the sequences of clonal
intratumoral antibodies, and conclude this chapter with a discussion in Section 2.8.
2.2 Background
2.2.1 Anti-tumor immunity from a B cell perspective
Very recently, the five-year follow-up of the combined nivolumab-plus-ipilimumab im-
munotherapy trial in advanced melanoma reported that the overall survival at five years
was 52% in the nivolumab-plus-ipilimumab group, compared to the 44% in the nivolumab
and 26% in the ipilimumab group [130]. While only a decade ago, patients diagnosed
with late-stage metastatic melanoma would survive at most six months [43], now, with
the advances in immunotherapies, the five-year survival rate is one in two patients.
However, a significant number of patients still show innate or acquired resistance to
immunotherapies [169]. The study of the TME prior to treatment can provide insight
into patient response.
The role of the T cell-mediated adaptive immunity in the anti-tumor immune response
is well established [235], [13], [202], [197], [140], and is the focus of successful cancer
immunotherapies [189]. It has been widely accepted that patients with melanoma tumors
infiltrated with T cells, the so-called “hot tumors”, have better long-term survival. The
role of B cell-mediated humoral adaptive immunity is less clear and has only recently
gained attention [241], [254].
B cells have been shown to infiltrate the tumors of melanoma, breast, and colorectal
cancers, among others [128], [151], [216]. In some tumors, B cells make up 25% of all the
intratumoral cells, and 40% of TILs are TIL-B in some breast cancer tumors [260]. B cells
are a heterogeneous population with functionally discrete sub-types. Depending on their
phenotype, intra-tumoral B cells may promote or inhibit anti-tumor immunity. Studies
of TIL-Bs have shown associations with positive prognosis [56], [141], [251]. B cells might
positively contribute to anti-tumor immunity through the production of antibodies which
target tumor antigens, and of cytokines and chemokines which can recruit other immune
cells, or via presenting antigens and partaking in other immunoregulation mechanisms
[241], [141], [251], [254]. On the other hand, there are cases where TIL-Bs result in the
progression of the tumor. For example, [185] demonstrated that IL-35 secreting TIL-Bs
were associated with facilitating tumor cell proliferation in pancreatic cancer, and [213]
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showed that tumor-infiltrating plasma cells which express IgA, interleukin (IL)-10 and
PD-L1 suppressed the cytotoxic function of T cells induced by chemotherapy in three
different mouse prostate cancer models. Both [185] and [213] were conducted using mouse
models.
In a clinical study, CD20+ B cells were detected around CD8+ T cells in the tumor
stroma, demonstrating a positive prognosis in ovarian cancer [167]. B cells might be acting
as APCs to T cells, promoting intratumoral T cell proliferation [260], thus indirectly
contributing to anti-tumor immunity. Furthermore, [123] described the positive impact of
tumor-infiltrating plasma cells on the anti-tumor immune response by showing that CD8+
TILs had increased prognostic benefits when detected alongside plasma cells, CD20+
TIL-Bs, and CD4+ TILs, suggesting cooperation of B and T cells within the TME to
promote anti-tumor immunity. Additionally, a recent study showed that tumor-associated
B cells are crucial to melanoma-associated inflammation as they may be guiding T cells
and other immune cells to the tumor [86]. The same study, using scRNA-seq, also showed
that CD19+CD20-CD38+CD138- plasmablast-like and naive-like B cell frequencies to
be significantly higher in the pre-immunotherapy melanomas of patients responding to
anti-PD-1 therapy. B cells are also relevant in ICB therapies. It is not just T cells
that express PD-1, PD-L1, and CTLA-4. When either PD-1 or CTLA-4 is blocked, the
proliferation of memory B cells and antibody production increase [260].
B cells can secrete lymphotoxin (LT) which has been reported to be tumor-promoting
in some contexts [10] but also to play an important role in the formation and maintenance
of TLSs [201]. While TIL-Bs revealed contradicting results in human and mouse models,
the number of TLSs showed a positive association with favorable outcomes in both
human disease and mouse models. Various human cancers, including melanoma, have
reported positive outcomes associated with a high number of TLSs. Additionally, it has
been shown that high amounts of B cells within TLSs predict longer patient survival in
lung cancer [77].
In summary, B cells might play a beneficial role in anti-tumor immune response with
the antibodies they secrete, and by cooperating with T cells within the TME, as well as
possibly by aiding in the development and maintenance of intratumoral TLSs. However,
the role of B cells in the anti-tumor immune response needs to be further studied in
human cancers, paying attention to the differences in molecular B cell sub-types.
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2.2.2 Generation of BCR diversity
The vast BCR diversity is generated by a series of complex processes [117, Chapter 5,
p. 117-122]. During the maturation of B cells, the BCR genes are rearranged from many
different possible gene alleles to form a complete chain. During this V(D)J recombination
step, the receptor is tested for functionality and eliminated when it shows self-antigen
reactivity in order to prevent autoimmunity.
As described in Section 1.1.1, matured naive B cells get activated when they encounter
an antigen and travel to the germinal centers in the secondary or tertiary lymphoid struc-
tures in order to gain further affinity via additional diversification processes. This section
will discuss in detail the different processes which contribute to BCR diversification.
Pre-antigen-challenge diversification
Before antigen encounter, the BCR repertoire of a human can generate more than 1012
unique Ig molecules, referred to as their preimmune antibody repertoire [34, Chapter 24,
p. 1319].
Combinatorial diversity is achieved via somatic DNA recombination which takes
place in the bone marrow. The different Ig loci which contain the gene fragments that con-
catenate to make up the different variable domains are located on different chromosomes
(Chr) in the human genome: IGH is on Chr14, IGK on Chr2, and IGL on Chr22. The
gene segments consist of different germline sequences. There are also several pseudogenes
which result in nonfunctional variable regions when undergoing recombination. The
number of gene segments are presented in Table 1.1. The recombination steps of the
heavy and light variable regions follow a specific order which is shown in Figure 2.1.
I have illustrated this V(D)J recombination process based on details provided in [34,
Chapter 24, p. 1316-1324].
Junctional diversity happens due to imprecise DNA joining. V(D)J joining is
mediated by RAG1 and RAG2 (recombination activating genes) recombinase [75]. During
the joining of Ig gene segments, individual nucleotides are often deleted from their ends,
and one or more random nucleotides may be inserted. This random loss-and-gain increases
the diversity of the CDR3 region significantly. However, it can also cause a shift in the
reading frame, producing nonfunctional genes [117, Chapter 5, p. 115].
Coupling diversity is a result of the combination of different variable regions of
the heavy and light chains. Though thought to be random, it has been reported that
pairing preferences do exist for a small proportion of germline gene segments [109].
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Fig. 2.1 The V(D)J recombination of the immunoglobulin heavy chain from
germline gene segments. The construction of the variable domain of the heavy chain
begins with the randomly chosen D and J genes’ recombination, and then the V gene joins
the DJ segment. The constant domain is then joined through RNA splicing of the primary
RNA. In immature B cells, the variable domain is transcribed with the constant µ or δ chain,
producing either of the mRNAs through alternative splicing, which are finally translated into
either IgM or IgD. Heavy Igs are then paired with a light Ig which are shown in dashed lines. I
have illustrated this V(D)J recombination process based on details provided in [34, Chapter 24,
p. 1316-1324]
Post-antigen-challenge diversification
After encountering the appropriate antigen, B cells may start a process aimed at making
high-affinity antibodies in order to produce a more efficient immune response.
Somatic hypermutations (SHMs) occur in the variable domains of the heavy
and light chains mediated by the activation-induced cytidine deaminase (AID) enzyme
[179], which is expressed and active in GC and TLS-activated mature B cells [231]. SHM
takes place in the dark zone of the GCs (see Figure 1.5). The SHM rate is about one
nucleotide per 103 base pairs per cell division [162, Chapter 10, p. 410]. If mutations lead
to a nonfunctional BCR, the B cell might die by apoptosis. Otherwise, it can migrate
into the light zone. In the light zone, low-affinity BCR-bearing cells are stimulated for
survival, proliferation, and possible re-entry into the dark zone for consequent rounds of
affinity maturation, whereas very low-affinity BCR bearing cells die by apoptosis. Final
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B cells leave the GC differentiating into antibody-producing plasma cells or memory B
cells.
Class switching allows B cells to switch from making one class of antibody to
making another in their heavy chains. On stimulation by antigens, some B cells are
activated to secrete IgM antibodies which dominate the primary antibody response. Only
after antigen stimulation, with the cytokines secreted by helper T cells, do many B cells
switch to making IgG, IgE, or IgA antibodies. The differentiated memory B cells and
plasma cells express these class-switched antibodies. In an individual’s Ig repertoire, a
particular antigen-binding site can be distributed among various classes. In a B cell,
once a switch has happened from IgM and IgD to one of IgG, IgE, or IgA, the change is
irreversible at the DNA level as every heavy constant coding gene sequences between the
assembled VDJ sequence and the particular constant heavy coding sequence is deleted
[34, Chapter 24, p. 1322-1324].
2.2.3 Integrated immune cell profiling
Fig. 2.2 Workflow describing the Chromium Single Cell Immune Profiling Solution. Image
adapted from [2].
10x Genomics provides a commercial method to link BCR/TCR targeted sequencing
with whole-transcriptome analysis of human and mouse single-cells in parallel employing
the droplet-based microfluidic platform Chromium 10x [269]. There are roughly 750,000
unique 10x barcoded gel beads that can index a cell in an input sample. In the Chromium
controller, 10x barcoded gel beads are mixed with cells, enzyme, and partitioning oil and
captured in droplets making up a GEM; gel bead in emulsion partition (see Figure 2.2).
The GEM provides the micro-environment in which cells are barcoded and reverse
transcribed into cDNA. Hence, all cDNA within the same cell are labeled with the same
barcode. The GEMs are then broken so that all barcoded cDNA are mixed together.
The mixed cDNA undergoes amplification and is divided for target enrichment and
library preparation of B and T cell V(D)Js, and for 5′ gene expression library preparation.
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V(D)J enrichment of B and T cell is performed on amplified cDNA by PCR, which uses
reverse-primers designed for the constant regions and a universal forward-primer designed
for a sequence added at the 5′ end 1. The prepared libraries are then RNA-sequenced
yielding reads with cell barcodes. 10x provides two pipelines which produce a (gene x
cell) expression matrix from the 5′ gene expression library reads, and V(D)J repertoires
from the B and T cell enriched libraries. These pipelines are described in Section 2.4.1.
2.3 Human melanoma samples
In this study, I had access to two patient samples. Both patients are enrolled in the
MelResist clinical trial, which is an ongoing study investigating the resistance to gene-
targeted melanoma therapies [51]. Both patients have metastatic melanoma. The samples
were collected prior to immunotherapy.
The patient referred to as patient1 received radiotherapy prior to sample collection.
The sample was taken surgically from this patient’s lung metastasis. This patient was
operated on as the tumor was compressing the lung [James Thaventhiran, personal
communication, August 8, 2018].
The second patient, patient2, did not receive any prior treatment. The sample was
collected with a needle biopsy [James Thaventhiran, personal communication, August 8,
2018].
2.4 Pre-processing of RNA-seq data
patient1 and patient2 samples were processed using the 10x Genomics Chromium Single
Cell Immune Profiling Solution to produce 10x-barcoded libraries. For sequencing, the
libraries were run on the HiSeq 4000 platform outputting 150 x 150 bp paired-end reads.
Prior to Cell Ranger v3.1, which introduced changes to the assembly algorithm2, the
required read lengths for GEX libraries were 26 x 98 bp, and 150 x 150 bp for the V(D)J
enriched libraries. When sequencing patient1 and patient2 samples, in order to cut the
sequencing cost, all libraries were placed on the same lane and sequenced for 150 x 150 bp
1It should be noted that the enrichment kits target neither the constant regions of TCR γ and δ
chains, nor the IgE antibody. However, it is possible to design custom primers to capture these sequences.
2Changes to the assembly algorithm allow V(D)J libraries to be sequenced at 26 x 91 bp instead
of 150 x 150 bp. This enables V(D)J and GEX libraries to be sequenced in a single run. So while our
sequencing step was cutting costs and simplifying the workflow by increasing the sequencing length of
the GEX libraries, 10x Genomics achieved this via improving their assembly algorithm which allowed
for the shortening of the V(D)J read configuration.
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paired-end reads. Therefore, following sequencing, V(D)J enriched library reads were
trimmed to 26 x 98 bp. Read 1 (R1) of GEX reads includes 16 bp of barcode and 10 bp of
UMI. Read 2 (R2) of GEX reads includes 91 bp of RNA-seq and 7 bp of the i7 index. R1
of V(D)J reads includes 16 bp of barcode, 10 bp of UMI, 13 bp of switch oligonucleotides,
and 111 bp of RNA-seq. R2 of V(D)J reads is all 150 bp of RNA-seq.
The raw data files generated by the Illumina platform are in Binary Base Call (BCL)
format. Using Illumina’s bcl2fastq, BCL files were converted into FASTQ format which
is a text-based sequence file format that records both raw sequence data and quality
scores. At this stage, for each library, there were multiple FASTQ files, ready to be
processed for UMI counting, and V(D)J reconstruction. The two main Cell Ranger
pipelines; cellranger count and cellranger vdj perform these steps, respectively.
2.4.1 The Cell Ranger pipelines
cellranger count performs GEX analysis on the RNA-seq data. The pipeline aligns
short reads to the specified reference transcriptome using the STAR aligner [57], performs
de-duplication of cDNA PCR duplicates, removes barcodes not associated with cellular
GEM partitions, and generates (gene x barcode) matrices by counting unique molecules.
cellranger vdj assembles all reads within a single cell, then annotates the assembled
contigs by aligning them to the provided BCR and TCR reference sequences. Alignment
is performed by seed-and-extend, where seeds are 12-mer perfect matches. Contigs that
are not productive are filtered out. Cells are grouped together into clones if they share the
same set of productive CDR3 nucleotide sequences by exact match. Hence, a clonotype
is defined as the set of exactly matching CDR3 nucleotides. This definition does not
account for B cell lineages arising via SHMs.
With cellranger count, I processed the FASTQ files in order to align, filter, and
count UMIs and generate a (gene x barcode) count matrix for each sample. I mapped
the sequences to the GRCh38 transcriptome.
2.4.2 Improving the Cell Ranger pipelines for accuracy
Cell detection
I processed the patient1 sample in June 2018, and the patient2 sample in August 2018,
with the then-current Cell Ranger version 2.2.0. The 10x Chromium platform has a cell
recovery rate of 65%. With approximately 14,000 loaded cells 3, the expected cell count
3For the patient1 sample, I do not have evidence of the actual cell count being 14,000. This load
was requested by the sequencing facility, but the actual numbers were not counted, but for the patient2
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for both samples was roughly 8K. However, overestimation in cell counting before loading
the sample and cell loss during sample preparation is common. Also, achieving a stable
cell count from human samples taken from the clinic, and maintaining it, is usually more
difficult when compared to cell harvest from mice.
cellranger count estimated 3,582 cells for the patient1 sample, and 993 cells for
the patient2 sample. These numbers were well below the expected count even after
considering the possible overestimation and deterioration of cells. Also, for both samples,
many of the reads 4 were not assigned to cell-associated barcodes. With droplet-based
sequencing, it is possible for some GEMs to have extracellular RNA rather than an intact
cell. Therefore we cannot just assume GEMs with positive UMI counts to be valid cells.
GEMs containing cells need to be differentiated from GEMs containing extracellular
RNA.
Let N be the expected number of recovered cells (which is 3000 by default and can
be specified by the user), and m be the top 1% of N barcodes. Cell Ranger version 2.2.0
cell calling algorithm sorts the UMI count of all barcodes in decreasing order and finds
the mth UMI count. The algorithm then determines a barcode as a valid cell if its UMI
count is greater than 10% of this count. However, in the context of tumor samples, this
assumption that RNA content varies by an order of magnitude among cells does not hold.
The TME comprises various type of cells, such as tumor cells, small TILs, large plasma
cells, and so on [111]. As the TME contains such cells that can be extremely diverse in
RNA content, this assumption would only recover the larger cells and consider smaller
cells to be background noise (see Figure 2.3).
Processing the B and T cell enriched libraries with cellranger vdj showed the total
unique immune cell receptor count to be higher than the total number of detected cells.
Moreover, after grouping the patient1 and patient2 samples based on cell type, clusters of
naive B and T cells could not be detected. The initial cell count was only representative
of large tumor cells, and highly active plasma B cells, whose expression levels were quite
high.
To overcome this limitation, I initially fit a mixture model to the UMI count to
filter out the background noise and also mark a low RNA barcode as a cell if it had a
productive BCR or TCR, as identified by cellranger vdj. I later discarded the falsely
called cells during quality check and clustering for cell-type identification.
sample, the loaded cell count was reported as 14,000 by the sequencing facility [Katarzyna Kania,
personal communication, June 20, 2018].
4The fraction of confidently-mapped-to-transcriptome reads with cell-associated barcodes were 57%
for the patient1 sample and 64% for the patient2 sample
































Fig. 2.3 UMI count distributions of samples patient1 and patient2 . Red dashed
lines show the UMI count threshold determined by the Cell Ranger version 2.2.0 cell calling
algorithm. Note how only the very large cell population is kept while majority of cell candidates
are discarded. Here, only barcodes with a UMI count of at least 10 are plotted.
However, a more elegant approach is presented in [150], where an expression profile
for GEMs containing extracellular RNA is identified, and each barcode is tested against
this profile and called as a valid cell if it shows a divergent expression profile. This
method is not based on the UMI count of a barcode but its expression profile, thus
ensuring that small TILs are kept while GEMs full of high levels of extracellular RNA
are discarded. Using this method as implemented in DropletUtils::emptyDrops(), I
obtained 8070 cells for the patient1 sample and 4241 cells for the patient2 sample (see
Figure 2.4), by specifying barcodes with UMI counts less than 150 and 60 to correspond
to empty droplets for each sample respectively. In each sample, barcodes with total UMI
counts less than the specified thresholds are used to estimate the profile of the ambient
RNA pool, and each barcode is then tested against this profile for deviations in order to
determine real cells. A fraction of these reads were later discarded during the QC step,
as described in Section 2.5.1.
Incorporating V(D)J reference from the IMGT database
I processed the BCR and TCR enriched RNA-seq data with cellranger vdj. Looking
at the reconstructed λ chains, we see that the J regions have a large deletion sequence.
This is a limitation in the default reference cellranger vdj uses. Due to licensing
restrictions, it is not able to distribute an IGMT-based reference. To this end, I built an
IGMT-based reference downloading the V, D, J, and C sequences from IGMT and used
it as a custom reference. Figure 2.5 shows the alignments using the default reference and
the IMGT reference. In addition to fixing the deletions, using IMGT has also allowed





























Fig. 2.4 UMI count distributions of the detected cells from the patient1 and patient2 samples.
for a better annotation of heavy and light V, D, J, and C segments, and revealed SHMs
within the variable domains. However, do note that the use of the custom IMGT reference
caused a discrepancy between the GEX and V(D)J gene annotations. In some cases, it is
no longer possible to detect the gene expression of an AgR sequence’s exact V, D, or J
gene directly from the (gene x barcode) UMI count matrix as the annotations are not
consistent. However, the gene family names are still the same.
Merging barcode information between GEX and V(D)J output
In version 3.0, Cell Ranger updated its cell-calling algorithm, which is heavily inspired
by [150]. This algorithm is further described in Section 4.3.4. Note that, in this
study, although I re-processed the samples using the updated pipelines (Cell Ranger
Version 3.0.25), I relied on DropletUtils::emptyDrops() to call cells. There is a
discrepancy between the cells called by the Cell Ranger pipelines cellranger count and
cellranger vdj. Barcodes accepted as cells via cellranger count with the updated
algorithm are not reflected in the AgR repertoires, i.e., a significant number of V(D)J
sequences are discarded claiming they are not reconstructed from real cells. In order to
keep the cell detection consistent, I retrieved these productive V(D)J sequences. Also,
the targeted cell calling algorithm implemented within cellranger vdj does not share
information with cellranger count, resulting in certain B and T cells going undetected
in the GEX analysis. I marked such barcodes as cells if the GEX profile was also consistent
with that of a B or T cell. I later inspected the additional B cells in Section 2.5.6.
5Cell Ranger Version 3.1 was deployed after the completion of this study
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(a) λ chain 1 (b) λ chain 1 with IMGT
(c) λ chain 2 (d) λ chain 2 with IMGT
Fig. 2.5 Screenshots from the Loupe VDJ browser showing alignments using the default
reference (a and c) and the IMGT-based reference (b and d). Here each row represents a chain
from a single cell, whose barcodes are given on the left. Consensus is the consensus of all the
chain sequences, and the reference is the V(D)J sequence to which they aligned to best.
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2.5 Gene Expression (GEX) Profiling
In this section, I present the downstream analysis of the patient1 and patient2 samples.
Within the remainder of this chapter, patient1 and patient2 samples refer to cells
harvested from each patient’s melanoma metastasis in the lung and processed with the
Chromium Single Cell Immune Profiling Solution.
2.5.1 Cell quality control and filtering
During the cell detection step, cells are separated from empty GEMs, however, there
may still be cells of low quality, such as dying cells, within the population. The three
main attributes used for cell quality check (QC) are (i) total UMI number per cell, also
referred to as library size, (ii) the total number of expressive genes per cell, and (iii) the
fraction of UMI count contributed by mitochondrial genes [105]. Outliers based on these
attributes may be removed as low-quality cells. However, the underlying biology must
be taken into consideration. For example, it is common in the literature to remove cells
with high levels of mitochondrial gene expression based on the fact that this could be an
indicator of dying or lysing cells. However, in tumor biopsies, this could be indicative
of the underlying biology as metabolic activity increases mitochondrial gene expression.
For example, mitochondrial activity may be indicative of activated B cells undergoing
class-switch recombination [108]. Additionally, these QC attributes must be inspected
together so that specific subpopulations are not removed. While it is common practice
to remove cells with low UMIs or a low number of expressed genes, in the TME these
can represent dysfunctional immune cells. Figures 2.6 and 2.7 inspect these attributes to
determine low quality cells.
Figure 2.7b shows that there are cells in the patient2 sample which are quite high
in mitochondrial UMI count but low in total expressed genes and UMI count. High
mitochondrial transcripts and a small library size or total detected genes is most likely
indicative of dead or dying cells (see Figure B.1 for plots of the mitochondrial UMI count
against the UMI count and uniquely detected genes).
I removed cells with total expressed gene count <100 in the patient1 sample, and <50
in the patient2 sample. Rather than placing a strict threshold on mitochondrial UMI
percentage, I used the robust Z-score method to detect outliers. Robust Z-score method,
instead of using the mean and standard deviation, uses the median and the deviation
from the median - median absolute deviation (MAD) - as the median and MAD are
robust measures of central tendency and dispersion. MAD is calculated by taking the
absolute difference between each point and the median, then calculating the median of
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(a) (b)
(c)
Fig. 2.6 (a) shows the library size distributions and (b) the detected gene distributions of the
patient1 and patient2 samples, while (c) plots them against each other to show cell complexity.
Each dot represents a cell. Color denotes whether an AgR was detected in a cell or not.
the differences. I determined outliers as cells having mitochondrial content more than 3
MADs away from the median. This removed cells with mitochondrial UMI percentage
>10.4% and >21.5% from the patient1 and patient2 samples respectively, resulting in
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(a) patient1 sample (b) patient2 sample
Fig. 2.7 For each sample, plots show the total number of detected genes versus the UMI count
colored by the percentage of UMI originating from mitochondrial genes. Cells with extremely
high mitochondrial percentage also have very low UMI counts and numbers of detected genes,
meaning these are dead/lysing cells. Without placing a threshold on the UMI count or number
of expressed genes, these are removed directly by filtering out high mitochondrial percentage.
an approximately 10% cell count decrease in each sample. High mitochondrial UMI
percentages have been reported in tumor samples [160].
2.5.2 Normalization
The UMI count of a single gene in a single cell is dependent on the successful capture,
lysis, reverse transcription, and sequencing of an mRNA molecule. When sufficient
sequencing saturation6 is realized, the UMI count can be a direct measure of the cDNA
molecules associated with that gene [226]. However, this does not account for the technical
variation that may have arisen during the mentioned sampling processes. Normalization
methods such as counts per million, where UMI counts are normalized for each cell by
the total UMI count and multiplied by a scale factor (1M in this case), aim to address
this issue [244]. This method assumes that all cell types include a similar number of
mRNA molecules and that count depth variation is only due to sampling. However, in
a highly heterogeneous population like the TME, this assumption does not hold. The
pooling-based method described in [148] accounts for this cellular heterogeneity. Cells
are pooled together based on similar library sizes, and expression values are summed
6Sequencing saturation is the measure of the fraction of the total number of different transcripts in
the final library that was sequenced. The inverse of this measure would be a proxy for the number of
additional reads it would take to detect a new transcript. As sequencing depth increases, so does the
number of observed genes, but then this reaches a saturation point where no new genes are detected.
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across all cells in the pool, resulting in fewer UMI counts of zeros. The pools are then
normalized against a reference which is obtained by averaging all cells in the dataset.
This gives per-pool size factors. Repeating the same process for many different cell pools
constructs a linear system of equations that can be solved to obtain the per-cell size
factors. scran::computeSumFactors implements this method [149].
Fig. 2.8 Size factors plotted against the UMI count show that they are well correlated except for
some of the AgR expressing cells in the patient1 sample. This was also evident in Figure 2.7a.
I used scran::quickCluster to pre-cluster the samples so that cells in a cluster
have similar expression profiles, and later used scran::computeSumFactors to normalize
cells in each cluster separately. scran::computeSumFactors re-scales size factors for
comparison between clusters. Finally, I used scater::normalize to normalize the count
data using the computed size factors, and log2 transformed the normalized data.
2.5.3 Determining cell-cycle stage
Cell-cycle is a biological effect which can introduce heterogeneity within the same cell
type [37]. During the cell-cycle, in the G1 stage cells increase in size, replicate their DNA
in the S stage, and in the G2 stage they continue to grow and get ready to enter the M
(mitosis) stage in order to divide into daughter cells. Two cells of the same type may be
at different cell cycle stages and thus have different expression profiles causing these cells
to be clustered separately. It is thus essential to determine the cell cycle stage of each
cell. To this end, [207] have developed the method Pairs to infer the cell cycle stage of
a cell directly from its gene expression profile. Their classification algorithm, using a
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training dataset, found pairs of genes such that their difference was positive in one phase
while negative in others, i.e., one gene is more highly expressed than the other in one
phase, whereas it is lowly expressed in the other phases. As these genes present a specific
behavior across phases, they are selected as marker pairs, which can classify cells into
phases. Then, using these pairs, cells in the test dataset are assigned probability scores
for phases G1 and G2M.
For each cell, when either G1 or G2M score is greater than 0.5, it is assigned to the
phase with the score higher than 0.5, when they are both less than 0.5 it is assigned to
phase S, and when they are both greater than 0.5 no assignment is carried out.
A slightly altered version of this method is implemented in scran::cyclone with an
existing pre-trained set of marker pairs for human data. Using this function, I assigned
cell cycle stages to cells based on their normalized gene expression data (see Figure 2.9).
(a) patient1 sample (b) patient2 sample
Fig. 2.9 Cell cycle phase scores of samples are plotted. Each point represents a cell. Red lines
separate cell phases and the proportion of cells in each phase is labelled.
It is possible to correct for the effects of cell-cycle stage using various methods [37],
[38], however cell-cycle stage can be informative of the underlying biology. The choice
should be made based on the research question and the required downstream analysis.
For example, correcting for cell cycle effects can reveal further differentiation trajectories
[37], but keeping the cell cycle information can help identify proliferating subpopulations.
In this study, I did not remove the cell cycle effects, but having identified the cell cycle
stage, I was able to identify separate clusters of the same cell type.
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2.5.4 Dimensionality reduction using PCA
For each of the samples, there are >20,000 genes with a positive average expression across
all cells. However, not all of these genes will be informative in the downstream analysis.
Highly variable genes (HVGs) are genes that reflect the variability in the data. In order to
select HVGs, I used the scran::decomposeVar function which decomposes the variance
of a gene into biological and technical components. Based on [149], I assumed that the
technical component follows a Poisson distribution. The biological component is then
computed by subtracting this from the total variance. HVGs are determined as genes
with positive biological components.
(a) patient1 sample (b) patient2 sample
Fig. 2.10 Normalized, log2-transformed expression values of the 20 HVGs with the highest
biological components in each sample. Each point represents a cell.
In the patient2 sample, mitochondrial (MT-*) and ribosomal genes (RPL*/RPS*)
seem to have large biological components. The low expression of ribosomal protein
mRNA can signify cells that are in atrophy or that the cell’s cytoplasm is damaged, and
usually in scRNA-seq data analysis these cells are discarded. However, in the context of
cancer these ribosomal genes can be determinant of normal and malignant human cell
types [88]. There are studies which have revealed that certain ribosomal genes act as
tumor suppressors while some contribute to tumor growth [230], [116]. In this study I
did not remove cells based on ribosomal expression content.
Gene selection reduced the gene count to half. However, the expression data can
be further reduced. scRNA-seq data is inherently low dimensional owing primarily to
the co-regulation of genes [97]. Hence, the high dimensional (gene x cell) matrix can
be represented in a lower-dimensional space. To summarize the gene expression data, I
used PCA as implemented in scran::denoisePCA where PCs linked only to biology are
identified and kept while discarding those corresponding to technical noise.
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I excluded the 13 protein-coding genes located on the mitochondrial chromosome
(MT-ATP6, MT-ATP8, MT-CO1, MT-CO2, MT-CO3, MT-CYB, MT-ND1, MT-ND2,
MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6) the ribosomal genes (RPL*/RPS*),
Ig genes IGH*/IGK*/IGL*, and the TCR coding TRA*/TRB* genes from the PCA as I
did not want these genes driving the clustering directly.
2.5.5 Graph-based clustering using community detection
In order to determine cell identity, it is common practice to group cells together based
on the similarity of their gene expression profile. The resolution of this grouping is
based on how detailed the cell identity should be. For example, adaptive immune cells
can be subgrouped as B and T cells, and the T cells can be further separated as CD8+
cytotoxic T cells, CD4+ helper T cells, and CD4+ FOXP3+ Tregs. In parallel, the same
cell types can be in different states. For example, in the TME, CD8+ T cells can be in a
gradient of dysfunctionality states [140], which can be further partitioned into multiple
groups. Furthermore, not all groups will represent true cell identity; partitioning may also
depend on various biological or technical variations, such as cells with high mitochondrial
content, cells in a specific cell cycle phase, or cells coming from the same batch, and so
on. Therefore, the resolution and the drivers of separation should be determined based
on the research question. In this study, I aimed to identify B and T cells, and more
specifically, the differentiation of B cells into plasma cells, and the abundance of these
plasma cells.
In order to characterize the heterogeneity of the cell population and group the cells
based on their gene expression profile without any user input, various unsupervised
clustering algorithms have been employed, including k-means clustering, hierarchical
clustering, and graph-based algorithms [119]. In this study, I used a graph-based method.
A graph is a collection of vertices (or nodes) that are connected by edges. The cell
population can be represented as a weighted-graph where each node is a single cell,
and cells similar in terms of their gene expression profile are connected with edges that
convey the strength of this similarity with associated weights. When the cell population
is represented as a similarity graph, clustering can be then achieved by finding highly
intraconnected but well-separated subgraphs.
To build this graph, I used a shared nearest neighbor (SNN) method [255] which cap-
tures the similarity between two nodes in terms of their connectivity in the neighborhood.
First, a similarity matrix between cells is computed using Euclidean distances in their
gene expression profiles. Next, for each cell ci, its k nearest neighbors are listed using
the similarity matrix, with ci as the first entry in the list. An edge e(ci, cj) is drawn
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between ci and another cell cj, only if they have at least one shared neighbor in their
list. The weight of the edge e(ci, cj) is equal to k - r, where r is the minimum averaged
sum of ranks in their nearest neighbor lists for any shared neighboring node. So cells
that are genuinely from the same cluster will have smaller r and hence highly weighted
edges, as the ranking of their shared neighbors are expected to be high. High-dimensional
data is usually sparse, and therefore the similarities measured by conventional distance
metrics tend to be low between nodes [19]. SNN takes the primary similarity, and using
ranks preserves its meaning in high-dimensional space. I applied this method to each
sample, computing the similarity matrices using Euclidean distances on the reduced PCA
space obtained previously via scran::denoisePCA, and specifying k=10 as the number
of nearest neighbors to consider when building the graph.
Having constructed an SNN graph to represent the cell population, clustering is now
about finding subgraphs. In graph theory, one approach in finding subgraphs is to look
for groups of nodes that are heavily connected within, but sparsely connected to the rest
of the network [69]. Such intraconnected nodes are referred to as “communities”. A good
number of community detection methods have been developed where the common goal is
to better identify meaningful communities while maintaining a reasonable computational
complexity. [69] and [256] provide a review and a comparative analysis of some of the
well-known community detection algorithms to date. WalkTrap [182] is a node-similarity
based algorithm where, at each time step, an agent moves from a node vi to a linked
node vj by randomly picking a neighbor of vi. The idea is that these random walkers
tend to get “trapped” in a community. If vi and vj are in the same community, the
probability of getting to a third node vk in the same community with a random walk
should be similar for both nodes. Another class of community detection algorithms,
namely modularity-based community detection, aims to maximize the assignment quality
score called modularity, which evaluates the connectedness of nodes in a community
compared to their connectedness in a random network. The Louvain algorithm [78] is an
efficient modularity-based algorithm that performs well with large networks. Initially,
each node is considered a community on its own. Step by step, nodes are moved to
other communities so that the highest contribution to modularity is achieved. When no
further improvement is possible, the network is aggregated such that each community
is considered to be a node on its own, and the same improvement process is repeated.
The algorithm stops either when only a single node is left, or the modularity cannot be
further increased.
I used both WalkTrap and Louvain community detection algorithms as implemented in
the functions igraph::cluster_walktrap and igraph::cluster_louvain in order to
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detect subgraphs within the cell network of the patient1 and patient2 samples. WalkTrap
found more communities when compared to Louvain7. WalkTrap was more granular, and
the communities it detected were in fact, subcommunities of the ones detected via Louvain,
so it was detecting further communities within Louvain communities. As mentioned
before, the resolution of clustering is a choice. For example, while Louvain did not separate
CD20+ B cells and T cells in the patient1 sample, WalkTrap detected these as separate
communities. However, by inspecting communities for gene expression, incremental
subclustering (clustering within communities) can resolve such communities. I chose
the Louvain algorithm as the resolution achieved with the algorithm was satisfactory
for me to answer my research question, and there was no assignment difference between
the algorithms other than the higher resolution (see Figure B.2 for the comparison of
community detection on the patient2 sample.).
Figures 2.11 and 2.12 show the cell frequency in each community as detected by
Louvain, as well as the distribution of library sizes, and of mitochondrial and ribosomal
UMI fractions. As expected, these vary noticeably among certain communities. This is
discussed further in Section 2.8. In the remainder of this chapter, communities will be
referred to as clusters or cell clusters.
2.5.6 2D visualizations with Uniform Manifold Approximation
and Projection (UMAP)
In order to explore a scRNA-seq dataset, we reduce the data to 2D or 3D and use these
reduced dimensions as coordinates on a scatter plot where each point represents a single
cell. A straightforward approach is to use the first two reduced principal components, PC1
and PC2, and visualize the scRNA-seq data. However, PCA is a linear dimensionality
reduction method meaning it can only capture linear structures in the features but not
the complex polynomial relationship between them. There are a number of non-linear
approaches to generate reduced dimensions, of which the most widely used for scRNA-seq
data visualization are t-SNE [245] and, more recently, UMAP [156].
t-SNE is a probabilistic dimensionality reduction technique that efficiently reveals local
similarity in the high-dimensional data and is the most widely used method in scRNA-seq
data visualization. However, t-SNE does not capture the global structure of the data;
while intraconnected points are projected onto lower dimension preserving their distances,
intercluster relationships are not reflected in the lower-dimensional projection [18]. With
7WalkTrap detected 20 communities for the patient1 sample and 27 for the patient2 sample, whereas
Louvain detected 14 and 15 communities for each sample, respectively.







































































Fig. 2.11 For the patient1 sample, (A) shows the cell frequency in each cluster, and (B-D)









































































Fig. 2.12 For the patient2 sample, (A) shows the cell frequency in each cluster, and (B-D)
show the distribution of library sizes, and of mitochondrial and ribosomal UMI fractions.
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t-SNE, the differences between different cell populations are no longer meaningful in the
low-dimensional space.
UMAP is a computationally more efficient alternative that also preserves both the
local and the global similarity present within the dataset. By preserving the global
structure, UMAP can recapitulate the differentiation stage of different cell types, while
t-SNE can only identify such trajectories within an individual cell type cluster [18].
Furthermore, UMAP helps in identifying less obvious cell cluster identities as similar
cell clusters will be in closer proximity. In this study, I used UMAP with the prior
reduced and denoised PCs in order to speed up the computations and reduce possible
noise. Figures 2.13 and 2.14 show the scRNA-seq data projected onto two dimensions
with UMAP where each point representing a cell is colored by cell metadata. In this
thesis, unless otherwise stated, all UMAP visualizations plot the UMAP estimated first
two dimensions.
By reflecting gene expressions onto the 2D projections, and observing the upregulation
of known biomarkers in distinct clusters, I determined cluster identity. For less obvious
clusters, I performed differential gene expression analysis between clusters with pairwise
Welch t-tests as implemented in scran::findMarkers. Figures 2.15 and 2.16 show the
expression of genes which distinguish clusters, and Figures 2.17 and 2.18 show the UMAP
embedded scRNA-seq data where each point is colored by cluster membership, and
clusters are annotated with cell identity.
Among some of the cells, I detected unexpectedly high levels of Ig gene expression
(see figure B.10). I further inspected these cells for their gene expression profile, and a
small number of them in the patient2 sample showed expression of only Ig genes (see
Figure B.11). These are ambient antibody transcripts rather than intact cells.
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Fig. 2.13 UMAP of the patient1 sample colored for UMI count, total detected gene count,
mitochondrial UMI percentage, and cell cycle phase. Each dot represents a cell.
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Fig. 2.14 UMAP of the patient2 sample colored for UMI count, total detected gene count,
mitochondrial UMI percentage, and cell cycle phase. Each dot represents a cell.
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Fig. 2.15 Cell identification of the patient1 sample. UMAP embedded data is colored by
known biomarker expressions from low expression (gray) to high expression (red).
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Fig. 2.16 Cell identification of the patient2 sample. UMAP embedded data is colored by
known biomarker expressions from low expression (gray) to high expression (red).
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Fig. 2.17 Cell identification of the patient1 sample. UMAP embedded data is colored by
cluster membership. Each cluster is annotated for cell identity.
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Fig. 2.18 Cell identification of the patient2 sample. UMAP embedded data is colored by
cluster membership. Each cluster is annotated for cell identity.
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2.6 V(D)J Reconstruction
In the patient1 sample, in 1,573 cells a full-length, productive BCR, and in 1,999 cells a
full-length, productive TCR was detected, while in the patient2 sample, 1,486 and 819
cells were found bearing a full-length, productive BCR and TCR, respectively.
2.6.1 BCR repertoire
The high number of Ig gene expressing cells in the samples can be due to background
noise introduced by plasma B cells and B cells with high levels of RNA, which might
have leaked during sample preparation, and thus we are picking up transcripts present in
the fluid rather than in intact cells. Further inspection of these cells for BCR expression
revealed that some of them only express single chains, and these chains are, in fact,
shared with a high-frequency clonotype with paired chains. Additionally, some of these
chains have only one UMI, which also strengthens the possibility of the detected BCR
coming from ambient RNA. To detect the likely B cells, I only kept cells with at least one
heavy and one light chain having a minimum of two UMIs. I also removed cells that had
an even number of multiple heavy and light chains that were shared with other, more
frequent clones as these were most likely doublets. This resulted in 236 BCR expressing
cells in the patient1 sample, and 237 in the patient2 sample. In the patient1 sample, I
detected 129 unique clonotypes, and 64 in the patient2 sample. Recall that clonotypes
are distinguished by the set of CDR3 amino acid sequences. In Figure 2.19b, observe
that the patient2 sample has a clonotype which makes up 59% of the BCR repertoire
while the most frequent ten clonotypes in the patient1 sample make up 46.55% of the
sample’s BCR repertoire.
2.6.2 TCR repertoire
Similar to the filtering with BCR expressing cells, I only kept the cells with at least one
TRA and one TRB chain with a minimum of two UMIs per chain and removed possible
doublets which had an even number of multiple TRA and TRB chains that were shared
with other clones. In the patient1 sample, this resulted in 810 TCR expressing cells and
631 unique TCR clonotypes, and with 561 TCR expressing cells and 338 unique TCR
clonotypes in the patient2 sample.
cellranger vdj pipeline detected more cells, especially T cells, in each sample
and AgR repertoire, however, the cellranger vdj pipeline does not check for possible
low-frequency chains present in clonotypes that share their other chains with a higher




















































(d) patient2 sample TCR repertoire
Fig. 2.19 BCR and TCR clonotype repertoires of each patient are shown either as the number
of occurrences or the fraction of clonotypes in the repertoires. The y-axes are free-scaled
between samples.
frequency clonotype. The pipeline does not consider possible residual transcripts; the
transcripts which are usually detected with a single UMI and create false clonotypes of
multiple chains. Furthermore, the pipeline does not analyze single-chain clonotypes. They
are kept as is without checking if they are, in reality, coming from a higher frequency
clonotype. Figures B.3 and B.4 show the clonotypes called by the cellranger vdj
pipeline. In Figure B.3, the 6th clonotype has a chain (IGKV3-11:IGKJ3:IGKC) which
has five contigs made of six UMIs while the other chains have a median UMI to contig
ratio >15. This chain is a residual transcript and is creating a false clonotype when,
in fact, these cells belong to the 1st clonotype, which also happens to be the most
clonally expanded. This is also the case for the 8th clonotype. Though not visible in
the screenshots, this is, in fact, the case for 14 clonotypes; they all merge with the
most dominant clonotype resulting in an additional 26 cells for this clonotype. Also, in
Figure B.4, observe the abundance of single-chain TCR clonotypes. This is also present
in Figure B.3.
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2.7 Results
2.7.1 Clonal plasma cell expansion
Integration of GEX and V(D)J data
Recall that once the cells are barcoded with the 10x beads inside individual GEMs, they
are broken, and all the transcripts mix. Some of these transcripts come from cells bearing
a BCR or a TCR. cellranger count and cellranger vdj rely on different algorithms
and assumptions when detecting cells, and therefore, a discrepancy can arise among
the detected cells. I aimed to overcome this by merging cells as previously described.
However, some BCR and TCR expressing cells may have been missed due to (i) low
expression levels for one of the chains resulting in a single chain receptor, or (ii) low
expression levels, in general, resulting in undetected chains by cellranger vdj, or (iii)
a cell being discarded by QC. Therefore, the cells here which I integrate in terms of the
GEX and V(D)J data are definitely B or T cells, but there may be more within the cell
population, but a chain-pair (or more) with sufficient UMI count was not detected in
those cells.
GEX profile of BCR bearing cells
I overlaid the clonotype information on the UMAP embedded scRNA-seq data in order
to visualize the clustering and abundance of the detected clonotypes. Note that, from
each AgR repertoire of each sample, I took the most clonal five clonotypes and assigned
them a unique id while keeping all the other clonotypes labeled as “other” in order to
prevent unnecessary noise. Figures 2.20 and 2.21 show the projections of each sample
with the t-SNE reduction. t-SNE allows for a spread out visualization (since the global
distances are not preserved) which is more helpful in this case. The UMAP visualizations
are shown in Figures B.5 and B.6.
Sample ID CDR3.aa Frequency Fraction
Patient1
P1.BCR1 IGH:CASGAGEDAAMVTILFDYW;IGL:CSYAGGYTWVF 45 0.190
P1.BCR2 IGH:CARGMDYDSSGYYFRFDYW;IGK:CQQRSNWPPWTF;IGL:CAAWDDSLNGGVF 34 0.140
P1.BCR3 IGH:CASGAGEDAAMVTILFDYW;IGL:CQVWDSSSDHWVF;IGL:CSYAGGYTWVF 10 0.042
P1.BCR4 IGH:CARGMDYDSSGYYFRFDYW;IGL:CAAWDDSLNGGVF 9 0.038
P1.BCR5 IGH:CARDGGDKQYCSGGNCYFFDSW;IGK:CQQSYSIPYTF 3 0.013
Patient2
P2.BCR1 IGH:CARRVGATSAFDIW;IGL:CQSGDSRLTFVVF 140 0.590
P2.BCR2 IGH:CARDIGVRGLFLKTYHYGLDVW;IGK:CQHCDDSNQAF 14 0.059
P2.BCR3 IGH:CAKDIIKGRGDYAMDVW;IGL:CGTWDSSLSAVVF 5 0.021
P2.BCR4 IGH:CATEISCSGDDCRDHW;IGK:CQQYDSWPRNTF 4 0.017
P2.BCR5 IGH:CAVDFWNGFLRGFFDSW;IGK:CQQYFTTPRTF 3 0.013
Table 2.1 Details of the BCR clonotypes that are reflected onto the 2D projections.
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Fig. 2.20 Clonotype projection of the patient1 sample. t-SNE projection is colored by clonotype
membership. A BCR was not detected in cells colored with dark gray (7,127 cells). P1.BCR1:45,
P1.BCR2:34, P1.BCR3:10, P1.BCR4:9, P1.BCR5:3 cells. Other:135 cells.
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Fig. 2.21 Clonotype projection of the patient2 sample. t-SNE projection is colored by clonotype
membership. A BCR was not detected in cells colored with dark gray (3,875 cells). P2.BCR1:140,








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2.22 Cell cycle stage distribution within the most dominant five clonotypes of each sample
are given in (a-b). Cell counts may be less than the actual count as not all cells were assigned
a phase. (c-d) overlays the G1 score on the t-SNE projections of each sample to further show
the replicating cells. Gray colored points indicate the cells which were not assigned a cell cycle
phase (52 cells in the patient2 sample, none in patient1 ).
P2.BCR1 clonotype in the patient2 sample displays a significant intratumoral clonal
expansion. Figure 2.22b further shows that it is also proliferating as cells bearing this
clonotype are in S and G2M cell cycling stages. Also, recall that the phase assignments
are based on thresholds on the G1 and G2M scores, so it is possible that there are, in
fact, more cells that are likely proliferating.
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Class-switching in BCRs
In both samples, IgG isotypes were the most common. The patient2 sample’s BCR
repertoire had very few IgM isotypes, and no IgD isotypes were detected. In the patient2















Fig. 2.23 Distribution of Ig isotypes in each sample’s BCR repertoire.
SHM
Other than GEX profile and class-switching, SHM is also an indicator of antigen challenge.
cellranger vdj detects mutations within the assembled contigs. With all the contigs
that belong to the same clonotype chain, a consensus contig is generated. Figure 2.24
shows the consensus alignment to the reference IMGT sequence for the chosen P2.BCR1
clonotype’s heavy chain. Here orange denotes the mutations, which are the possible
SHMs. However, as I only have scRNA-seq data, I cannot say with certainty that these
are SHMs; they could be point mutations in the patient’s genome.
Fig. 2.24 The consensus contig alignment of the P2.BCR1 clonotype’s heavy chain to the
IMGT reference. Image is a cropped screenshot of the Loupe VDJ Browser, Version 3.0.0, with
the cellranger vdj output of the patient2 sample loaded. Orange lines denote mismatches,
purple deletions, green start codon, dark gray is the CDR3 region, and light gray denotes the
contig coverage.
However, the GEX profile and the class-switching is enough evidence to show an
intratumoral expansion of the plasma cells within both samples, with the patient2 sample
demonstrating a highly clonal expanded one.
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2.7.2 Sequences of clonal intratumoral antibodies
In the patient2 sample, the P2.BCR1 clonotype demonstrates high clonality. Furthermore,
this clonotype has the GEX profile of mature and proliferating plasma cells. Class-
switching and SHM is further evidence of antigen challenge. Sequences in Listing 2.1 are
the nucleotide sequences of the heavy and light chains of this antibody, and Listing 2.2
is their IgBlast alignment to the IMGT reference which includes possible SHMs. This
antibody is a candidate for finding a melanoma tumor-antigen. With these sequences,
we can express the antibody, and further detect which antigen it binds. I discuss this in
Section 2.8.












13 > P2.BCR1.H{IGHV5 -51: IGHD1 -26: IGHJ3: IGHG2_CDR3 }
14 TGTGCGAGAAGGGTGGGAGCTACCTCTGCTTTTGATATCTGG













28 > P2.BCR1.L{IGLV3 -25: IGLJ2: IGLC3_CDR3 }
29 TGTCAATCGGGAGACAGCCGTCTTACTTTTGTGGTTTTT
Listing 2.1 Sequences of tumor-antigen specific antibody candidate


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.7.3 Tertiary lymphoid structure detection
Lymph nodes are where immunological components meet: T cells, B cells, DCs, plasma
cells, and macrophages gather inside a meshwork of connective tissue created by SLO-
resident fibroblasts, also known as fibroblastic reticular cells (FRCs) [68]. Lymph nodes
facilitate the initiation of an adaptive immune response by funneling the antigens and
antigen-presenting cells towards B and T cells. Tertiary lymphoid structures (TLSs) are
ectopic lymphoid-like structures, and they have been observed in various solid tumors,
including melanomas [48].
Tumor-associated TLSs are composed of a T cell rich outer zone that contains mature
DCs, surrounding a ring of naive B cells around a GC that contains mostly B cells,
with a smaller number of T cells, follicular DCs (FDCs), macrophages, and FRC-like
reticular cells [80], [36]. FRCs can be defined by the expression of the surface molecules
podoplanin (PDPN) and platelet-derived growth factor receptor-α (PDGFRα) and the
lack of platelet endothelial cell adhesion molecule (PECAM1) and CD45 (PTPRC) [36].
The FRCs and FDCs may be the source of the chemokines CCL19, CCL21, CXCL13,
and CXCL12, which are known to regulate the SLO microenvironment and have also
been observed in the intratumoral TLS microenvironment [63].
Various studies have proposed TLS gene signatures, and they are either chemokine
or cell population based [201]. One geneset comprising 12 chemokines, including the
aforementioned CCL19, CCL21, CXCL13, and CXCL12, have been used as a proxy
for TLS presence in melanoma [158]. Also, a plasma cell specific signature comprising
the expression of TNFRSF17 has been proposed to characterize the TLS in ovarian
cancer [158]. For both samples I have previously demonstrated the presence of B lineage
cells (CD19+, CD20+, MZB1+/TNFRSF17+ plasma cells), and T cells (including CD8+,
CD4+, CD4+FOXP3+). In Figure 2.25a, observe the presence of FRCs which carry
the gene expression profile PDPN+PDGFRA+PECAM1-PTPRC-. The patient2 sample
lacks such cells; recall however that this sample was obtained with a needle biopsy. In
addition to the FRCs, observe the cells which are CD45+CD4+CD3-. These cells show a
hematopoietic lymphoid tissue inducer (LTi) cell profile [16] and are potentially important
for lymph node formation. Besides these cell populations, I have also inspected both
samples for chemokine expression. Figures 2.26 and 2.27 show the expression levels of the
12-chemokine signature geneset taken from [158], comprising CCL2, CCL3, CCL4, CCL5,
CCL8, CCL18, CCL19, CCL21, CXCL9, CXCL10, CXCL11, and CXCL13. Figures 2.26a
and 2.27a evaluate the expression of the the 12-chemokine signature by calculating the
mean expression of the geneset on the normalized counts.







Fig. 2.25 t-SNE projections of biomarker expressions showing the presence of FRC-like reticular




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2.26 t-SNE projections of TLS associated chemokine expressions in the patient1 sample.
(In (a), gray: low, blue: high expression. In (b-d) gray: low, red: high expression)
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 2.27 t-SNE projections of TLS associated chemokine expressions in the patient2 sample.
(In (a), gray: low, blue: high expression. In (b-d) gray: low, red: high expression)
2.8 Discussion 69
2.8 Discussion
The role of the effector T cells in anti-tumor immunity has been studied in depth,
revealing that effective ICB therapies require the revival and clonal-proliferation of the
pre-existing mass of antigen-experienced TILs in the TME [242], [214], [6], [26]. The role
of B cells, however, is less clear and has only recently gained attention [241], [254]. In
this study, I characterized TIL-Bs in melanomas, revealing CD19+, CD20+, and plasma
B cells, as well as proliferating B cells at various differentiation stages. Furthermore, by
coupling their gene expression profile with their BCR clonotype, I was able to detect
clonally expanded plasma B cells.
The abundance of TIL-Bs and TILs show the cooperation of the two adaptive immune
system lymphocytes. Also, in both samples, I detected CD3-CD4+CD45+ cells which
show an LTi cell profile [16]. Some of these cells also expressed BCL6, which could
indicate the presence of BCL6+ T follicular helper (Tfh) cells [168]. Tfh cells help B cells
during GC reactions by mediating class-switching and SHMs, and facilitating affinity
maturation. Additionally, I showed the presence of FRCs which carry the gene expression
profile PDPN+PDGFRA+PECAM1-PTPRC- and the 12-chemokine signature. The
detection of such cells suggests the formation of an intratumoral TLS, and our findings
are in agreement with previous studies [48]. The scRNA-seq results would need to be
further confirmed by a visual analysis of the stained sections of these tumor biopsies.
While it is widely accepted that CD8+ T cells drive anti-tumor immunity, studies of
TLSs suggest that B cells may also play an essential role [63]. Additionally, an association
between the presence of TLS and favorable prognosis has been reported for many solid
tumors [201]. In our study, the presence of TLS along with proliferating and clonally
expanded plasma B cells which express class-switched antibodies at baseline, may suggest
that there is already an ongoing coordinated intratumoral immune response. The presence
of a TLS is less obvious in the patient2 sample, however, it is important to note that this
sample was obtained with a needle biopsy, which usually recovers only a limited amount
of tissue. It has been shown that TLSs are more abundant in the invasive margin or the
stroma, and a wider sampling of the tumor is beneficial in detecting a TLS [201].
Both samples showed presence of plasma B cells where the patient2 sample’s Ig
repertoire demonstrated higher clonality and clonal proliferation. By using single-cell
sequencing coupled with targeted VDJ sequencing, we were able to detect the proliferation
of this antibody-secreting plasma cell. The most dominant clonotype in this sample,
P2.BCR1, expressed the heavy chain IGHV5-51:IGHD1-26:IGHJ3:IGHG2 and the light
chain IGLV3-25:IGLJ2:IGLC3. The heavy chain shows both class-switching and possible
SHMs. This intratumoral antibody is generating an immune response towards an
70 Characterization of the melanoma TME and antibody repertoire
intratumoral antigen which is a candidate for a melanoma tumor-antigen. Using the
sequences given in Listing 2.1, it could be possible to express this antibody in mammalian
cells (i.e. HEK293 cells), and find the antigen it binds upon successful antigen-antibody
recognition.
The TME is a highly heterogeneous microstructure [111]. Ideally, the clustering of
cells should be driven mainly by the biological component of the gene expression profile.
However, it can be reasoned whether other factors such as the differences in library
sizes of different cell types or mitochondrial gene expression levels should be considered
biological or technical in nature. For this analysis, I decided not not remove the effects
of library size and mitochondrial UMI count proportions from the scRNA-seq data. The
fact that clustering is exploratory data analysis is much more evident when immune
components are in question. While it is possible to cluster based on high-level cell types
(B, T, DC, NK, and so on), we can further zoom in to separate CD8+ T cells from CD4+
T cells, or mature plasma B cells from high-metabolic-activity proliferating plasma B
cells. It should be noted that all of the cell QC and clustering outlined in this study was
an incremental process which took many attempts. Another source of variation, the cell
cycle heterogeneity in scRNA-seq data, may assign the same type of cells into multiple
clusters. Therefore it is common practice to remove the cell cycle effect from the data.
The effects of cell cycle can be most evident in homogeneous cell populations. However,
in this study I was not interested in detecting a new cell type or trajectories, but was
instead aiming to determine the clonality and proliferation of the components within the
TME. Hence I only determined the cell cycle phase of each cell but did not remove this
effect.
In this study, I characterized the TME of two melanoma metastases taken pre-
immunotherapy. Using the same technique, we can study all the patients in the MelResist
clinical trial for both pre- and post-immunotherapy in order to determine the effect of
baseline TIL-B and TLS presence on patient response. Moreover, we can determine
the fate of the clonally expanded antibodies post-immunotherapy and potentially find





The TME is infiltrated by various immune cells, and their presence has been shown to be
associated with clinical outcomes in some cancer types [206], [82], [264], [71]. The interplay
between the tumor and the immune cells is a complex process that determines the fate
of tumor immunity. To date, the majority of research has focused on tumor-infiltrating
T lymphocytes [260]. In this chapter, I focused on the tumor infiltration capabilities
of B lymphocytes instead, specifically in two highly immunotherapy resistant cancers,
colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). Furthermore, I
studied the effect of a particular compound called AMD3100 [65] on the B cell responses
in CRC and PDAC. Ultimately in this study, using paired data from a clinical trial of
AMD3100 [50], I aimed to identify antibody sequences expanded after this particular
treatment in PDAC and CRC.
In Section 3.2, I explain immune privilege in PDAC and CRC and the ineffectiveness
of current immunotherapies towards these cancers. Next in Section 3.3, I present the
CAM-PLEX clinical trial [50], which assesses the efficacy of a new immunotherapy drug.
In Section 3.4, I use RNA-seq data of each biopsy pair to reconstruct patient immune
repertoires computationally. Later in Section 3.5, I introduce my findings, which reveal
the clonal expansion of single antibody clonotypes in some of the patients after therapy
and present the nucleotide sequences of these antibodies. Finally, in Section 3.6, I suggest
a possible future direction that could result in finding tumor-antigens of CRC and PDAC.
72 Intratumoral antibody sequences reconstructed from RNA-seq
3.2 Background
3.2.1 Immune privilege in CRC and PDAC
CRCs are malignant tumors of the colon and rectum arising primarily from neoplastic
colon polyps, which are small clusters of cells that form on the lining of the colon. CRCs
are the third most common cancers worldwide, with 1.8 million reported cases in 2018
and the second most common cause of cancer-related mortality, resulting in 862,000
deaths [250]. CRC has a reasonable chance of survival compared to other cancer types;
the five-year overall survival rate is 64%, with 90% of patients with localized cancer
surviving at least five years [9].
The pancreas has many functions, two of which are especially important: it harbors a
pool of exocrine glands aiding digestion, but has also an endocrine role. In particular, the
endocrine pancreas is composed of small islands of cells, namely the islets of Langerhans,
which release hormones, such as insulin, into the bloodstream. On the other hand, the
exocrine glands secrete various enzymes through the pancreatic duct into the duodenum
[40, Chapter 1, p. 3-20]. Uncontrollable growth of the exocrine cells may result in
pancreatic exocrine tumors, which make up 93% of pancreatic cancers [41]. PDAC,
a type of exocrine pancreatic cancer [100], which, even though is only the eleventh
most common cancer in women and the twelfth most common in men worldwide, is the
seventh most common cause of cancer-related deaths with a five-year survival rate of
only 9% [187]. The most effective treatment is surgery; however, only a small fraction is
resectable at the time of diagnosis, and even after resection, the five-year survival rate is
not particularly encouraging [267].
Although popular ICIs such as PD-1 and CTLA-4 inhibitors have delivered clinical
benefits in various solid tumors [130], [189], PDAC was not found to be responsive to ICIs.
In a Phase I trial, a total of 207 patients with advanced cancers, including melanoma,
CRC, and PDAC, were administered anti–PD-L1 antibody [31]. While a complete or
partial response was observed in nine of 52 patients with melanoma, no objective response
was observed in patients with CRC1 or PDAC. Similarly, in a Phase II trial evaluating
the efficacy of anti-CTLA-4, none of the enrolled 27 patients with advanced or metastatic
PDAC showed a response, and progression was rapid with a short survival [195]. It is
crucial to investigate which mechanisms protect these specific cancer types from immune
attack.
1It is important to note that, a number of clinical trials looking at the efficacy of ICIs in microsatellite-
instability-high (MSI-H) CRC [90], reported the objective response rate to be between 30% and 52%
[170].
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In PDAC, unlike other solid tumors that respond positively to immune checkpoint
blockade (ICB) therapies, intratumoral effector T-cells are rare [45], and certain immuno-
suppressive cells such as cancer-associated fibroblasts (CAFs) within the TME might
restrict the function of intra-tumoral effector T cells [65]. According to one hypothesis,
PDAC does not respond to anti-PD-L1 because the T cells may not be getting enough
contact with the cancer cells, as they are coated with high densities of chemokine (C-X-C
motif) ligand 12 (CXCL12), which is known to repel T cells [65]. In one well known
study, fibroblast activation protein (FAP) expressing CAFs have been shown to induce
CXCL12 mediated immunosuppression on the basis of three observations: intra-tumoral
T cells were not in the vicinity of cancer cells, cancer cells were coated with CXCL12,
and the FAP+ CAF was the primary source of CXCL12 in the tumor [65]. In order
to test this hypothesis, [65] used two different approaches. First, they demonstrated
that the depletion of FAP+ CAFs results in the immune control of tumor growth, and
recover the efficacy of anti-PD-L1 in PDAC bearing mice. Moreover, administering
AMD3100, a molecule known to disrupt the interaction between CXCL12 and its receptor
on immune cells CXCR4, increased the accumulation of effector T cells among cancer
cells. Finally, the combination of AMD3100 with anti-PD-L1 significantly diminished the
number of detectable cancer cells; however, anti-CTLA-4 did not augment the anti-tumor
effect of AMD3100. These findings led to a Phase I clinical trial of AMD3100, enrolling
patients with PDAC or microsatellite stable CRC (MSS-CRC) [90], which is discussed in
Section 3.3.
The immune repertoire in pancreatic cancer has been studied in the past. For instance,
[14] analyzed the TCR repertoire in pancreatic cancer. T cells were obtained from both
the primary pancreatic tissues and matched blood samples of 16 cancer patients, and
only from blood in the case of 8 healthy donors. Using deep sequencing of the TCRs,
they found no significant differences in the TCR repertoires between cancer patients and
controls. They did not identify any significantly expanded T cell clones. However, TCR
clonotypes with low frequencies were relatively more abundant in tumors when compared
to the matching blood samples.
In a different study, [99] investigated whether TCR repertoires could provide insights
into the mechanisms of immunotherapy and predict outcome in pancreatic cancers. TCR
repertoires were recovered using targeted deep sequencing. They examined the TCR
repertoires recovered from the peripheral blood of 25 metastatic pancreatic cancer patients
treated with ipilimumab (targeting CTLA-4) with or without GVAX (a pancreatic cancer
vaccine), and from the peripheral blood and tumor biopsies from 32 patients treated with
GVAX and mesothelin-expressing Listeria monocytogenes with or without nivolumab
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(targeting PD-1). Their results demonstrate a change of diversity in the peripheral TCR
repertoires of patients who received treatment, especially those receiving ipilimumab in
combination with GVAX. They determined the combination of low baseline clonality
and a high number of expanded clones post-therapy associated with significantly longer
survival in patients who received ipilimumab but not in patients receiving nivolumab.
Importantly, their study shows that TCR repertoire profiling can serve as a biomarker
of clinical response in pancreatic cancer patients receiving immunotherapy. It should
be noted that, neither study investigated the B cells and the BCR repertoire, and by
solely focusing on TCRs, they captured only one aspect of the adaptive immune response.
Analyzing the BCRs would give a more complete picture of the immunological status of
cancer patients and a better understanding of the anti-tumor immune response in PDAC
and CRC.
3.3 CAM-PLEX clinical trial
As already mentioned, [65] demonstrated that the blockade of the CXCL12/CXCR4
axis in a mouse model of PDAC resulted in the effector T cells and cancer cells to
intermingle, and reduced tumor growth when combined with anti–PD-L1 immunotherapy.
Consequently, a phase I clinical trial investigating plerixafor (AMD3100) in the same
cancer type was initiated [50].
3.3.1 Setup
CAM-PLEX clinical trial enrolled patients with MSS-CRC, PDAC, and ovarian cancers.
The aim of the phase I trial was two-fold: (i) study the molecular profiling of the
underlying mechanisms to determine if AMD3100 helps the immune cells to intermingle
with the cells of these cancers in humans, and (ii) find the highest safe dose of AMD3100
to administer. Cancer tissue biopsies and blood samples were taken from each enrolled
patient before (day 0) and after (day 8) AMD3100 treatment. It should be noted that
CAM-PLEX was a phase I single-agent only trial, i.e., patients were only administered
AMD3100 and no other ICB therapies. The main scientific aim of this investigation was
to assess whether the blockade of the CXCL12/CXCR4 axis would result in increased
immune cell infiltration and activation in humans.
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3.3.2 Dataset
In this thesis, I studied the RNA-seq data of the paired biopsies collected pre and post
AMD3100 therapy from metastatic sites. Table 3.1 shows the dataset. I had paired-end
RNA-seq reads from 21 patients, of which five had PDAC and 16 MSS-CRC. There were
a total of 37 samples, as five MSS-CRC patients (pat06, pat07, pat09, pat13, patX) did
not have post-therapy RNA-seq data.
Patient Time Pool Barcode Cancer Read count
pat01 day0 SLX-13655 D710_D503 crc 28,607,517
pat01 day8 SLX-13655 D710_D502 crc 31,681,242
pat02 day0 SLX-13655 D711_D501 crc 32,135,594
pat02 day8 SLX-13655 D710_D508 crc 27,091,124
pat03 day0 SLX-13655 D711_D505 crc 28,080,365
pat03 day8 SLX-13655 D711_D507 crc 25,628,945
pat04 day0 SLX-13655 D712_D505 crc 29,641,275
pat04 day8 SLX-13655 D712_D508 crc 26,712,999
pat05 day0 SLX-13655 D712_D502 crc 29,390,888
pat05 day8 SLX-13655 D711_D508 crc 26,519,678
pat06 day0 SLX-13655 D701_D501 crc 25,628,169
pat07 day0 SLX-13655 D701_D502 crc 32,607,604
pat08 day0 SLX-13655 D712_D506 crc 27,660,974
pat08 day8 SLX-13655 pat08day8 crc 51,126,382
pat09 day0 SLX-13655 D702_D501 crc 28,176,280
pat10 day0 SLX-13655 D710_D506 crc 26,534,718
pat10 day8 SLX-13655 D710_D507 crc 28,231,905
pat11 day0 SLX-13655 D710_D501 crc 31,990,182
pat11 day8 SLX-13655 D709_D508 crc 31,006,244
pat12 day0 SLX-13655 D711_D503 crc 27,994,609
pat12 day8 SLX-13655 pat12day8 crc 54,299,083
pat13 day0 SLX-13655 D702_D502 crc 26,357,112
pat14 day0 SLX-13655 D711_D504 crc 27,177,453
pat14 day8 SLX-13655 D712_D501 crc 29,629,240
pat15 day0 SLX-13655 D711_D502 crc 29,361,589
pat15 day8 SLX-13655 D710_D505 crc 28,333,433
patX day0 SLX-13655 D711_D506 crc 30,096,987
pat19 day0 SLX-15110 D701_D503 pdac 88,177,787
pat19 day8 SLX-15110 D702_D503 pdac 93,452,302
pat20 day0 SLX-15110 D701_D504 pdac 95,515,600
pat20 day8 SLX-15110 D702_D504 pdac 93,628,229
pat23 day0 SLX-16181 UDI0006 pdac 87,681,016
pat23 day8 SLX-16181 UDI0001 pdac 109,405,081
pat24 day0 SLX-16181 UDI0005 pdac 81,298,367
pat24 day8 SLX-16181 UDI0008 pdac 39,288,930
pat25 day0 SLX-16181 UDI0004 pdac 77,410,241
pat25 day8 SLX-16181 UDI0002 pdac 103,516,169
Table 3.1 CAM-PLEX trial dataset
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3.4 BCR repertoire recovery from paired data
In Section 1.3, I separated the current strategies of AgR reconstruction into two: targeted
repertoire sequencing-based protocols and computational reconstruction of unselected
RNA-seq reads. Here I will present the justifications of the chosen method and describe
the workflow.
3.4.1 Computational reconstruction of BCRs from RNA-sequencing
reads
The CAM-PLEX samples were sequenced with whole-exome sequencing, RNA-sequencing,
and AgR targeted sequencing, however only for TCRs. As I wanted to study the dynamic
BCR repertoire, I opted to reconstruct the BCR clonotypes directly from the available
unselected RNA-seq. Section 1.3.2 describes this approach and Section 1.3.5 presents a
review of the state of the art in computational reconstruction tools.
I investigated whether BCR repertoire clonality, class-switching, and SHM load and
location had an association with patient survival in melanoma. To this end, I used the
TCGA SKCM (Skin Cutaneous Melanoma) RNA-seq dataset comprising 468 cases [165].
I reconstructed BCRs from this dataset using MiXCR and V’DJer and observed that
MiXCR showed better computing performance. V’DJer requires the STAR aligner [57]
to align unselected RNA-seq reads prior to the assembly of V-J contigs. With STAR, the
alignment of a large set of 400+ data samples requires significant computation power.
Additionally, V’DJer has to be run three times in order to analyze all IGH, IGK, and
IGL chains, as tool execution expects a chain name as a parameter. Finally, V’DJer does
not analyze TCR chains. I did not evaluate TRUST on the TCGA dataset as it was
initially developed for TCR reconstruction and only recently provided BCR support. A
benchmarking of MiXCR, TRUST, and V’DJer can be found in [24], with a follow-up in
[101].
Based on computational performance and MiXCR specific features, I opted to use
a pipeline running sequential MiXCR tools to reconstruct the BCR clonotypes from
the CAM-PLEX unselected RNA-seq data. MiXCR can assemble full BCR and TCR
CDR3 sequences from unselected/non-enriched RNA-seq data and identify SHMs. The
developers of MiXCR added several enhancements in order to identify AgR clonotypes
from unselected RNA-seq data. The original tool is described in [25], whereas the
enhanced version is presented in [24].
MiXCR starts with aligning RNA-seq reads against reference V, D, J, and C genes. It
uses an altered version of a multi-seed strategy, called seed-and-vote, described in [142].
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With this strategy, from each read, many short, equal distanced subreads (seeds) that are
mapped without mismatches are found, and the number of consensus subreads (votes)
determines the best location for the read being aligned. Then using dynamic programming,
the alignment is completed by filling in the mismatch and indel information between the
subreads that make up the winning voting block. MiXCR has made further enhancements:
(i) Modified the seed size setting default as 5 bp, in order to handle short alignments.
(ii) In the voting step, a scoring function, calculated from the number of matching and
absent seeds and offsets of seeds relative to the optimal position in the sequencing read,
is maximized. Offsets are introduced to account for indels. After the selection of single
or multiple candidates, alignments for between seeds (using the Needleman–Wunsch
algorithm) and for outside seeds (using the Smith-Waterman algorithm) are built. Next,
alignment scores (scoring matrix and penalties for indels) are calculated for all candidates
to filter the best alignment. In [24], they further enhanced their alignment algorithm
to account for cases where V or J segment alignment is ambiguous by switching to
Smith-Waterman/Needleman-Wunsch algorithms directly in such cases. Performance is
only hindered for these specific cases, but they achieve higher sensitivity. After alignment,
two rounds of partial-contig-assembly are run. Here, aligned reads which cover only the
left boundary of CDR3 are merged with reads which do not cover the left CDR3 boundary
and cover part of the J gene. Merging is based on rules such that the minimum overlap
region is 12 bp, the overlap covers at least 7 non-germline-derived bases, and sequences
are a perfect match inside the overlap. This results in assembly of short, fragmented
sequencing reads into longer reads/contigs which contain a CDR3. After these steps,
MiXCR runs the assembly of aligned reads with clustering. Finally, the assembled contigs
are exported. The code snippet in Listing 3.1 is from this study’s pipeline and shows the
MiXCR component assembling the BCR and TCR contigs:
1 # align RNA -Seq reads
2 mixcr align --library imgt -p rna -seq -s hsa --report report .align.txt
-t 24 --save -reads -OallowPartialAlignments =true $read1 $read2
alignments .vdjca
3
4 # assembly of short reads
5 mixcr assemblePartial alignments .vdjca alignments_rescued_1 .vdjca
6 mixcr assemblePartial alignments_rescued_1 .vdjca alignments_rescued_2 .
vdjca
7 mixcr extend alignments_rescued_2 .vdjca alignments_rescued_2_extended .
vdjca
8
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9 # assemble default CDR3 clonotypes (--write - alignments is required for
further full contig assembly )
10 mixcr assemble --report report . assemble .txt -t 24 --write - alignments
alignments_rescued_2_extended .vdjca clones .clna
11
12 # assemble full BCR receptor sequences




16 mixcr exportClones -c IG -p fullImputed full_clones .clns full_IG_clones
.txt # full BCR receptors
17 mixcr exportClones clones .clna clones .txt # BCR and TCR assemblies
18 mixcr exportClones -c IG --filter -out -of - frames --filter -stops -count -
fraction -vGene -dGene -jGene -cGene -nFeature CDR3 -aaFeature CDR3
clones .clna clones .IG.txt # custom BCR dataframe output
19 mixcr exportAlignments clones .clna alignments .txt # alignments
Listing 3.1 Code snippet for assembling AgR contigs from paired-end RNA-seq reads
where $read1 and $read2 are the paired-end reads coming from a single sample. I have
passed imgt to the library parameter in mixcr::align in order to specify annotation
with the IMGT database.
3.4.2 Analysis of reconstructed clonotypes
Table 3.2 is an example of an output from MiXCR exported via mixcr::exportClones
passing the filtering parameters -c IG --filter-out-of-frames --filter-stops in
order to write only Ig chains that are not out-of-frame and do not contain stop
codons. Also, -count -fraction -vGene -dGene -jGene -cGene -aaFeature CDR3
were specified in order to customize the list of fields that were exported. Table 3.2 shows
the top six most clonal CDR3 Ig chains. cloneCount is the number of reads that make
up a clonotype, best<V,D,J,C>gene is the best <V,D,J,C> hit gene name.
cloneCount cloneFraction bestVGene bestDGene bestJGene bestCGene aaSeqCDR3
115929 0.1455473 IGLV2-14 IGLJ3 IGLC2 CSSYAITNSLVF
57129 0.0717247 IGHV3-30 IGHD6-13 IGHJ4 IGHG2 CAKDLRGNSWSFDYW
35502 0.0445723 IGKV1-12 IGKJ5 IGKC CQQAKSFPITF
30524 0.0383225 IGKV1-39 IGKJ4 IGKC CQQSHTNPLTF
25389 0.0318755 IGKV1-39 IGKJ2 IGKC CQQGYSSPYTF
17282 0.0216973 IGHV4-59 IGHD6-13 IGHJ2 IGHA1 CARGVSSSWYGPNWYFDLW
Table 3.2 Example of customized mixcr::exportClones output
MiXCR assembled a total of 1,522,531 BCR and TCR sequences, detecting 33,591
unique clonotypes. In all samples, the number of unique BCR assemblies was significantly
3.4 BCR repertoire recovery from paired data 79
higher than TCR assemblies, which is indicative of intratumoral antibody-secreting
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Fig. 3.1 Total number of uniquely detected BCR clonotypes plotted against the uniquely
detected TCR clonotypes. These clonotypes include both heavy and light Igs, and α and β
TCRs. Colors denote which type of cancer the sample belongs to. Annotated points are samples




























Fig. 3.2 Distribution of Ig isotypes across cancer types and time of sampling.
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Of all the Ig isotypes, IgG was the most abundant class, followed by IgA, and IgM
(see Figure 3.2). This shows that the majority of the detected Ig clonotypes are from the
secondary immune response, where B cells have encountered an antigen and differentiated
into plasma B and memory cells.
3.4.3 Normalizing clonotype count across samples
Looking at Table 3.1, we can see that some samples have relatively higher read counts.
This is because they are a combination of multiple re-sequencing runs. I merged all
sequencing reads per sample into a single read fastq file. Therefore we need to normalize
for read count when calculating the clonotype count (CC).
To normalize clonotype counts across samples I simply defined clone counts per
million (CCPM) reads which is clone counts scaled by the number of reads we sequenced,





where CCi is the clone count of the ith clonotype, and Nj is the number of fragments
sequenced for sample j.
However, it should be obvious that using this scaling, we cannot compare repertoires
across samples with highly variant read counts. Recall that MiXCR, and similar recon-
struction tools, rely on the number of AgR reads in a sample. It is more likely to detect
more unique AgR clonotypes the more RNA-seq reads a sample has. That is, the chance
of detecting an AgR increases with the number of reads processed. Furthermore, MiXCR
removes low-quality reads and performs error correction with clustering. The counts
reflected as CC are not all the reads, but the reads selected after QC and merged after
error correction. In order to accurately scale CCs to a comparable measure, one needs to
downsample the aligned reads to an equal amount, and better yet, use bootstrapping 2
to obtain CC confidence intervals per single-chain clonotype. However, on inspection of
Table 3.1 more closely, we see that the read count variation is between different cancer
type samples (crc vs. pdac), whereas reads coming from the same cancer tissue are more
or less the same. Although not 100% accurate, we can use CCPM when comparing
samples within tumor types, but not between. Furthermore, it is not the focus of this
thesis to compare different patient samples. I am interested in detecting an adaptive
immune response and recovering expanded clonotypes within a single sample. Also,
2In statistics, bootstrapping is a resampling method used to estimate statistics of a population by
sampling a dataset with replacement [60]. A confidence interval can be calculated to bound the estimate.
















































































































































































































































































































































































Fig. 3.3 CRC heavy (a) and light (b), and PDAC heavy (c) and light (d) clonotype frequency
distributions. Here, for each sample, the CCPM of top five most clonal clonotypes are shown.
Each color denotes a unique clonotype.
note that I am not calculating repertoire diversity/clonality. Though common in AgR
repertoire analyses, it is not the focus of this thesis. In such cases, we would need to set
all sample sizes to the size of the smallest sample to interpolate the diversity estimates
with a number of resamplings.
3.4.4 Aggregating clonotypes
In the MiXCR output, there are clonotypes with the same CDR3 amino acid sequence,
but different V, D, or J genes (see Table 3.3). The most likely interpretation of this
result is that MiXCR is mis-annotating some of the genes, as it is very unlikely for an
entirely different VDJ combination to have the same CDR3 amino acid sequence; this
would require an incredibly strong evolutionary convergence. Moreover, as we see this
82 Intratumoral antibody sequences reconstructed from RNA-seq
happen in almost every sample, for many different Ig chains, I think that a technical
artifact remains the most likely explanation.
cloneCount cloneFraction Best V;D;J;C gene aaSeqCDR3
2432 23.493 IGHV4-61;IGHD3-3;IGHJ3;IGHG2 CAREPLEFEGDFGPYDIW
78 0.753 IGHV4-34;IGHD3-16;IGHJ3;IGHG2 CAREPLEFEGDYGPYDVW
23 0.222 IGHV4-31;IGHD1-26;IGHJ3;IGHG2 CAREPLRFEGDYGAFDVW
16 0.154 IGHV4-4;IGHD3-16;IGHJ3;IGHG2 CAREPLEFEGDYGPYDVW
12 0.116 IGHV4-31;IGHD3-16;IGHJ3;IGHG2 CAREPLEFEGDFGPYDIW
8 0.077 IGHV4-28;IGHD3-16;IGHJ3;IGHG2 CAREPLEFEGDYGPYDVW
2 0.019 IGHV4-31;IGHD1-14;IGHJ3;IGHG2 CAREPLRFEGDYGAFDVW
Table 3.3 Example of incorrect clonotype annotation. Clonotypes with the same row color
have the same CDR3 amino acid sequence but differing VDJ gene combinations. Note that
cloneFraction is the fraction of the chain in the whole repertoire.
MiXCR determines clonotype uniqueness based on CDR3 nucleotide sequences. In-
stead, I define two clonotypes to be the same if they have identical CDR3 amino acid
sequences. Hence, I further merged all clonotypes by CDR3 amino acid sequences. More
abundant clonei will absorb less abundant clonej if clone count Nj < clone count Ni,
and both clonej and clonei have the same CDR3 region. This way we will be creating a
more compact clonotype list for each sample.
































































































Fig. 3.4 Decrease in clonotype count across samples after aggregation by CDR3 amino acid
sequence. Color separation is based on chain type where heavy chains are colored red and light
chains blue. Certain samples did not experience any decrease.
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3.5 Results
I define clonal expansion as the difference in the CCPM (3.1) of a clonotype between post
(day8) and pre (day0) immunotherapy. For this analysis, I am interested in detecting
Ig repertoires showing high B cell infiltration and clonal expansion, both of which are
summarised in Figure 3.5. From the plot we can immediately observe that patients 2,
8, and 11 from the CRC cohort, and 25 from the PDAC cohort show the highest B cell
infiltration, as well as the most clonally expanded clonotypes.
pat20 pat23 pat24 pat25
pat12 pat14 pat15 pat19
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Fig. 3.5 Clonal expansion of all Ig heavy clonotypes in a patient’s pre- and post-immunotherapy
repertoire. Each point signifies the difference between post- and pre-immunotherapy CCPM of
a clonotype. Note that the y-axes vary across patients.
Here, observe, for example, why patients 23 and 24 were not chosen. Both patients
had a high count of uniquely detected BCRs (see Figure 3.1). However, when we further
inspect the sum of the most clonally expanded clonotypes’ CCPM, we see that these
patients had a diverse BCR repertoire, i.e., even though they have a significant amount
of BCR clonotypes, none of them have expanded, as we can clearly see in Figures 3.5 and
3.6. We can observe that patient 25 has a high count of uniquely detected IgH clonotypes
as well as a high sum of CCPM, meaning its top clonal clonotypes expanded significantly.
This is not true for patients 23 and 24.
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Fig. 3.6 Sum of CCPM of top IgH clonotypes plotted against total uniquely detected IgH
clonotypes. Colors denote which type of cancer the sample belongs to. Annotated points
are samples with >350 detected IgH clonotypes. This threshold is chosen merely for ease of
readability.
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Furthermore, although patient 23 had an increase in uniquely detected BCRs, the
clonality of these clonotypes did not increase. However, do note that this could be due
to the increase in sequencing read count (see Table 3.1). The pat08.day8 sample has
roughly two-fold read count compared to most other CRC samples, due to multiple
re-sequencing. However, the same patient at day 0 also has a high CCPM. Hence it is
justifiable to select patient 8 as a strong immune response candidate.
3.5.1 BCR distributions
Here I present the Ig heavy and light chain CCPM distributions of the selected patients.

















































































































Fig. 3.7 Ig heavy and light chain CCPM distributions of the selected patients. Repertoires are
of pre-treatment (day 0) and post-treatment (day 8). For each repertoire, the most clonal 50
clonotypes are plotted. Note that the y-axes vary across patients, days, and chain types.
3.5.2 Pre and post-therapy BCR repertoires
Here, for the selected patients, I present the possible tumor-antigen specific antibody
sequences, and investigate the clonal expansion of the most clonal Igs in the post-
immunotherapy Ig repertoire. In some cases, the most clonally expanded clonotype of
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the post-immunotherapy repertoire is not present in the pre-immunotherapy repertoire.
This could be due to a lack of sequencing reads in the pre-treatment repertoire. We
could speculate that, although the Ig was expressed, it could not be picked up by MiXCR
as there were not many cells expressing that particular Ig mRNAs. We might recall
that MiXCR needs a certain number of assemblies in order to error correct for PCR
and sequencing noise. Furthermore, the low signal in the pre-immunotherapy repertoire
could also be due to read coverage. Observe that for each of the samples there are
other dominant clonotypes, and these could be dominating the read space. Hence the
first explanation is that the clonal Igs of post-immunotherapy are, in fact, present pre-
immunotherapy as well, but either the RNA-seq or MiXCR could not detect them. The
second explanation is that the plasma cells generating these antibodies were not in the
tumor pre-immunotherapy, or they were present in minute amounts. I discuss this further
in Section 3.6.
Sequences of reconstructed antibody chains
Below are the CDR3 nucleotide sequences of the possible pairings of Ig heavy and light
chains. It is conceivable that these antibodies, if expressed, could help us identify PDAC
and CRC specific antigens. The full nucleotide sequences are given in Appendix A.
1 > pat02 Heavy chain CDR3
2 TGTGTGAACGGCATATCAGATAGTCGTGGTCGCTACTACTTTGACTACTGG
3 > pat02 Light chain CDR3
4 TGTCAACAGAGTTACAGTACCTGGTGGACGTTC
5 > pat11 Heavy chain CDR3
6 TGTGCGAAAGAAGAACTACGACGAGGGCCCCATGACTACTGG
7 > pat11 Light chain CDR3
8 TGTCAACAGAGTTACATTACCCCTCGGACGTTC
9 > pat25 Heavy chain CDR3
10 TGTGCGAAGGATTTGAGAGGCAACAGCTGGTCTTTTGACTACTGG
11 > pat25 Light chain CDR3
12 TGCAGCTCATATGCAATCACTAATTCTCTCGTTTTC





































CDR3 CCPM day0 CCPM day8 CC day0 CC day8
Ig Heavy
CVNGISDSRGRYYFDYW 0.00 76.48 0 2072
CARGGGYLEPFDYW 0.31 25.43 10 689
CARVLTGFARGPW 0.47 22.18 15 601
CARDSFRGVFDYW 0.37 20.71 12 561
CAREEHYYDSSGLDYW 1.90 18.79 61 509
CAKSASFDNW 0.03 18.64 1 505
CVRGLRYFDRLLSDAFEIW 0.46 14.54 15 394
CVRPNYSNGWYGRNWFDPW 0.00 11.88 0 322
CVRGPYSAGWFDPW 0.09 10.11 3 274
CARCHTSGCPTGFDYW 0.00 9.23 0 250
Ig Light
CQQSYSTWWTF 0.00 208.74 0 5655
CQQYGSSLTF 6.44 112.80 207 3056
CQQYDNLPPFTF 0.81 111.71 26 3026
CQQYGGSPPIYTF 0.00 68.80 0 1864
CLQDYNYPITF 1.09 60.28 35 1633
CMQGTHWPRTF 0.28 49.65 9 1345
CQQYNSYPRTF 1.27 48.43 41 1312
CQQYNNWPPLTF 2.37 45.96 76 1245
CNSRDSGGNLVVF 0.00 44.37 0 1202
CQETYSTPLTF 0.34 39.53 11 1071
Fig. 3.8 The change in CCPM and CC of the most clonally expanded clonotypes detected in
the post-treatment sample of patient 2.



































CDR3 CCPM day0 CCPM day8 CC day0 CC day8
Ig Heavy
CAISNGLSGWSYSYYAFDVW 0.61 52.81 17 2700
CARLRVSSVRGVPYFDSW 0.00 52.28 0 2673
CATQMRVLTFSEWVFSGAYDVW 0.00 45.08 0 2305
CARTAPYYGSSGSNDAFDLW 0.00 17.64 0 902
CAFLYSSNWYGYYFDYW 0.00 15.19 0 777
CARLAYNYGYGANYFDYW 0.00 9.52 0 487
CARSSGPAPLDFW 0.00 7.90 0 404
CAKDLWFGELYEMPFESW 0.00 6.63 0 339
CAKDRGYSSGWKYFNYGLDVW 0.00 6.47 0 331
CARERLVRTLGGWFDPW 1.92 6.29 53 322
Ig Light
CQQYNNWPPFAF 0.00 93.53 0 4782
CQVWDSSNDHPVF 0.000000 87.52820 0 4475
CQQFGTSGFTF 1.482233 72.21321 41 3692
CQQRLNWPPTF 0.000000 28.61536 0 1463
CVLYMGSGIVVF 1.988361 28.55669 55 1460
CQQYNSHSYTF 0.000000 17.72079 0 906
CSSYSGTSSVLF 0.000000 16.33208 0 835
CSSYTSSSTPYVF 2.024513 13.92627 56 712
CQQYDNLITF 3.398290 12.85051 94 657
CQVWDSTSDRPFF 0.000000 12.10725 0 619
Fig. 3.9 The change in CCPM and CC of the most clonally expanded clonotypes detected in


































CDR3 CCPM day0 CCPM day8 CC day0 CC day8
Ig Heavy
CAKEELRRGPHDYW 0.00 160.29 0 4970
CARERFGMDVW 0.00 46.41 0 1439
CLTLSTYW 0.94 35.09 30 1088
CARDFRHFDYW 1.56 31.83 50 987
CARTGREFGDPRDAFDIW 0.06 21.99 2 682
CARDLSSTYGMDVW 0.68 20.44 22 634
CAVVVISANTYFDYW 0.18 16.70 6 518
CARARAYSGYGPVDYW 0.00 15.93 0 494
CRSGGDADDFDIW 2.50 14.12 80 438
CARDLWRGGGSSFGYW 0.06 13.25 2 411
Ig Light
CQQSYITPRTF 0.032 399.92 1 12400
CCSYAGGPTVF 0.00 159.49 0 4945
CQQYDILPPKLTF 0.50 124.26 16 3853
CQQSYRDSSF 1.53 79.53 49 2466
CASYTSSSTAVF 0.00 64.95 0 2014
CQVWDDSSDCVF 0.25 53.82 8 1669
CQQSYNDSSF 1.15 50.90 37 1578
CQSYDSSLSGYVF 3.28 43.25 105 1341
CQQYYKIPWTF 0.09 43.18 3 1339
CQQYYSTPWTF 0.00 42.70 0 1324
Fig. 3.10 The change in CCPM and CC of the most clonally expanded clonotypes detected in
the post-treatment sample of patient 11.

































CDR3 CCPM day0 CCPM day8 CC day0 CC day8
Ig Heavy
CAKDLRGNSWSFDYW 0.00 551.89 0 57129
CARGVSSSWYGPNWYFDLW 0.00 166.95 0 17282
CARAGRVDGLPALFDPW 0.00 164.26 0 17004
CARSPVAVAGTPDVFDIW 0.00 153.84 0 15925
CARGTGDFWTGRVSDGFDVW 0.00 59.95 0 6206
CARDGLGDDVTRFSWDAYDIW 0.00 51.38 0 5319
CSGWWTLNWFDPW 0.00 47.89 0 4958
CARENWKVVDVW 0.29 46.16 23 4779
CARHAWDANAPYYYFYYPMDVW 0.00 42.46 0 4396
CARHVLEGVPGNVDFW 5.15 36.64 399 3793
Ig Light
CSSYAITNSLVF 0.00 1119.91 0 115929
CQQAKSFPITF 0.00 342.96 0 35502
CQQSHTNPLTF 0.00 294.87 0 30524
CQQGYSSPYTF 0.35 245.26 27 25389
CQQYDNLPLTF 0.14 133.61 11 13831
CQSYDTSLSGLVVF 0.00 95.83 0 9920
CQQYGSSSWTF 0.00 91.09 0 9430
CQQFGASPHSF 11.64 82.01 901 8489
CGTWDSSLSAGWVF 0.00 76.15 0 7883
CSSFTTSTTLDVVF 4.51 73.55 349 7614
Fig. 3.11 The change in CCPM and CC of the most clonally expanded clonotypes detected in
the post-treatment sample of patient 25.
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Intratumoral B cells are a critical component of the TME, and they have been observed in
multiple tumor tissues, including breast, colorectal cancers, and melanomas [128], [151],
[216]. B cells recognize tumor antigens mainly via the CDR3 region on their antigen
receptors. Upon antigen challenge, B cells undergo SHMs and class-switching in order to
differentiate into plasma B cells, which begin secreting vast quantities of high-affinity
antibodies in order to eliminate the tumor cells.
CRC and PDAC are two cancer types that are resistant to popular ICIs. However,
it has been shown that this immunosuppression can be overcome by targeting other
molecular targets prior to standard ICIs in mouse. As previously mentioned, [65]
demonstrated that administering PDAC-bearing mice with AMD3100, an inhibitor of the
CXCL12 receptor, CXCR4, revealed the anti-tumor effects of the anti-PD-L1 antibody
and significantly reduced cancer cells.
Efforts have been made to study the TCR repertoire in PDAC [14], [99], however,
BCR repertoire recovery in PDAC tumors after immune treatment, to the best of my
knowledge, has not been undertaken before.
With tumor tissue samples collected from CRC and PDAC patients before and
after AMD3100 treatment as part of a phase I clinical trial [50], I reconstructed BCR
sequences directly from unselected RNA-seq data. Analyzing the BCR repertoire, I
observed that the number of unique BCR assemblies was significantly higher than that
of TCR assemblies, and that the detected BCRs had undergone class switching, which
suggested the presence of intratumoral antibody-secreting plasma cells. Furthermore, in
some patients, I detected clonal expansion of individual antibodies after treatment with
AMD3100. This finding is in alignment with a recent study where, before and after PD-1
inhibitor therapy, RNA-seq data of seven patients with glioblastomas were processed
with MiXCR to recover TCR and BCR repertoires [266]. Patients who did not show an
objective response to therapy had a greater increase in clonal diversity among B and T
cells relative to patients who responded to therapy [266].
Based on our findings, we can hypothesize that administering AMD3100, which
blocks the CXCL12-CXCR4 axis, to PDAC patients may have, directly or indirectly,
increased the level of intratumoral immune response, thus allowing for the effective
differentiation of plasma B cells post-treatment. Furthermore, AMD3100 may have also
allowed for better homing of plasma cells into the TME and let plasma cells persist longer
in the TME and patient bone marrow. Another possibility is that both quantitative
and qualitative improvement of B cell function, i.e., increased Ig production levels and
the ability to produce more specific antibodies, may have been achieved as AMD3100
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recovered T helper cells, and through them, APC function. Thus, B cells were called
to the TME more efficiently, and they were presented with antigens by APCs more
efficiently. This would need to be supported by looking at the effects of AMD3100
treated CXCL12/CXCR4 axis on APCs. Furthermore, it has been shown that, in mice,
AMD3100 redistributes B cells from the bone marrow into the circulation [146]. It is
possible that the administration of AMD3100 induced a redistribution of B cells from
the patients’ bone marrow into the tumor. These theories could potentially explain the
abundance of antibodies post-treatment, but more functional studies are required to
determine the mechanisms behind my results.
The absence of abundant post-treatment clonotypes in the pre-treatment repertoire
can be due to these clonotypes having shallow signals falling below detection limits. These
Igs may have existed pre-treatment, but it could not be picked up by the reconstruction
algorithm as there were not many cells expressing those Igs. Furthermore, the low
signal in the pre-immunotherapy repertoire could have also gone undetected due to read
coverage. Recall that for each of the samples, there are other dominant clonotypes.
These clonotypes could be dominating the read space. Hence the clonally expanded Igs
of post-immunotherapy are, in fact, present pre-immunotherapy as well, but either the
RNA-seq or reconstruction algorithm could not detect them. This explains the technical
reason why we could not pick up the BCRs. But why are these BCRs so rare before
therapy? Low counts of plasma cells could perhaps explain the reason behind the low
signal in the TME, which could again be due to obstructed homing, hindered T cell
calling, and APC presentation, or impaired class-switching or affinity maturation, possibly
due to the immunosuppressive action of the CXCL12/CXCR4 axis in this context.
In the absence of an abundant post-treatment clonotype in the pre-treatment reper-
toire, as future work we can search for such BCRs in the pre-treatment dataset by direct
alignment. As we have the full recombined and affinity-matured antibody sequence, the
task at hand would be reduced to a straightforward alignment of reads to a reference
sequence. For this, we would append the reconstructed post-treatment BCR sequences
to the reference genome, as reads, in general, tend to align to non-specific regions as well.
Another approach could be to pool together reads obtained pre- and post-AMD3100
treatment for each patient in order to intensify the signal of lowly observed clonotypes
within each collection time. However, using this approach we would be making the
assumption that an antibody present pre treatment is also to be present post treatment,
and vice versa, which may or may not be true. Therefore we need to take into account that
certain erroneous sequences might be regarded as true clonotypes as the true and high
signal in one collection can increase the signal of the not only lowly present clonotypes
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but also of the sequences reconstructed from erroneous reads. This can be mitigated by
setting a reasonable base threshold on true clonotypes. Nevertheless, this is an approach
that we can further investigate.
One of the ultimate goals in personalized medicine in cancer is to develop patient-
tailored targeted cancer immunotherapy treatments. This requires finding the target
which will distinguish cancer cells from normal cells. In this study, I was able to detect
certain antibodies that were significantly clonally expanded after treatment. In the
post-immunotherapy BCR repertoire of patients 2, 11, and especially 25, I detected
highly clonal heavy and light Ig chains, and these chains are clonal enough to pair. With
the sequences of these paired heavy and light Ig chains, we can have the specific antibody
expressed in mammalian cells. These antibodies could then be used to detect cancer
antigens targeted by the immune response after immunotherapy.
Although reconstructing BCR repertoires from unselected RNA-seq allowed for the
detection of clonally expanded heavy and light Ig chains, we cannot always pair them
with certainty. While highly clonal heavy and light chains may indicate a possible
pairing, in other cases, the pairing may not be as obvious. Furthermore, using RNA-seq
approaches, we cannot determine the activation status of cells that express a certain
BCR. Based on these limitations of RNA-seq, it would be more beneficial to use 10x
Genomics Chromium Single Cell Immune Profiling Solution in order to retrieve the gene
expression profiles and VDJ sequences simultaneously from single B cells before and after
AMD3100, and possibly anti-PD-L1, immunotherapy. With the gene expression data, we
can obtain the activation and differentiation status of each cell by investigating specific
biomarkers, and therefore identify Igs which recognize specific antigens in the tumor.
These antibodies would, in turn, allow for the identification of antigen candidates likely






In the previous two chapters, my work mainly focused on B lymphocytes. The other
major actor of the adaptive immune system is the T lymphocyte. T (thymus-derived)
lymphocytes defend the host against unwanted intracellular events; they recognize and
attack infected cells such as those that have been penetrated by a virus or bacteria, or
cancerous cells that deviate from healthy self cells, or non-self cells from transplants. T
cells recognize the antigens on the surface of such cells using T cell receptors (TCRs)
[117, Chapter 1, p.10].
In the present study, I link the TCR repertoire with whole-transcriptome scRNA-seq
data. Combining the two at a single cell level allowed me to investigate the relationship
between T cell transcriptional phenotypes and TCR repertoires. Furthermore, by examin-
ing the transcriptional profile of both intratumoral and splenic T cells that could be linked
via shared TCR clonotypes, I was able to study the differences between tumor-infiltrating
T cells and the T cells in the spleen.
In Section 4.2, I give an overview of how the T cells generate and develop in the
primary lymphoid organs, describe their maturation and differentiation process, and
briefly explain their activation. I then discuss T cell diversity and TCRs focusing on CD8+
cytotoxic T lymphocytes. I explain how tumor cells can impair CD8+ tumor-infiltrating
lymphocytes in order to suppress immune responses, and how current immunotherapy
methods are trying to reverse this process. Later in Section 4.3, I describe our approach
that combines single-cell gene expression profiles with TCR information at the cellular
level in order to uncover the links and transitions between transcriptional states. I then
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present a novel transgenic mouse model, developed by Dr. James Thaventhiran, which
can help track the clonal CD8+ T cell response to tumor antigens. I describe how, using
this mouse model, Dr. James Thaventhiran and Mr. Ty So were able to harvest and
sequence tumor-reactive T cells, and how I obtained their gene expression profile and
TCR repertoires from the scRNA-seq data. In Section 4.4, I give a detailed account of my
analysis on the obtained dataset from the single-cell RNA sequencing of the mouse model,
focusing on investigating the clonality and diversity of T lymphocytes. In Section 4.5, I
present our findings and end this chapter with a discussion in Section 4.6.
4.2 Background
4.2.1 T cell development
Before starting, it is worth noting that the development of T cells is a complex and
fascinating process, yet not completely understood. In the following paragraphs I will
attempt a summary of the most consolidated knowledge on this topic. However, a
complete review of the matter would be beyond the scope of this thesis, and is available
elsewhere [125], [122], [117, Chapter 10, p. 221-229], [3, Chapter 4, p. 42-58].
T lymphocytes originate from ancestral lymphoid progenitor cells which differentiate
from hematopoietic stem cells found in the bone marrow [3, Chapter 4, p. 42-58].
Progenitors of T cells migrate to the thymus. The thymus is a primary lymphoid organ of
the immune system which “trains” the progenitor T cells into mature T cells. Thymocytes,
the hematopoietic progenitor cells present in the thymus, go through multiple stages of
development. These stages are characterized by the expression of specific cell surface
markers. Early-stage thymocytes generally lack the cell-surface proteins CD4 and CD8,
and are called double negative (DN) cells. Note that CD4 and CD8 are the two essential
markers when discussing T cell development, but various other markers are also crucial
in distinguishing between stages: CD44 and CD25 markers further characterize the DN
population [212]. I have briefly illustrated the T cell developmental stages that take place
in the thymus in Figure 4.1. The somatic recombination of the genes that encode the
receptor proteins take place during the DN stage. First, TCRδ and TCRγ, as well as the
TCRβ gene segments rearrange: genes that encode the variable domain of TCRs are in an
array of separate germline DNA gene segments and are recombined and joined together
[110]. If the developing cell makes a productive γδ gene rearrangement, it expresses a
TCRγδ receptor. Alternatively, if the cell completes a productive β gene rearrangement,
then the TCRβ chain is expressed on the cell surface coupled with a surrogate chain
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Fig. 4.1 T cell developmental stages in the thymus. Thymocytes differentiate from
immature DN to immature single CD8 positive (ISP8), DP, and single-positive thymocytes.
Each DN stage is characterized based on expression of cell surface markers CD25 and CD44:
DN1 (CD25-CD44+), DN2 (CD25+CD44+), DN3 (CD25+CD44-), and DN4 (CD25-CD44-).
My illustration here is based on details from [212]. Also note that the cell surface markers
CD44 and CD25 are expressed in murine thymocytes and the corresponding human DN stages
are characterized by the differential expression of CD34, CD38 and CD1A [110].
called pre-Tα, producing the pre-TCR complex. If neither of these gene rearrangements
happen productively, the cell undergoes apoptosis [212].
Expression of pre-TCR stimulates recombination in the TCRα locus of these develop-
ing cells, induces their proliferation and the expression of CD4 and CD8 on their surfaces,
allowing them to develop into CD4+CD8+ double positive (DP) thymocytes committed
to the αβ lineage. Next, the TCRα chain pairs with the TCRβ to form a functional
signaling complex. At this point, DP thymocytes are TCRαβ+CD3+CD4+CD8+ [212].
CD3 serves as a T cell co-receptor that associates with the TCR and is a defining marker
of the T cell lineage [117, Chapter9, p. 212].
As a next step, maturing T cells undergo two important processes: positive and
negative selection. Positive selection only retains thymocytes which bear receptors that
can recognize self-MHC molecules, while negative selection discards any thymocyte with a
receptor that recognizes self-MHC molecules or self-antigens presented by self-MHC with
high affinity. Cells that do not pass positive selection undergo apoptosis. The remaining
cells go through negative selection ensuring that only the self-tolerant thymocytes survive.
However, this poses the problem that negative selection would also remove any thymocyte
that recognizes self MHC molecules, and therefore deplete the T cell population. Different
hypotheses have been proposed to explain this contradiction, and are reviewed extensively
in [258]. The exact process is currently a matter of debate, and it is possible that multiple
mechanisms play a role in thymic selection [117, Chapter 10, p. 223-229].
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Thymic selection further ensures that CD4+CD8+ DP thymocytes differentiate into
CD4+CD8- or CD4-CD8+ (SP, single positive) cells. However, the exact process is not yet
established and several models have been proposed. For example, while one model suggests
that the ability of a DP thymocyte to recognize MHC class I or class II molecule dictates
whether it will commit to the CD8 or CD4 lineages respectively, some others suggest
that this progression is stochastic and independent of T cell receptor MHC specificity. A
review of the major models of CD4/CD8 lineage choice, including the aforementioned
can be found in [220]. Additionally, it should be noted that CD4+CD8+ DP mature T
cells have been reported in various disease settings [171], including melanoma [55].
Having gone through thymic selection, mature and functional T lymphocytes exit the
thymus, traveling to peripheral tissues, or circulate in the blood or lymphatic system,
ready to be activated upon encounter with the appropriate antigenic stimulus.
4.2.2 T cell activation
Mature lymphocytes are called naive (immunologically inexperienced) until they encounter
the antigen for which they are specific. T cells do not directly interact with antigens
but with antigen presenting cells (APCs). The interaction between antigen-specific T
cell receptors and antigen-major histocompatibility complex (MHC) molecules found on
the surfaces of APC initiates the activation of naive T cells. A small number of T cells
that express the γδ receptor do not require display by MHC proteins [126, Chapter 6,
p. 188-198].
Naive T cells that exit the thymus travel to the periphery where they can encounter
a multitude of APCs and get activated. If not, they keep circulating between the lymph
and blood until a possible encounter occurs [34, Chapter 24, p. 1311-1313].
T cell activation leads to the proliferation and differentiation of naive T cells into
effector cells. Upon activation, CD8+ naive T lymphocytes may differentiate into cytotoxic
T lymphocytes (CTLs or Tc) which have the ability to directly kill infected or neoplastic
cells. Activation of CD4+ T cells differentiates them into CD4+ helper T cells (Th)
and may initiate several downstream events, including synthesis of cytokines, signaling
molecules, and the recruitment and activation of other immune cells. Another type of
essential immune cells called regulatory T cells (Treg) have the phenotype CD4+CD25+
[196]. These cells are thought to monitor and control immune responses, thus preventing
excessive immune activation and limiting potential collateral damage to healthy tissue.
FOXP3, a transcription factor that confers immune suppressor function in this context,
is commonly used as a marker to distinguish T regulatory cells from effector T cells [95].
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Helper T cells can further differentiate into more specialized effector cells such as Th1,
Th2, Th17, Th9, among others [28]. This subsetting is mainly based on the cytokine
expression profile of the cell. Each helper T cell subtype performs a different function to
regulate the immune response. Immune cell differentiation is not yet fully characterized;
however, recent advances in single-cell genomics are helping distinguish further specialized
subpopulations [209].
4.2.3 T cell diversity
T cells present a vast array of highly specific antigen receptors on their surface to detect
pathogens. Each T cell expresses a specific T cell receptor as it develops into a functionally
competent cell. A majority of the T cells (95%) express a combination of α and β chains
[126, Chapter 6, p. 190]. The TCRαβ recognizes antigens which are presented by MHC
molecules on the surfaces of antigen-presenting cells [193]. A small population of TCRs
expresses TCRγδ which can recognize non-protein molecules such as lipids, without the
need for display by MHC molecules [126, Chapter 6, p. 191].
Each TCR chain has a variable domain which recognizes and binds to the antigen,
and a constant domain. TCR α and δ chains’ variable domain is encoded by one of many
V (variable) and J (joining) genes, and TCR β and γ chains have another D (diversity)
gene between the two domains (Figure 4.2). During V(D)J recombination, one allele
of V, D, and J genes recombine, forming the functional variable region. This variable
region, combined with a constant gene segment, makes up the functional TCR chain [227].
Insertion and deletion of random nucleotides at the V-D, D-J, and V-J junction sites
introduce junctional diversity. Later, the pairing of α and β or γ and δ chains provide
an additional layer of diversity. This combinatorial, junctional, and coupling diversity
creates an incredibly vast TCR repertoire guaranteeing the recognition of millions of
antigens, including those of neoplastic cells. Analyzing this diversity can be crucial in
assessing the immune response to cancer.
TCR chains contain three complementarity determining regions: CDR1 and CDR2
are encoded solely by V genes in the germ-line DNA segments, whereas CDR3 is encoded
by the terminal of V genes, the D genes in the case of TCRβ chains, the beginning of J
genes, and the junctional sites between those genes, making it the most variable region in
a TCR chain [117, Chapter 9, p. 207]. It is also the region which is primarily in contact
with the peptide antigen presented by an APC [74]. Due to these characteristics, TCR
clonal lineages can be identified by their CDR3 regions. When the receptor of a T cell
detects a specific antigen and binds to it, that cell might receive a proliferation signal,
leading to clonal expansion.
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Fig. 4.2 TCR diversity. TCR α and β chains are generated by gene recombination. Multiple
stages of diversity lead to a vast TCR repertoire. The germline V, D, J, and C alleles are
randomly selected for recombination of the α and β chains (1,2 and 1′,2′). Random nucleotides
are inserted and deleted at the junction sites, shown here in light gray (3,3′). α and β chains
couple to create an additional layer of diversity (4). I illustrated this process based on the details
provided in [117, Chapter 9, p. 204-212]. In this figure I have omitted the γδ gene segments to
simplify the process. See Figure 9-6 in [117, Chapter 9, p. 206] for a precise depiction.
T cells expressing identical receptors are said to be of the same clone and their TCRs
of the same clonotype [137]. As mentioned before, since equality is determined via the
CDR3 region, TCRs with the same productive CDR3 regions in their α and β chains are
considered to be of the same clonotype. With some exceptions [239], it is highly unlikely
that different cells with no common predecessor express the same CDR3, hence cells
from the same clone are considered to have proliferated from the same T cell. All TCR
clonotypes expressed by all the T cells of a host make up its TCR repertoire. The CDR3
amino-acid sequences can be considered as the unique index of the TCR repertoire.
In theory, there can exist between 1015 and 1020 unique TCR chains [131]. However,
considering there are about 3.72 ×1013 non-bacterial cells in the human body [20], and
that clonotypes tend to cluster in large groups due to thymic selection and antigen
specificity, it is impossible that the full repertoire is realized in a single individual.
The TCR repertoire diversity varies throughout life, and in health and disease. For
instance, by using high-throughput sequencing of TCRβ samples taken from patients
with multiple sclerosis (MS) and control subjects, [147] demonstrated that the TCRβ
sequences of Epstein-Barr virus (EBV) reactive CD8+ T cells were enriched in MS patients
only, while EBV-reactive CD4+ T cells were enriched in both MS patients and control
subjects. In cancer, CD8+ cytotoxic T are believed to play a key role in killing cancer
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cells [154] via perforins and granzymes, potent toxins secreted by cytotoxic lymphocytes.
[87] assessed the phenotypic traits expressed by CD8+ tumor-infiltrating lymphocytes
(TILs) and the TCRβ chain clonotypic immunoprofiling in melanoma patients to identify
the diverse repertoire of tumor-reactive cells. Studies have shown that profiling immune
repertoires of TILs can provide a powerful platform to study anti-tumor T cell responses
[118], [218], [14].
4.2.4 Tumor-infiltrating lymphocytes
The lymphatic system plays a vital role in immunity. A complex network of lymph
vessels transports antigens and APCs to lymph nodes to generate adaptive immune
responses [172]. In order to interact with an antigen and achieve activation, naive T cells
circulate through secondary lymphoid organs which harbor a concentrated population of
antigens. Activated effector T cells then travel to any site necessary in order to eliminate
the specific antigen for which they were activated [126, Chapter 6, p. 194].
T cells are thought to recognize and eliminate cancer cells through the recognition of
cancer-associated antigens, namely tumor antigens. Tumor antigens are expressed on the
surface of tumor cells. In the broad sense, they can be tumor-specific antigens (TSA) -
restricted only to tumor cells - or tumor-associated antigens (TAA) - present on both
tumor and normal cells, but expressed at abnormal concentrations in a tumor cell [152,
Chapter 16, p. 423-455]. The T cell response can differ based on the type of the tumor
antigen: TAAs may trigger a weak immune response as T cells are programmed to be
tolerant to self-antigens. Conversely, TSAs deemed foreign by the immune system may
trigger a stronger immune response [263]. Cells involved in anti-tumor immunosurveillance
such as T cells may recognize the tumor antigens resulting in a possible intratumoral
immune response [117, Chapter 22, p. 507-512].
Tumor infiltration of lymphocytes is achieved via selective trafficking [223]. During
activation in the secondary lymphoid organs, T cells improve their adhesive ability via the
expression of specific homing receptors1 which target ligands in the tumor tissue, allowing
them to travel to and infiltrate specific tumors. Also, in recent studies, it has been shown
that naive T lymphocytes can enter tumor tissue containing tertiary lymphoid structures
(TLS) through lymph node (LN)-like blood vessels in tumors [63]. This infiltration is
dependent on expression of L-selectin in lymphocytes and CCR7 expression in lymphoid
tissue and mediated by the LN-like blood vessels that express PNAd and CCL21. The
TME might be an essential site of tumor-specific T cell clonal expansion [234]. The
1Lymphocyte homing receptors are molecules that enable cell adhesion
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abundance of tumor-infiltrating lymphocytes (TILs), especially CD8+ T cells, is associated
with better prognosis in most solid tumors [206], [163], [82], [264]. This association has
been extensively discussed in [71]. Along with activated T cells, the presence of naive T
cells which activate within the tumor also results in increased tumor control [63]. It is
therefore vital to analyze the TCR repertoire of TILs and identify efficient cancer cell
fighting T cell subclones.
Although the immune system can deploy a large array of TILs to protect the host from
tumors, the tumors themselves have elegant methods to create a microenvironment that
obstructs immune responses. For instance, tumor cells can lose TAA/TSA expression,
secrete immunosuppressive cytokines, generate a vasculature that represses T cell influx,
or they can exhaust and inactivate TILs [152, Chapter 16, p. 423-455]. Hence, besides
identifying efficacious tumor-reactive TILs, it is just as crucial to study how the tumor
may impair them, and how they can be reinvigorated.
4.2.5 T cell impairment
When the metabolism or function of antigen-specific CD8 T cells is diminished, they can
differentiate into a hyporesponsive state. Hyporesponsive T cells are usually referred to
as exhausted in chronic infections [67], [249], and dysfunctional or again exhausted in the
context of cancer [204], [235].
[262] first described exhaustion with virus-specific CD8+ T cell responses during
chronic lymphocytic choriomeningitis virus (LCMV) infection of mice. Responding CD8+
T cells lost their effector functions during chronic infection in a hierarchical manner
becoming unresponsive to the virus. Since then, various studies have investigated the
phenotypic and functional traits of exhausted T cells in chronic viral infections showing
they overexpressed various inhibitory receptors, including PD-1, TIM-3, LAG-3, CTLA-4,
and 2B4 [124], [249], failed to secrete effector cytokines such as Interleukin-2 (IL-2),
a cytokine with immune-modulating and anti-neoplastic effects, and expressed certain
transcription factors such as Blimp-1 [217] and Eomesodermin (Eomes) [173].
In the context of cancer, although the accumulation of antigen-specific CD8+ T
cells in tumors is a positive prognostic marker, these immune cells deteriorate and
become unresponsive to cancer within the TME due to a wide range of tumor-regulated
immunosuppressive mechanisms [6], [15]. CD8+ TILs that were once killing cancer cells
differentiate into a dysfunctional state and, losing their effector functions, fail to perform
as cytotoxic killer cells. Such dysfunctional T cells are a distinct lineage of differentiated
T cells [235]. Similar to exhausted CD8+ T cells in chronic infections, dysfunctional CD8+
TILs show upregulation of inhibitory receptors such as PD-1 [6], [15] which has become
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a major focus in cancer immunity along with CTLA-4 [210], have their effector cytokine
productions corrupted [6], and display particular gene expression profiles. [181] provides
an up-to-date review of exhaustive and dysfunctional T cell state studies in chronic viral
infections and cancer and lists the distinguishing molecular signatures determined so far.
4.2.6 Immune checkpoint inhibitors in cancer therapy
PD-1 (also known as PDCD1), the programmed cell death protein 1, shows a sustained
expression in exhausted T cells in chronic viral infections [240], [53], and has become
a significant marker of T cell dysfunction in cancer [6]. PD-L1 is the host cell surface
receptor which interacts with the inhibitory receptor PD-1 on T cells. Cancer cells express
this ligand in order to overwhelmingly suppress the T cells through the PD-1/PD-L1
axis [228].
In checkpoint blockade therapy, a monoclonal antibody, eg. anti-PD-1 or anti-PD-L1,
binds to the relevant membrane protein, PD-1 or PD-L1, to block the natural interaction
of PD-L1 with the PD-1 receptor. This blockade removes cancer imposed suppression on
the T cells resulting in the enhanced killing of the tumor cells. Anti-PD-1 checkpoint
blockade therapy has been especially effective in malignant melanomas [191]. CTLA-4,
cytotoxic T-lymphocyte antigen 4, is another “brake” on T cells, and anti-CTLA-4
checkpoint blockade therapy, though less effective than anti-PD-1 [252], has been shown
to extend the life expectancy of advanced melanoma patients. Some studies suggest that
PD-1 and CTLA-4 play complementary roles, and a combination of both therapies yield
better outcome [253].
While checkpoint blockade therapy provides significant improvement in patient out-
come, it only helps a minority of patients and is not effective long-term [140]. It is thus
vital to associate the mechanisms that regulate or hinder permanent positive response
with checkpoint therapy, in order to transform immunotherapy into a broadly applicable
cancer treatment.
Furthermore, studies analyzing the TME have observed that response to immune
checkpoint blockade favors pre-existing T cell infiltration in tumors, which they call “hot
tumors”, as opposed to “cold tumors” that lack T cell infiltration [26]. One common
interpretation of this phenomenon is that hot tumors have already been infiltrated by
substantial quantities of T cells, resulting in an elevated level of ongoing intratumoral
immune response. Although the existing T cells have not completely eradicated the
cancer cells, their level of activity can be increased by ICIs. Indeed, ICI therapy is
thought to lift the restraints burdening dysfunctional T cells, thus allowing them to
resume their effector functions.
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Recent studies, while characterizing T cell states, have looked at biological markers
that can predict clinical response to checkpoint therapy. For instance, [235] analyzed a
total of 4645 malignant and tumor cells from 19 human melanoma samples. The authors
examined CD8+ T cells to identify exhaustion programs. The number of CD8+ T cells
extracted from the five selected tumors (where the selection was based on high CD8+
T cell count) changed between 68 and 214. Their core exhaustion signature yielded
28 constantly up-regulated genes, including CXCL13, TNFRSF9, TIGIT, and CD27.
Another study determined that TCF7 (TCF1 in mice) expression can predict positive
clinical response [197]. TCF7, IL7R, and FOXP1 were shown to be associated with
responder CD8+ T cells, while previously discovered exhaustion markers such as TIM3
[199] and ENTPD1 were associated with non-responder CD8+ T cells and dysfunction
state. In addition, via TCR analysis, they showed that T cells can transition from one
state to the other. This was later confirmed by [140] where again combining scRNA-seq
and TCR-seq they showed that the dysfunctional CD8+ T cell state rather than being
a discrete pool constituted a gradient spectrum going from transitional state to early
dysfunction, and highly dysfunctional. This seems to be a unique feature of melanoma
infiltrating CD8+ T cells. [140] too characterize dysfunction by LAG3 and PDCD1.
However, they determine ETV1 and AKAPF as additional markers of dysfunctional
CD8+ T cells. Additionally, based on the coupled analysis of scRNA-seq and TCR-seq,
they observed that dysfunctional T cells displayed the highest level of clonality.
As confirmed by [140], cells defined as dysfunctional could be in the initial state of
dysfunctionality, which is thought to be reversible. For example, several recent studies
have looked into the role that a specific nuclear factor, thymocyte selection-associated
HMG box protein, TOX, plays in the differentiation of exhausted CD8+ T cells in
both chronic infection and tumors [257], [208], [211], [114]. TOX is highly expressed in
melanoma, as well as other solid tumors. Their findings suggest that regulation of TOX
could potentially reverse T cell exhaustion in human cancers.
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4.3 Integrated approach to expose reactive-TIL dys-
function at single cell level
It is clear that there is a need to study the TME, focusing on the interactions of
intratumoral malignant and non-malignant cells. If we can fully resolve the mechanisms
behind tumor-infiltrating T cell dysfunction, we can improve the benefits gained from
checkpoint blockade therapies. The TME is highly heterogeneous, as it comprises
different populations of cancer cells, and a variety of resident and infiltrating host
cells. This heterogeneity also characterises tumor-infiltrating T cells: the (i) type of T
cells (e.g., CD8+, CD4+, Tregs) which can be (ii) at various states of (dys-)function,
and (iii) target different antigens based on its antigen-specific TCR, lead to many T
cell subpopulations. Resolving this heterogeneity requires an unbiased, single-cell level
analysis of the TME, a cellular analysis which does not rely on pre-determined markers
to allow for the discovery of new components. Additionally, the combined analysis of T
cell transcriptional profiles together with their TCR clonotypes at single-cell level can
uncover the links and transitions between transcriptional states. As previously shown
[197], [140], analyzing shared TCRs between distinct cell states can shed light on the
differentiation processes of TILs by unveiling which states they can occupy.
However, combining single-cell gene expression profiles with TCR information at the
cellular level alone will not suffice. We need novel approaches which allow the coupling
of cell state with the inherent potential of a T cell’s ability to recognize specific tumor
antigens [233]. Even though by linking single-cell transcriptional profiles and TCR
sequences we can potentially determine tumor reactivity via clonality measures, the
result may be confounded by different factors. For instance, the proliferation of the
tumor-reactive T cells could be hindered by exhaustion or other immuno-suppressive
mechanisms. More importantly, recent work provides evidence that intratumoral T cells
may be bystanders with no tumor reactivity [219]. In order to provide opportunities to
reinstate effective and long-lasting intratumoral T cell response, we need to determine,
unambiguously, which specific T cells are responsible for tumor antigen recognition.
4.3.1 Antigen-Receptor Signalling Reporter (AgRSR) mouse
For this work, I collaborated with Dr. James Thaventhiran who has developed a novel
transgenic mouse model, namely the Antigen-Receptor Signalling Reporter (AgRSR),
which allows in vivo clonal tracking of activated B and T cells [93]. In this model,
with the administration of a specific chemical trigger, tamoxifen, activated cells can be
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fluorescently marked upon AgR signalling. AgRSR mice have been genetically modified
by injecting a bacterial artificial chromosome (BAC) transgene which has been modified
by inserting Katushka, a red fluorescent protein derived from the sea anemone Entacmaea
quadricolor [215], and an E2A linked tamoxifen-regulated Cre-ERT2 recombinase, into the
translation initiation codon of the Nur77 gene. The Nur77 gene is expressed upon AgR
signaling in both B and T cells [12]. In this model, the activation signal can be detected
with red fluorescence signals, via the expression of Katushka. This red fluorescence
signal decays as the AgR trigger is removed, i.e., Katushka is not permanent. Therefore,
in order to permanently mark activated B and T cells this mouse was crossed to the
ROSA-Lox-Stop-Lox-EYFP reporter strain establishing a new strain in which, upon AgR
activation, the administration of tamoxifen induces Cre-ERT2 recombinase mediated
excision of the Stop cassette, which prevents the expression of the yellow fluorescent
protein (EYFP). As a result, the administration of tamoxifen leads to the expression of
EYFP. Since EYFP expression is determined by DNA-recombination, it is inheritable,
so all clonal progeny of the marked cells remain EYFP+ [James Thaventhiran, personal
communication, September 10, 2018].
Model validation
Fig. 4.3 Assessment of antigen specificity of marking. EYFP expression in spleen and
tumor CD8+ T cells, marked before and after melanoma tumor injection. Plots show that the
marking is specific to cells recognizing tumor antigens. Cartoon and plots courtesy of Mr. Ty
So.
Experiments carried out by Dr. James Thaventhiran and Mr. Ty So demonstrated
that EYFP expression in T (and B) cell clones is dependent on tamoxifen exposure.
Furthermore, in T cells receiving inflammatory or cytokine signaling, expression of EYFP
is dependent on MHC molecules, confirming the TCR-specificity of the marking (Fig-
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ure 4.3). This model can help track the clonal CD8+ T cell response to tumor antigens.
Furthermore, as this model kinetically timestamps TCR activation via tamoxifen admin-
istration, it can fate-map TCR activated CD8+ T cell clones within an experimentally
defined time frame [93].
4.3.2 Immune profiling of EYFP+ cells
Current single-cell transcriptomic techniques provide limited insights on the causes of
clonal T cell dysfunction as they do not allow us to determine how particular dysfunctional
states and inherent tumor reactivity are linked. By immune profiling the EYFP+ cells
of the AgRSR mouse model, we aimed to overcome this limitation and provide a fully
unambiguous analysis of T cell dysfunction within the TME.
4.3.3 Cell harvest and sequencing
Mr. Ty So challenged three mice with subcutaneous melanoma tumors at day 0 (Fig-
ure 4.4). The mice were later administered different dosages of tamoxifen at day 7.
The first two mice were given half the amount the third mouse received. At day 15,
the first mouse was sacrificed by cervical dislocation to harvest and digest the tumor
and the spleen. Following FACS surface staining, tumor and spleen cells were sorted
for CD45+CD11B-EYFP+ [James Thaventhiran and Ty So, personal communication,
September 10, 2018]. During FACS, in order to obtain EYFP+ lymphocytes from mouse
tumor and spleens, non-target cells, along with doublets, dead cells, non-lymphocytes, as
well as EYFP- cells were removed (Figure 4.5).
As described in detail in Chapter 2, using 10x Genomics’ Chromium Single Cell
Immune Profiling Solution, libraries were generated for both tumor and spleen cells to
obtain gene expression profiles, and full-length, paired, TCR repertoires from the same
Fig. 4.4 Experimental timeline. All three mice were challenged with subcutaneous
melanoma-tumors at day 0, later administered tamoxifen at day 7. The mice were sacri-
ficed and their tumor and spleen cells were harvested and processed with the Single Cell
Immune Profiling protocol at days 15, 19, and 25.
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Fig. 4.5 Cell filtering. Regions with black borders are the selected cells. Forward Scatter
Area (FSC-A) by Side Scatter Area (SSC-A) gate is used to remove debris. FSC-Height
(FSC-H) by FSC-Area (FSC-A) gate is used to detect single cells which fall on the diagonal.
Lymphocytes are CD45+CD11B-. Plots courtesy of Mr. Ty So.
input sample. Sequencer-ready scRNA-seq libraries with unique sample indices were
sequenced on the Illumina HiSeq 4000 platform. The next two mice went through the
same process later at day 19 and day 25. As mentioned previously, mice sacrificed on
days 15 and 19 were given half the tamoxifen dosage given to the mouse sacrificed on
day 25.
4.3.4 Chromium scRNA-seq output processing pipeline
Raw Illumina reads were converted into FASTQ files and processed using CellRanger
v3.0.2. I used the default cellranger count arguments to align, filter, and count unique
molecular identifiers (UMIs) to generate a (gene x cell) count matrix. I mapped the
sequences to the mm10 genome and counted with the GRCm38 annotation. When
reconstructing TCRs via cellranger vdj, as described in Section 2.4.2, I generated a
V(D)J reference from the IMGT database. We obtained a total of six GEX profiles, and
six TCR repertoires. Throughout this chapter, each mouse is labelled based on day of
sacrifice; mouse_d15, mouse_d19, and mouse_d25.
cellranger count summary metrics
Table 4.1 and 4.2 list the summary metrics of the GEX barcoding and sequencing process
on the cells obtained from the tumors and the spleens of each mouse, respectively. In
both tumor and spleen samples, the total number of read pairs that were assigned to
mouse_d25 is significantly less compared to the other two samples. Nevertheless, they
are still above the acceptable threshold of minimum 20,000 read pairs/cell [1]. It should
be noted that mouse_d25 samples were the first to be sequenced. The two other mouse
samples were sequenced deeper to increase the read count per cell. However note that the
sequencing saturation, i.e., the measure of the fraction of the total number of different
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mouse_d15 mouse_d19 mouse_d25
Estimated Number of Cells 7,633 5,343 8,351
Mean Reads per Cell 39,707 61,371 24,978
Median Genes per Cell 2,571 2,415 1,342
Number of Reads 303,085,056 327,908,254 208,593,470
Valid Barcodes 94.1% 94.9% 95.2%
Sequencing Saturation 61.8% 77.6% 72.6%
Reads Mapped Confidently to Genome 94.3% 95.2% 95.8%
Reads Mapped Confidently to Transcriptome 81.5% 83.1% 82.8%
Fraction Reads in Cells 95.6% 95.7% 95.0%
Total Genes Detected 17,069 16,825 18,149
Median UMI Counts per Cell 9,115 8,202 2,886
Table 4.1 GEX analysis metrics of the tumor samples
mouse_d15 mouse_d19 mouse_d25
Estimated Number of Cells 3,992 3,082 4,918
Mean Reads per Cell 75,212 104,996 42,152
Median Genes per Cell 2,083 1,799 660
Number of Reads 300,249,980 323,599,839 207,304,501
Valid Barcodes 93.5% 94.8% 93.5%
Sequencing Saturation 87.4% 92.9% 83.8%
Reads Mapped Confidently to Genome 94.0% 95.3% 95.7%
Reads Mapped Confidently to Transcriptome 79.3% 81.6% 79.6%
Fraction Reads in Cells 97.1% 95.8% 36.9%
Total Genes Detected 15,621 15,046 14,896
Median UMI Counts per Cell 5,915 4,689 1,242
Table 4.2 GEX analysis metrics of the spleen samples
transcripts in the final library that was sequenced, of mouse_d25 is similar to that of the
other mice, again suggesting that the summary metrics are not a source of concern. As
the sequencing saturation increases, additional sequencing does not result in many new
unique UMIs for the library. In terms of the number of cells detected for each sample;
as of version 3.0, Cell Ranger has implemented a cell-calling algorithm, based on [150],
which can identify low RNA content cells even when mixed with high RNA content cells.
The implemented algorithm is two-step:
• Step 1 - Cutoff based on total UMI counts: The Cell Ranger cell calling
algorithm prior to version 3 is used to identify high RNA content cells using the
cutoff method described in Section 2.4.2.
• Step 2 - Captures low RNA content cells whose UMI counts may resem-
ble empty GEMs: Based on [150], the RNA profile of each barcode not called as
a cell in step 1 due to its relatively low RNA content is compared to a background
model which is created by modeling the RNA profile of a set of selected barcodes
with low UMI counts that most likely represent empty GEMs. Barcodes whose
RNA profile deviate from the background model are kept as cells.
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In the TME, large tumor cells might be mixed with relatively smaller TILs. As the
cells in our samples are tumor-reactive TILs, we expected to see cells with relatively
lower UMI counts. This is most obvious in mouse_d25. The low median UMI counts per
cell along with lower than expected median genes per cell could be indicative of a large
population of TILs. This is later explored and clarified in Section 4.4.1. The mouse_d25
spleen sample looks to be troublesome in terms of the fraction of reads in cells. This
is explained by high ambient RNA in a sample. Ambient RNA comes from lysed/dead
cells. Although the reads are aligned confidently, they are not associated with a valid
cell-containing GEM. I have run cellranger count with the --force-cells option to
increase the expected number of cells, however, did not achieve a significant increase in
the cell count, suggesting that these cells may have been degraded. mouse_d25 spleen
sample was the first to be processed in the lab, and a low cell count was observed, which
was speculated to be due to the delay in processing the sample. For the other spleen
samples, they have reduced the time it takes to harvest the cells and RNA-sequence
them which has increased the recovery of splenic cells, as observed both in the lab and
post immune profiling analysis (Table 4.2). For all samples, the percentage of cells
that mapped back to the mm10 genome is high, showing that there was no external
contamination and that the detected cells were efficiently lysed.
cellranger vdj summary metrics
Tables 4.3 and 4.4 contain metrics about the barcoding and sequencing of the VDJ
enrichment process. Looking at the metrics, other than the low fraction of reads in cells
in the mouse_d25 spleen sample, there is no noticeable issue.
Merging barcode information from cellranger count and cellranger vdj
Within the Chromium Single Cell Immune Profiling Solution workflow, GEMs are
generated after cell suspension is loaded on to the Chromium controller, followed by
reverse transcribing full-length cDNA in single-cell GEMs. The cDNA is then amplified
and divided into two or three aliquots depending on whether VDJ is enriched for both
BCR and TCR, or only for either type. Lastly, the preparation of libraries for 5′ gene
expression and enrichment of VDJs followed by library preparation takes place.
Cell Ranger does not provide a consistent cell calling algorithm between GEX profiling
and TCR reconstruction. There are barcodes accepted as cells via cellranger count
but not cellranger vdj and vice versa. There were productive, full-length chains
called with confidence by cellranger vdj that were not considered to be valid as the
associated barcode was not detected as a cell with cellranger vdj, but was kept by
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mouse_d15 mouse_d19 mouse_d25
Estimated Number of Cells 6,881 4,734 5,999
Mean Read Pairs per Cell 2,462 7,946 4,763
Number of Cells With Productive V-J Spanning Pair 6,076 4,274 5,046
Number of Read Pairs 16,942,983 37,620,817 28,577,686
Valid Barcodes 96.2% 96.4% 95.8%
Reads Mapped to Any V(D)J Gene 88.9% 88.1% 86.8%
Reads Mapped to TRA 35.9% 38.3% 33.2%
Reads Mapped to TRB 36.2% 26.4% 27.1%
Cell Count Confidence 97.6% 97.1% 95.1%
Mean Used Read Pairs per Cell 2,142 6,936 4,042
Fraction Reads in Cells 96.3% 96.4% 93.9%
Median TRA UMIs per Cell 14 12 5
Median TRB UMIs per Cell 30 24 6
Cells With Productive V-J Spanning Pair 88.3% 90.3% 84.1%
Cells With Productive V-J Spanning (TRA, TRB) Pair 88.3% 90.3% 84.1%
Cells With TRA Contig 98.4% 98.1% 97.1%
Cells With TRB Contig 98.9% 99.2% 98.0%
Cells With CDR3-annotated TRA Contig 95.8% 96.3% 94.2%
Cells With CDR3-annotated TRB Contig 92.8% 92.8% 89.2%
Cells With V-J Spanning TRA Contig 96.8% 97.1% 95.8%
Cells With V-J Spanning TRB Contig 93.4% 93.2% 89.9%
Cells With Productive TRA Contig 95.1% 95.9% 93.6%
Cells With Productive TRB Contig 91.9% 92.3% 88.9%
Table 4.3 VDJ analysis metrics of all mouse samples taken from the tumor
mouse_d15 mouse_d19 mouse_d25
Estimated Number of Cells 3,748 2,901 1,851
Mean Read Pairs per Cell 4,283 15,079 15,443
Number of Cells With Productive V-J Spanning Pair 3,102 2,407 1,304
Number of Read Pairs 16,055,573 43,746,295 28,586,455
Valid Barcodes 96.9% 97.3% 94.5%
Reads Mapped to Any V(D)J Gene 88.7% 89.0% 84.8%
Reads Mapped to TRA 27.6% 27.6% 25.4%
Reads Mapped to TRB 40.1% 40.1% 35.2%
Cell Count Confidence 98.9% 100.0% 48.3%
Mean Used Read Pairs per Cell 3,892 13,635 4,068
Fraction Reads in Cells 97.9% 96.5% 29.6%
Median TRA UMIs per Cell 6 5 2
Median TRB UMIs per Cell 17 13 5
Cells With Productive V-J Spanning Pair 82.8% 83.0% 70.4%
Cells With Productive V-J Spanning (TRA, TRB) Pair 82.8% 83.0% 70.4%
Cells With TRA Contig 93.6% 93.5% 83.6%
Cells With TRB Contig 99.8% 99.8% 99.6%
Cells With CDR3-annotated TRA Contig 88.8% 89.1% 77.9%
Cells With CDR3-annotated TRB Contig 91.5% 91.9% 91.3%
Cells With V-J Spanning TRA Contig 91.1% 91.0% 81.0%
Cells With V-J Spanning TRB Contig 92.2% 92.6% 91.7%
Cells With Productive TRA Contig 87.9% 88.1% 76.4%
Cells With Productive TRB Contig 90.4% 90.7% 90.7%
Table 4.4 VDJ analysis metrics of all mouse samples taken from the spleen
cellranger count. I updated the associated barcode of these VDJs as a true cell if it
was detected with cellranger count. I discarded a portion of these cells, along with
others, during QC, which I explain in Section 4.4.1.
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4.4 Analysis
I present the downstream analysis of all the tumor samples. In the remainder of this
chapter, “tumor samples” refer to cells harvested from the tumor of an AgRSR mouse,
sorted with FACS for CD45+CD11B-EYFP+, and processed with the Chromium Single
Cell Immune Profiling Solution.
4.4.1 Gene expression analysis of EYFP+ cells
Unlike in Chapter 2, I did not call cells from empty droplets as Cell Ranger version
3.0 has implemented its own cell-calling algorithm based on [150] to detect cells more
accurately than the prior versions. As mentioned before, the output of 5′ GEX analysis
is a (gene x cell) UMI count matrix, henceforth referred to as the count matrix. The
values in the count matrix represent the number of molecules for each gene, detected in
each cell.
QC: Library sizes
The sum of UMI counts, detected within a cell is referred to as the library size of the
cell. Figure 4.6a shows the library sizes of each sample distinguished by whether it bears
a TCR or not. Here, TCR- cells may not be T cells, or a productive TCR may not have
been detected. Furthermore, cells with small library sizes tend to be TCR-, which may
suggest that these are artifacts, non-T cells, or damaged or dead cells. There is also a
noticeable difference in the UMI count per cell in the mouse_d25 sample, which was
discussed in Section 4.3.4. Additionally mouse_d25 has high UMI count cells which are
TCR-.
QC: Unique genes detected
The number of uniquely detected genes within each cell, i.e., the count of all genes
with UMI>0 within a cell, is a QC metric which can determine whether a cell is of low
quality or an empty droplet (very few detected genes). High gene count may signify
doublets/multiplets. Figure 4.6b shows unique gene count and TCR- seem to correspond
in low gene counts. These may be low-quality cells.
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(a) Library size distributions.
(b) Uniquely detected gene count distributions.
Fig. 4.6 Library size (shown on log10 scale) and uniquely detected gene count distributions in
the tumor samples. Each point represents a cell. Color denotes whether the cell bears a TCR
or not.
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Fig. 4.7 Cell complexity of tumor samples. Each point represents a cell. Total genes detected
and UMI count are shown on log10 scale.
QC: Cell complexity
Directly removing cells which have too few or too many detected genes, and large or
small library sizes can remove specific cell populations. In a heterogeneous population
like the TME, there may be different cell types belonging to different states, and hence
expressing different numbers of genes at different rates.
Combining library sizes and uniquely detected gene counts QC metrics gives us cell
complexity. Looking at Figure 4.7 we can see that there are TCR- cells with small library
sizes that also, in their majority, express less than 300 genes, which is especially evident
in sample mouse_d25. These are most likely to be artifacts. However, they can also be a
particular type of cell.
4.4 Analysis 115
Fig. 4.8 Percentage of UMIs mapped to mitochondrial genes plotted against the UMI count
(shown on log10 scale). Each point represents a cell.
QC: Mitochondrial UMI
Cells with high counts of UMIs that map to the mitochondrial genome may indicate
stressed cells, or incomplete lysis [105]. Looking at Figure 4.8, we see that specific cells
have very high mitochondrial content, and these cells do not bear a TCR.
QC: Mitochondrial UMI and uniquely detected genes
In Figure 4.9 we can see that genes with high mitochondrial expression have less uniquely
detected genes, most of which are TCR-. Based on Figures 4.7 and 4.9 I remove cells
with uniquely detected gene count less than 300. However, I make sure that these cells
are not enriched for a certain cell type (see Section 4.4.1, QC: Discarded cell inspection).
Next, I determine a threshold on mitochondrial gene expression to discard cells with
high mitochondrial content, which may indicate dead/stressed cells or incomplete lysis.
Assuming that the mitochondrial UMI proportions are normally distributed, I use
the robust Z-score method to identify outliers as described in Section 2.5.1. I consider
cells to be outliers if their mitochondrial content is more than 3 MADs away from the
median. Figure B.12 shows which cells are dropped/kept after this filtering.
Also observe that I increased the threshold of total genes detected to 600, 600, and
500, for samples mouse_d15, mouse_d19, and mouse_d25 respectively. I determined
this threshold in an iterative manner: visually inspecting Figure B.12 we can see that
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Fig. 4.9 Percentage of UMIs mapped to mitochondrial genes plotted against the number of
detected genes (shown on log10 scale). Each point represents a cell.
there are dispersed TCR- cells with less than 1000 uniquely detected gene counts in
samples mouse_d15 and mouse_d19, and cells with less than 800 in sample mouse_d25.
Starting at these levels, I decreased the threshold to the determined levels by examining
the differences in gene expression between the dropped and kept cells, as described next.
QC: Discarded cell inspection
Figure B.13 shows the correlation between the average UMI counts of dropped and
kept cells. For all samples, the populations are mostly in concordance. However, there
are some distinct set of genes that are expressed higher in the dropped cell pool. For
example, the genes HBB-BS, HBB-BT, HBA-A1 are hemoglobin markers. They are
expressed higher in the dropped cell pool, indicating the removal of red blood cells. I
examined the upregulation of genes in the discarded pool by computing log-fold changes
between the two pools. The genes upregulated amongst the dropped cells are: MT-*:
mitochondrial genes, HBB-BS, HBB-BT, HBA-A1 expressing hemoglobin genes. LARS2
is a mitochondrial, tRNA synthesis gene. MCPT1, MCPT2 expression indicate MAST
cells, but only a few cells are expressing them (see Figure 4.10). FN-1 is a fibronectin gene,
suggesting endothelial cells. AY036118 is a mouse transcription factor, and COL6A3,
COL18A1, COL3A1 are collagen α chain genes which have been reported as biomarkers
for various cancers.
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These genes together are either not specific to a certain cell type, or they mark blood
components. Hence it is reasonably safe to remove them. Removing cells with higher
UMI counts (>600) caused certain naive lymphocytes to be discarded, hence I selected
the determined thresholds for cell removal iteratively. After QC, each sample was reduced
by approximately 10% in size.
(a) mouse_d15 (b) mouse_d19
(c) mouse_d25
Fig. 4.10 Discarded cells’ distinguishing gene expression.
Normalization
Our samples do not have cells with equivalent RNA abundances due to the heterogeneity
of the TME. As described in Section 2.5.2, I used the deconvolution method presented in
[148] to calculate size factors, after a pre-clustering step with the scran::quickCluster
[149] function, specifying igraph as the clustering method to use. Figure 4.11 shows
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Fig. 4.11 Computed size factors plotted against the UMI count (shown on log10 scale)
the correlation of size factors against the library sizes. I normalized the samples using
scater::normalize and log2-transformed the normalized data.
Highly variable genes
In the remainder of the analysis, I focus only on genes which show high variation in expres-
sion between cells. These highly variable genes (HVG) are highly expressed in some cells
while lowly expressed in others. To determine these genes, I used scran::decomposeVar
which decomposes the variance of each gene into biological and technical components
while assuming the technical noise has a Poisson-based trend. I took the subset of genes
which had a positive biological component. I also removed all TCR expressing genes,
i.e., TRA* and TRB* genes as I did not want them to affect the downstream analysis
directly.
Figure 4.12 shows the distributions of normalized log2-transformed expression values
of the top ten most highly variable genes of each sample. We see some promising T cell
genes which mark different states and different functions.
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(a) mouse_d15 tumor HVGs
(b) mouse_d19 tumor HVGs
(c) mouse_d25 tumor HVGs
Fig. 4.12 Highly variable genes (HVGs) in the tumor samples.
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Fig. 4.13 The plots show the percentage of variance explained by the selected variables for
each successive PC.
Dimension reduction using PCA
Using denoisePCA [149] with the assumed Poisson technical noise, I identified PCs most
likely associated with actual biological phenomena, rather than technical artifacts. Here
it is assumed that the underlying biology drives most of the variance and should be
captured within the initial PCs, but technical noise is uncorrelated across genes and
should be visible in later PCs. denoisePCA [149] removes these later PCs. I used only
the HVGs when running denoisePCA but note that when selecting HVGs we did not lose
any genes that are upregulated in rare populations as our filtering is very relaxed and is
carried out primarily to remove TRA*/TRB* genes so that they do not drive any of the
PCs directly.
In all samples, PC1 and PC2 correlate with the number of detected genes. This
correlation is often observed. Also in moused_25 PC1 correlates with the mitochondrial
fraction. A correlation with library size can also be seen in the first PC. Immune cell
populations are not equivalent in terms of size. For instance, T cells make cytokines, and
plasma B cells make antibodies, which increase library size immensely. Here library size
could be reflecting biological variation. I did not regress out the variation caused by the
mitochondrial fraction or the library sizes as this could result in losing genuine biology.
The correlations of clonotypes and V genes with the PCs are interesting. It is
important to recall that I omitted the TCR genes, hence this is not driven directly by the
TRA*/TRB* genes. This could suggest that TCR clones express specific set of genes.
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Projection
Based on my justifications in Section 2.5.6, I used the Uniform Manifold Approximation
and Projection (UMAP) non-linear dimensionality reduction technique [156] to visualize
the cells in two dimensions. The fact that UMAP captures global structure better than
t-SNE is especially useful when visualizing cells of the TME. It allows us to see distinct
clusters of CD4+ and CD8+ further apart from each other while CD8+ cells in different
stages or (dys-)functionality separate less apart. Also, as UMAP preserves distances, it
tends to preserve the continuity of cell states. I performed UMAP on the prior reduced
and denoised PCs. This helps reduce the computational time necessary to embed the
data with UMAP.
Figures 4.14 and 4.15 display the UMAPs overlaid with UMI count, uniquely detected
gene counts, mitochondrial UMI percentage, TCR presence, and the normalized, log2-
transformed gene expression of CD3, CD8, CD4, and FOXP3. We can see that subsets
of T cells have separated further apart, as well as the cells with no TCR.
Clustering
As described in-depth in Section 2.5.5, I clustered the cells by first building a shared
nearest neighbor (SNN) graph [255] using the pre-computed PCs. Then I compared
different community detection algorithms (Fastgreedy [46], Walktrap [182], Louvain [78],
and Infomap [194]) and Louvain showed an ideal2 separation. Here the initial idea is to
stratify the cells into high-level groups based on cell type rather than finding functional
clusters. Using the Louvain algorithm, I found the community structure, i.e., clusters,
which best captured the distinct Tc, Th, and Treg clusters. Figure 4.16 shows the
clustering of each mouse tumor sample where the UMAP embedded data are colored by
cluster membership.
To identify clusters I examined the upregulated genes in each cluster which I found
using findMarkers [149]. Figures B.14, B.15, and B.16 show the top marker gene
expression via heatmaps. Gene expression levels are colored by the normalized, log2-
transformed, and row-scaled expression of each gene in each cell. Also, in order to stratify
cells into an initial high level grouping I inspected the expression of CD3, CD4, CD8,
and FOXP3 genes (see Figure 4.15). Note that mouse_d25 has a relatively small CD8+
cell population.
2“Ideal” here means a desired separation in terms of biologically meaningful clusters. One may use
the modularity score as a measure of good separation (which is of course only a technical measure and
not a biologically informative one) but considering there is no right or wrong clustering, it is best to
inspect the clusters in terms of gene expression.
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(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.14 UMAP of each sample overlaid with UMI count, uniquely detected gene counts,
mitochondrial UMI percentage, and TCR presence. Each dot represents a cell.
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(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.15 UMAPs of each sample overlaid with normalized, log2-transformed CD3, CD8, CD4,
and FOXP3 gene expressions.
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(a) mouse_d15 (b) mouse_d19
(c) mouse_d25
Fig. 4.16 UMAP embedded data is colored by cluster membership. Each cluster is denoted
with a different color. Points represent cells.
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Based on their gene expression, in sample mouse_d15 ; cells in clusters 1, 2, 3, 4, 5,
6, 9, and 10 are CD8+, cluster 8 are Tregs, and cluster 11 are naive T cells. In sample
mouse_d19 ; cells in clusters 1, 5, 7, 8, 10, 12, 13, and 14 are CD8+, clusters 2, 3, 4, and
6 are Tregs. And in sample mouse_d25 ; cells in clusters 1, 3, 4, and 6 (partially) are
CD8+, while cells in clusters 2, 6 (partially), 7, 9, and 12 are Tregs, and cells in clusters
11 and 13 are CD4+.
At this point, there are a few things to note. Certain T cells cluster apart from their
specific class of CD8+ or CD4+ based on the expression of ribosomal genes (RPL*/RPS*).
For example, cluster 6 in mouse_d19 can merge with cluster 2, but it has a very low
RB-* expression. The low expression of ribosomal protein mRNA can signify cells that
are in atrophy or senescence or the cell’s cytoplasm could have been completely damaged.
This can be used as another QC, but in this study, I let these cells cluster on their own
instead, based on my justifications made in Section 2.5.1.
We can also observe cells displaying co-expression of CD8 and CD4, which is distorting
the top-level clustering. One possible interpretation of this result is that we are detecting
CD8+CD4+ DP mature T cells, which indeed have been reported in melanoma [55].
However, this observation could also be explained as an artifact introduced by the
single-cell sequencing protocol. This second explanation is more likely to be true for
some of the cells I found co-expressing IGHM and CD8A. These cells also bear TCRs
and express genes which are normally involved in BCR recombination. While we could
be observing a rare case of dual receptor-expressing lymphocytes as presented in [7],
the artifact explanation remains more likely at this point. Since the V, D, and J gene
expression levels are too low to be picked up directly from the GEX analysis, it is difficult
to distinguish between real signal and noise in this case. It would be intriguing to
speculate about IGHV genes expressed in these cells (Figure 4.52) and the correlation
between CD8 and CD4, IGHM, and IGKC genes (Figure 4.51). However, at this point
we cannot draw any conclusions without further, more complex validation experiments.
It would be interesting to study the functionality and the TCR/BCR driven states of
these cells and their receptor repertoires.
Lastly, looking at the heatmaps in Figures B.14, B.15, and B.16, we can see cell
cycling clusters which are marked with genes such as TUBA1B, TOP2A, and STMN1.
In order to distinguish the cell cycling clusters more surely, I took the cell cycling gene
module of T cells from [140] and visualized their expression in a heatmap.
Based on the heatmaps shown in Figure 4.17, cluster 6 in mouse_d15, clusters 3, 7,
and 12 in mouse_d19, and clusters 4 and 6 in mouse_d25 are cell cycling. According
to [140], the highest fraction of proliferating cells was among dysfunctional cells, and
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(a) mouse_d15 (b) mouse_d19
(c) mouse_d25
Fig. 4.17 Normalized, log2-transformed, and row-scaled expression of cell cycling genes
determine the cell cycling clusters.
proliferation was most prominent in the earlier stages of dysfunctionality. However,
dysfunctional cells occupied all stages of the cell cycle. Within the remainder of my
analysis, I took cell cycle into consideration by assigning each cell to a cell cycle phase as
previously described in Section 2.5.3.
Clonotype distribution within clusters
Having determined the clusters and their cell identities, I proceed to examine the
clonotypes. First I investigated whether clonotypes were separated by top-level cell type;
i.e., the presence of CD8+, CD4+ and CD4+ FOXP3+ clonotypes. In Figure 4.19 specific
clonotypes are indeed of certain cell types. All of the clonotypes with at least 100 cells in
mouse_d15 and mouse_d19 are CD8+. However, this changes in mouse_d25 ; the most
clonally expanded, i.e., the clone with the most number of cells, bears Treg clonotypes.
Only clonotypes 2 and 5 are CD8+. There is also a CD4+ clonotype which we do not see
in the other samples. As I mentioned before mouse_d25 has a relatively small CD8+ cell
population. We can also see that some of the clonotypes are cluster-specific, suggesting
that they are associated with the underlying gene expression profiles. Considering I
did not use the TCR recombining genes when clustering the cells, any separation we
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see is not driven directly by the TRA*/TRB* genes. As a next step, I overlaid the
clonotypes on the UMAPs of each sample to visualize how the underlying GEX profile
associates with the clonotypes in 2D space (see Figure 4.20). In samples mouse_d15
and mouse_d19 cells bearing the same clonotypes are not cluster-specific, however as
expected they are cell type specific and they group close together in the 2D projection,
whereas sample mouse_d25 has clonotypes that cover specific clusters. At this stage
it is of course not possible to draw any conclusions as the clustering can be made to
be much more granular and for samples mouse_d15 and mouse_d19 we can start to
see cluster-specific clonotypes as well. In order to investigate clonal specificity, I took
the clonotypes as a unit of identity. For each sample, I calculated the cell-to-cell HVG
expression correlation within clonotypes which have at least 100 cells; these are the
clonotypes shown in Figure 4.20. Figure 4.18 shows heatmaps where grids are the
calculated Pearson correlation coefficients for normalized log2-scale gene expression levels
between all cells. In samples mouse_d15 and mouse_d19 we don’t see an obvious
difference within or between clonotypes (except maybe for clonotype3 in mouse_d19 )
but cells in clonotypes 2 and 5 in sample mouse_d25 display greater correlation within
clonotypes when compared to others. This may suggest that more granular clustering
will not result in other cluster-specific clonotypes to emerge in sample mouse_d25. Note
that clonotypes 2 and 5 of mouse_d25 are CD8+ whereas the others are Treg and CD4+.
(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.18 Cell-to-cell correlation matrices for the normalized log2-scale gene expression levels
between all cells within the top clonotypes. Each grid cell is colored based on the Pearson
correlation coefficient.
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(a) mouse_d15 (b) mouse_d19
(c) mouse_d25
Fig. 4.19 Plots show the normalized, log2-transformed expression of CD4, CD8, and FOXP3
genes within each cluster. Each point represents a cell and is colored by its clone, i.e., its TCR’s
clonotype. Only the clonotypes represented with at least 100 cells are shown. None specifies
cells with no TCR (TCR-), and other specifies any other clonotype that did not make the cut
as it had less than 100 cells. Each clonotype name is exclusive in its own sample; they are not
shared between samples.
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(a) mouse_d15 (b) mouse_d15
(c) mouse_d19 (d) mouse_d19
(e) mouse_d25 (f) mouse_d19
Fig. 4.20 Clonotype overlay on UMAPs.
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Fig. 4.21 UMAP of CD8 ex-
pression of the all cells in
clusters 1, 3, 4, and 6 of
mouse_d25, without any fil-
tering on UMI count. Here
all the cells with no CD8
UMIs cluster apart further to
the right. They do not con-
tribute to the analysis but
can distort clustering due to
purely technical reasons.
4.4.2 V(D)J and Gene Expression Analysis of CD8+ TILs
Next, I subsetted the tumor samples for CD8+ cells to further investigate their clone
specific gene expression profiles. I took all the clusters defined as CD8+, i.e., differentially
expressing CD8 (Figure B.17), and filtered out cells in which no CD8 UMI was detected.
As our initial clustering was not very granular, it is possible to see some cells which do
not express CD8 but still cluster together with CD8+ cells based on the closeness of other
gene expression distances. I could have left these cells to cluster apart (see Figure 4.21
for a UMAP of the subsetted cells when keeping all the cells without filtering on positive
CD8 UMI count) however I aimed to avoid their UMI count to distort normalization.
When compared to the other two samples mouse_d25 has many fewer CD8+ cells (see
Figure 4.22). The TME of mouse_d25 has a much more heterogeneous tumor-reactive
cell population. I also removed cells that did not bear a TCR (less than 2%, 2%, and
4% in samples mouse_d15, mouse_d19, and mouse_d25 respectively) as I wanted to
focus on the clonotype specific response. Instead of performing further clusterings within
clusters, I used the initial clustering as a single cell stratification. The immune cells
vary in size, and when normalizing their UMI count, specific cell types may pull the size
factors to the extreme and hence distort the gene expression levels. Here I pool together
all the subsetted CD8+ T cells and normalize them following the same pre-clustering and
deconvolution method. See Figure 4.23 for the library size and uniquely detected gene
count distributions, as well as cell complexity and the newly calculated size factors for
the subsetted cells. It is worth noting that the range of the size factors is now narrower.
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Fig. 4.22 CD8 expressing cell proportions. mouse_d25 has
much less CD8+ cells when compared to the other samples.
The TME of sample mouse_d25 is much more heterogeneous
which could be due to both the suppression of CD8+ cells and
the global response of the immune system mobilizing various
immune cells to the tumor over time.
(a) Library size distributions (b) Uniquely detected gene count distributions
(c) Cell complexities (d) Size factors
Fig. 4.23 Subsetted CD8+ cells
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Cell cycling
As I mentioned before in Section 4.4.1, our samples comprise cells from different cell
cycle phases. I identified this by observing the expression of known cell-cycle marker
genes. As such, [207] have proposed a method (Pairs) to infer the cell cycle phase of
a cell directly from its gene expression profile. Their classification algorithm, using a
training dataset, found pairs of marker genes that can assign a phase to a cell. This
method is described in-depth in Section 2.5.3. A slightly altered version of this method
is implemented in scran::cyclone with an existing pre-trained set of marker pairs for
mouse data. Using this function I assigned cells into cell cycle phases based on their
































































Fig. 4.24 Cell cycle phases of subsetted CD8+ cells. Cell cycle phase scores of samples where
each point represents a cell. Red lines separate cell phases and proportion of cells in each phase
are written in red.
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(a) mouse_d15 CD8+ HVGs (b) mouse_d19 CD8+ HVGs
(c) mouse_d25 CD8+ HVGs
Fig. 4.25 HVGs of CD8+ cells.
Next, similar to before, I found the HVGs (Figure 4.25), performed dimension
reduction to determine PCs driven by biology, projected data onto two dimensions with
UMAP (Figures 4.26, 4.27), and clustered (Figure 4.28) each sample.
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(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.26 UMAP of each CD8+ subset overlaid with UMI count, uniquely detected gene counts,
mitochondrial UMI percentage, and cell cycle phase. Each dot represents a cell.
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(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.27 UMAPs of each CD8+ subsets overlaid with normalized, log2-transformed CD3,
CD8, CD4, and FOXP3 genes.
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(a) mouse_d15 (b) mouse_d19
(c) mouse_d25
Fig. 4.28 CD8+ cell clusterings. UMAP embedded data are colored by cluster membership.
Each cluster is denoted with a different color. Points represent cells.
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Figure 4.29 shows the cell frequency in each cluster colored by the cell cycle phase.
Cluster 6 in mouse_d15, 8 in mouse_d19, and 3 in mouse_d25 are cell cycling. There
are also cells in S and G2M phases in other clusters, but these are negligible. When
finding the cluster biomarkers, I discarded these cells and the cell cycling clusters.
mouse_d15 mouse_d19 mouse_d25
















Fig. 4.29 For each sample, the bar plots show the cell count in clusters. Bars are colored by
phase membership.
The rationale behind discarding the whole cell cycling cluster instead of only the
G2M and S phase cells is that the phase allocations of these cells have a low degree of
confidence when compared with the G1 phase cells in other clusters. Figure 4.30 shows
this with mouse_d19 as an example. This could suggest that these cells are cycling as





























































































































Fig. 4.30 G1 score distribution of cells in each cluster that are in the G1 phase.
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Identifying clusters







































































































































































































































































































































Fig. 4.31 Heatmaps show the log2-transformed average normalized expression of biomarkers.
I found the upregulated genes in each cluster to identify cluster biomarkers. Within
this sub-clustering we can, for example, see that cluster 2 of mouse_d15 are naive T
cells (SELL, TCF7), cluster 4 of mouse_d19 are cytotoxic T cells, and so are cluster 4
of mouse_d25. I next took CCR7, TCF7, LEF1, and SELL naive T cell markers, and
4.4 Analysis 139
NKG7, CCL4, CST7, PRF1, GZMA, GZMB, IFNG, CCL3 cytotoxic T cell markers
[235], and the intersection of tumor CD8+ dysfunction-related genes identified in [235],
[265], [268], and [89], and looked at their average normalized expression in each cluster
in order to distinguish naive, cytotoxic, and dysfunctional clusters.










































































































Fig. 4.32 Heatmaps show the log2-transformed average normalized expression of naive, cyto-
toxic, and dysfunctional biomarkers for CD8 cells.
The separation is mostly clear for naive T cell clusters. However, it is possible to
cluster the cytotoxic and dysfunctional clusters further. Instead of sub-clustering until
“biologically desired” clusters are achieved, I took the clonotypes as the unit of grouping
and found the clonotype biomarkers.
Identifying clonotype biomarkers
Figure 4.33 shows the overlay of clonotypes on the UMAPs of each sample. Observe
that the gene expression clustering and clonotype bearing overlaps in sample mouse_d25.
If we find the up/down-regulated genes of these clusters, we can identify the state
of the clonotypes. Note that the overlays include the cell cycling clusters; however,
when determining the clonotype markers, I did not include them in my analysis. I also
do not consider the clonotypes that are represented by less than 50 cells. I ran both
scran::findMarkers and scran::overlapExprs to identify the differentially expressed
genes. scran::overlapExprs performs pairwise Wilcoxon rank sum tests between groups
of cells, whereas scran::findMarkers uses the Welch t-test. Heatmaps showing the
expression of clonotype biomarkers of each mouse can be found in Figures B.18 - B.23.
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(a) mouse_d15 (b) mouse_d15
(c) mouse_d19 (d) mouse_d19
(e) mouse_d25 (f) mouse_d19
Fig. 4.33 Clonotype overlay on UMAPs.
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Fig. 4.34 Graphical overview of the integrated approach. Single cells were collected from the
AgRSR mouse tumor and spleen, sorted with FACS, processed with Chromium Single Cell
Immune Profiling Solution, and analyzed in combination.
I analyzed the cells harvested from the mouse tumor and spleen together to identify
shared and differentiated cell states. I also wanted to see whether the immune response
was localized, or if there were common clonotypes between the tumor and spleen. For
this, I first compared each mouse’s tumor and spleen TCR clonotypes. We might recall
that cells with the same productive CDR3 regions in their TCRs’ α and β chains are
considered to be of the same clone, and their TCRs the same clonotype. Hence I compared
the CDR3 regions of tumor and spleen cell TCRs with the requirement that they are an
identical match in their amino acid sequence. For the tumor samples, I considered only
the clonotypes with at least two cells, however, for the spleen samples I did not specify a
cutoff as the clone frequencies are much lower in the spleen when compared to the tumor.
Additionally, I discarded clonotypes with single chains. Table 4.5 shows the similarity
between each mouse’s tumor and spleen samples based on different metrics.
Compared to the other two samples, mouse_d15 has the most overlapping clonotypes
with the top clonotype (clonotype1) having 912 cells in the tumor and 136 in the spleen
(see Figure 4.35). Also, we know that some of the cells within this clone express CD8+
dysfunctional-state markers such as LAG3, and PDCD1. I say some as this clonotype
spans multiple clusters: 5, 6, 8, and 9 (see Figure 4.33a) where cluster 6 is cell cycling.
Furthermore, all of the top clonotypes, except for one (clonotype5), which are present in
the tumor are also represented in the spleen.
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mouse_d15 mouse_d19 mouse_d25
Shared clonotypes 58 51 39
Shared CDR3s 119 109 55








Table 4.5 The similarity between tumor and spleen samples.
20% 10% 0% 10% 20% 30%
mouse_d15
10% 0% 10% 20% 30%
mouse_d19





Fig. 4.35 Shared clonotype proportions in tumor and spleen samples.
Sample mouse_d19 has its highest overlap in clonotype2 with 261 cells in the tumor
and 10 cells in the spleen. The top clonotype of the tumor with 897 cells is not represented
in the spleen. The next highest clonotype with 139 cells is represented with only 5 cells
in the spleen. In fact, except for these two clonotypes, none of the clonal tumor sample
TCRαβ chain pairings are represented in the spleen.
Although mouse_d25 has overlapping clones these are not CD8+ cells. The two
cluster specific clonotypes 2 and 5 are not represented in the spleen. Figure 4.36 shows
the clonotype proportions of all the clonotypes in the tumor, and the proportions of the
overlapping clonotypes in the spleen.
It is also important to note that the cluster specific clonotypes 2 and 5 of mouse_d25
express dysfunctional-state markers such as LAG3, TOX, TIGIT, and PDCD1. The top
overlapping clones (clonotype1) are Tregs; this is clear in Figure 4.19c. This clonotype is
represented with 863 cells in the tumor and with 26 cells in the spleen.
Because of our interest in the dysfunctional CD8+ cells, and due to the significant
number of cells in overlapping clonotypes, I decided to analyze the tumor and spleen
cells of sample mouse_d15.
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(a) mouse_d15 (b) mouse_d15
(c) mouse_d19 (d) mouse_d19
(e) mouse_d25 (f) mouse_d19
Fig. 4.36 UMAPs show the clonotype proportions, before CD8+ stratification, in tumor and
spleen samples.
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UMI counts cannot be directly compared between samples: multiple reads with the
same UMI and barcode which align to the same gene counts once towards the absolute
number of observed transcripts per gene in a cell. However, these absolute counts are
not normalized for sequencing depth or RNA content per cell. Furthermore, technical
sources of variation may be added to the samples during handling. Called batch effects,
these variations include external factors associated with labwork such as who prepared
the libraries and when, what equipment they used, what was the reagent quality, what
was the lab temperature that day, and so on. These circumstantial differences can cause
systematic differences in gene expression in cells coming from different samples, making
it difficult to identify the real biological variation by masking or intertwining the real
signal with noise. Therefore, we need to correct for batch effects when analyzing the
spleen and tumor samples together.
Preprocessing of the mouse_d15 spleen sample
Fig. 4.37 mouse_d15 spleen sample QC plots.
Just like the tumor samples, cells were harvested from the spleens of the AgRSR
mice, sorted with FACS for CD45+CD11B-EYFP+, and processed with the Chromium
Single Cell Immune Profiling Solution. And as before, I ran cellranger count and
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cellranger vdj on the obtained spleen sample RNA-seq reads to obtain the gene
expression profiles and the TCR repertoires, respectively.
cellranger count estimated a total of 3,992 cells in the mouse_d15 spleen sample.
Using the same QC approach as before (see Section 4.4.1) I removed 195 low quality cells
which can be seen in Figure 4.38. Also see Figure 4.37 for the QC diagnostic plots. The
cells with low numbers of uniquely detected genes and high mitochondrial read fractions
are mostly TCR-; hence, it is safe to discard them.
Fig. 4.38 mouse_d15 spleen sample cells colored based on discard/keep, and differentiated by
shape based on TCR detection.
I next merged the two tumor and spleen datasets subsetting on the shared HVGs
(7,331 genes) between the samples. We can explore the possible batch effects with a PCA.
Figure 4.39 plots the first two dimensions of the PCA; PC1 and PC2, which explain
22 and 7 percent of the total variation, respectively. Here each dot represents a cell
colored by its originating sample. Having performed a PCA using the merged datasets,
we can see a clear separation between the two samples: Cells from different samples
mostly cluster together. As mentioned above, an apparent cause of this separation is the
difference in the sequencing depth between samples. In order to remove this technical
consequence, I used the aggregation method implemented as part of the Cell Ranger
analysis pipelines.
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Fig. 4.39 PCA projection of mouse_d15 merged tumor and spleen samples before batch
correction where each dot represents a cell colored by its origin.
Normalizing for differences in sequencing depth between samples
The cellranger aggr pipeline aggregates the individual cellranger count outputs
of each sample by normalizing them to the same sequencing depth, producing a single
count matrix on the combined data. I first ran cellranger count on each sample
separately. Then, to be able to compare them, I aggregated them with cellranger aggr.
The cellranger aggr pipeline normalizes for sequencing depth by subsampling the
reads. When subsampling, the pipeline only considers reads which aligned to valid
barcodes and UMIs. No cell calling is performed as it directly uses the cells called via
cellranger count. The pipeline finds the sample with the lowest number of reads and
downsamples all the other samples to this threshold by computing a subsampling rate
for each sample and keeping only the necessary fraction of reads. The subsampling rate
is based on the mean number of filtered reads mapped to the transcriptome per cell.
Table 4.6 lists the summary metrics of the GEX barcoding and sequencing process on
the cells obtained from the spleen and the tumor of mouse_d15. Here mean reads per cell
is calculated by dividing the total number of sequenced reads by the estimated number of
cells. This average is based on all the reads and not just the ones that mapped confidently
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Spleen Tumor
Estimated Number of Cells 3,992 7,633
Mean Reads per Cell 75,212 39,707
Median Genes per Cell 2,083 2,571
Number of Reads 300,249,980 303,085,056
Valid Barcodes 93.5% 94.1%
Fraction Reads in Cells 97.1% 95.6%
Reads Mapped to Genome 95.9% 96.1%
Reads Mapped Confidently to Transcriptome 79.3% 81.5%
Table 4.6 GEX analysis metrics of mouse_d15 samples
to the transcriptome. The mean number of confidently-mapped-to-transcriptome, valid-
barcode reads per cell in the spleen sample, prior to depth normalization, is 55,938, and
for the tumor, it is 29,949. So cellranger aggr took the lower count of 29,949 of the
tumor sample as a threshold, and downsampled the spleen sample reads until they both
had an equal number of confidently mapped reads per cell. The results can be seen in
Table 4.7.
Estimated Number of Cells 11,625
Post-Normalization Mean Reads per Cell 39,899
Median Genes per Cell 2,267
Pre-Normalization Number of Reads 603,335,036
Post-Normalization Number of Reads 463,836,466
Fraction of Reads Kept in Tumor 100%
Fraction of Reads Kept in Spleen 53.5%
Pre-Normalization Confidently Mapped
Barcoded Reads per Cell in Tumor 29,949
Pre-Normalization Confidently Mapped
Barcoded Reads per Cell in Spleen 55,938
Table 4.7 Aggregate metrics of mouse_d15 samples.
Here 53.5% of the spleen sample reads are kept so that the tumor and spleen samples
both have the same sequencing depth, measured in terms of reads that are confidently
mapped to the transcriptome per cell.
After normalizing the samples for sequencing depth, I processed the combined count
matrix. I removed the barcodes that were discarded when processing the mouse_d15
tumor and spleen samples separately. I then normalized the count matrix using the
previously described method (see Section 4.4.1) and subsetted on the shared HVGs. The
sequence-depth-corrected combined sample PCA projection can be seen in Figure 4.40.
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Fig. 4.40 PCA projection of mouse_d15 after normalizing for differences in sequencing depth
between the tumor and spleen samples where each dot represents a cell colored by its original
sample.
After correction, samples associate more closely than before. However, separation is
still apparent. At this point, we can assume that the biology of the tumor and spleen is
so drastically different such that the separation between the cells is as clear-cut. This is
not a realistic assumption as we expect to see some overlapping cell types, such as CD4+
T helper and CD8+ T suppressor/cytotoxic cells. We do, however, expect differing cell
types as well; the T lymphocytes which differentiated into different states within the
TME as the tumor took control of their transcriptional mechanism. Hence we have two
samples with both distinct and common cell types and states. Furthermore, even when
the cell types/states are the same, they can be present in differing abundance due to the
proliferation/clonalization of immune cells which takes place in the tumor, resulting in
differing cell population compositions.
Batch effect correction with mutual nearest neighbors
To further correct for possible batch effects, I used a method based on the detection of
mutual nearest neighbor (MNN) pairs [94]. The MNN approach assumes that, across
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the merged samples, there is a shared subset of the cell population, but does not require
predefined or identical population compositions. This approach is ideal for our case as
we cannot assume cell populations of identical or known compositions between the tumor
and spleen samples; however we know they share common cell sub-populations.
Briefly, for each cell ia in sample A, the MNN-based method finds k cells in sample
B that are nearest neighbors to ia in the high-dimensional gene expression space, thus
obtaining its k nearest neighbors in sample B. Then for each cell in sample B, it finds
their k nearest neighbors in sample A. Cells from different samples that are within each
other’s set of nearest neighbors are pairs of cells that are mutually nearest neighbors.
These pairs of cells are thought to belong to the same biological cell type/state before any
batch effect corrupted their signals. Hence, the difference in expression profiles between
these paired cells should give an estimate of the batch effect which needs to be removed.
This difference is then subtracted from all cells, including those that were not part of an
MNN. Hence the batch effect correction is applied to both shared and distinct cell types.
The batchelor::fastMNN() function implements the MNN approach with a slight al-
teration: To decrease computational work, it performs a PCA to obtain a low-dimensional
representation of the input data. All cells are projected into this low-dimensional space
defined by the top d chosen principal components, and batch effect correction is performed
in this space.
I applied batchelor::fastMNN() on d=50 principal components computed from
the shared HVGs. Here the shared HVGs are genes with a positive average biological
component across the two samples. In total there were 11,164 HVGs. I excluded all the
TCR generating V, D, J, and C genes. Figure 4.41 shows how the cells separate by the
sample of origin after MNN correction.
We can now see a further association between the cells coming from the two different
samples. To interpret the separation, we can also look at the corrected expression of T
cell marker genes CD3, CD4, CD8, and FOXP3. In Figure 4.42 we see that T helpers,
CD8 T cells, and Tregs have grouped tightly suggesting that we were able to separate
the cells irrespective of their sample of origin, or less so.
The MNN-corrected values no longer make sense in terms of gene expression: As seen
in Figure 4.42, they can take negative values. This is expected since we are subtracting
vectors to correct for batch effects. However, we can still use these corrected values for
cell-cell analysis where we only need the Euclidean distances between cells.
I used the MNN-corrected values to build a shared nearest-neighbors graph for all
cells and applied the Walktrap community detection algorithm to identify the possible
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Fig. 4.41 UMAP of mouse_d15 after MNN correction where each dot represents a cell colored
by its original sample.
clusters. Figure 4.43a shows the detected clusters overlaid on the two-dimensional UMAP
of the merged samples.
In Figure 4.43 we see that clusters 6, 12, 13, 14, and 15 have cells that do not
bear TCRs. Additionally, cluster 4 in majority comprises spleen sample cells (1372
spleen and 38 tumor sample cells). To identify these clusters, I performed differential
expression analysis between clusters, but within each sample using the uncorrected
gene expression data, then combined the p-values across samples to find the top cluster
markers. Figure B.25 is a heatmap showing the uncorrected scaled gene expression of the
cluster biomarkers. Cluster 1 shows high expression of TUBA1B, TOP2A, and STMN1,
indicating it is a cell cycling cluster. Cluster 4 comprises naive CD4+ cells.
I next overlaid the shared clonotypes on the merged samples selecting only the top
15 most frequent ones (see Figure 4.44). There are 912 tumor cells and 136 spleen cells
that bear the common_clonotype_1 TCRs. This clonotype spreads over clusters 1, 2, 3,
and 11. Considering cluster 1 is cell cycling, I focused on the remaining clusters.
I took the clonotype as the unit of identity and found the markers that distinguish
between tumor and spleen to see how this clonotype differentiates between the two
samples. There are a total of 776 cells in this subset consisting of 104 spleen and 672
tumor cells.
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Fig. 4.42 UMAP of mouse_d15 after MNN correction where each dot represents a cell colored
by the corrected expression of CD3, CD4, CD8, and FOXP3 genes.
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(a) Cluster membership (b) Cell type
(c) TCR presence (d) Cluster proportions by sample
Fig. 4.43 (a-c) UMAPs of the merged mouse_d15 sample after MNN correction where each
dot represents a cell and is colored by cluster membership, TCR presence, and cell type. (d)
Proportions of cells, relative to within samples, in each cluster separated by sample of origin.
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Fig. 4.44 UMAP of mouse_d15 after MNN correction where each dot represents a cell colored
by the shared clonotypes between the tumor and spleen samples.
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Fig. 4.45 Heatmap showing mouse_d15 common_clonotype_1 tumor and spleen cells’ uncor-
rected gene expression of biomarkers found to differentiate the tumor and spleen cells. The
gene expression is not scaled.
Looking at Figure 4.45 we can see the TME-immune response interplay in action.
The common_clonotype_1 cells differentiate in the tumor expressing granzymes (GZMC,
GZME, GZMF), meaning these cytotoxic T clones are inducing apoptosis to eliminate
cancerous cells. We also see the differential expression of PDCD1, CTLA-4, and LAG3 in
the tumor sample clones, which shows that the TME is trying to counteract the immune
response by putting the clones in a dysfunctional state.
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(a) mouse_d25 spleen B cells (b) mouse_d25 spleen T cells
(c) mouse_d25 tumor B cells (d) mouse_d25 tumor T cells
Fig. 4.46 cDNA QC plots show very low yield for BCR enrichment. Plots courtesy of
Ms. Katarzyna Kania, CRUK CI Genomics Core
4.5 Results
4.5.1 Lack of intratumoral B cells
BCR enrichment was performed along with TCR enrichment only for mouse_d25 reason
being that no B cells were detected in the tumor sample. The QC results of the
cDNA manufactured from the tumor sample showed a very low yield for BCR enrichment
(Figure 4.46). This was consistent with a follow-up FACS analysis: Remaining tissue from
FACS were stained with CD19 to check for B cells. However there were no CD19+EYFP+
expressing cells detected (Figure 4.47).
Looking at Table 4.8, we see that 1,060 B cells have been detected in the tumor where
only 11 of them have a productive V(D)J pair. Only 54.9% of the reads have mapped to
any VDJ gene, and very low portions have mapped to Ig genes. The fraction of reads is
very low as well, indicating ambient RNA and hence dead cells or artifacts. The first
obvious explanation of why we see 1,060 cells, but only 11 of them have productive Ig
chains is that these barcodes have been falsely called as cells. Next, as very few reads










CD19 CD4 CD8 Non−T/B cells
Fig. 4.47 Composition of EYFP+ sorted cells. Non-T/B cells are defined as
CD45+CD11B-F4/80-CD8-CD4-CD19-
mouse_d25 spleen mouse_d25 tumor
Estimated Number of Cells 1,579 1,060
Mean Read Pairs per Cell 16,407 35,611
Number of Cells With Productive V-J Spanning Pair 1,505 11
Number of Read Pairs 25,908,141 37,748,147
Valid Barcodes 97.1% 87.5%
Reads Mapped to Any V(D)J Gene 97.3% 54.9%
Reads Mapped to IGH 17.1% 17.6%
Reads Mapped to IGK 65.5% 14.3%
Reads Mapped to IGL 11.3% 0.3%
Cell Count Confidence 77.7% 58.1%
Mean Used Read Pairs per Cell 9,922 3,302
Fraction Reads in Cells 73.4% 34.4%
Median IGH UMIs per Cell 18 0
Median IGK UMIs per Cell 67 0
Median IGL UMIs per Cell 240 0
Cells With Productive V-J Spanning Pair 95.3% 1.0%
Cells With Productive V-J Spanning (IGK, IGH) Pair 90.1% 0.8%
Cells With Productive V-J Spanning (IGL, IGH) Pair 6.6% 0.2%
Paired Clonotype Diversity 27.48 11.00
Cells With IGH Contig 97.3% 18.0%
Cells With IGK Contig 95.8% 29.6%
Cells With IGL Contig 42.1% 1.1%
Cells With CDR3-annotated IGH Contig 96.2% 1.0%
Cells With CDR3-annotated IGK Contig 94.6% 0.8%
Cells With CDR3-annotated IGL Contig 6.8% 0.2%
Cells With V-J Spanning IGH Contig 95.8% 1.0%
Cells With V-J Spanning IGK Contig 95.5% 0.8%
Cells With V-J Spanning IGL Contig 10.8% 0.2%
Cells With Productive IGH Contig 95.5% 1.0%
Cells With Productive IGK Contig 94.6% 0.8%
Cells With Productive IGL Contig 6.8% 0.2%
Contigs Unannotated 0.2% 0.3%































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 4.48 UMAP of the 1,060 cells showing the gene expression for MS4A1, CD19, TNFRSF17,
PTPRC, CD3, and LYZ2
map to Ig genes, it is possible that some of the cells are instead T cells. In order to
further investigate, I analyzed these cells’ gene expression profiles.
Figure 4.48 visualizes feature expression of selected genes on a UMAP of the 1,060
cells. Looking at the expression of MS4A1, CD19, and TNFRSF17, we can see that there
are only a few B cells or plasma B cells. Majority of the cells express CD3 suggesting if
these are real cells, they are in fact T cells. Figure 4.49 shows the expression heatmap of
the top markers for each cluster. Only cluster 6 shows B cell markers. So if we are to
accept these barcodes as cells, it is evident that they are in majority T cells.
Having investigated the nature of the aforementioned 1,060 cells, we need to address
the lack of B cells in our samples. There are multiple possible explanations for this
observation. One possible explanation is that during B cell differentiation CD19 might be
downregulated. Our B cells might represent activated B cells of a different developmental
158 Tumor-reactive immune cell clonality












































































Fig. 4.49 Majority of the markers determine that the cells are T cells. Only cluster 6 expresses
B cell biomarkers MZB1, IGLC3, and MS4A1.
stage, e.g., plasma cells, which were not recovered by the CD19 FACS analysis. Moreover,
the AgRSR mouse cells are sorted for CD45+CD11B-EYFP+. Indeed CD45 is expected
to be low in plasma cells and plasmablasts [183], thus impairing the recovery of these cell
populations in our experimental system. This explanation would be consistent with what
we observed in the human melanoma samples presented in Chapter 2. In these unselected
cell populations, the plasma cell cluster does not express PTPRC, the gene which encodes
for the CD45 molecule, or expresses it at very low levels (see Figure 4.50). While we
have not directly observed a presence of plasma cells in our mouse single cell sequencing
data, we cannot exclude their presence as they might have been counterselected by our
CD45+ FACS analysis.
Additionally, to further account for the absence of B cells, I can hypothesize that
considering this melanoma is an injected tumor, rather than one that has developed
naturally over time, it is possible that the immune system of this mouse model does
not portray one that developed naturally over time, either. Injected tumors form very
quickly, showing accelerated disease progression, and as a result contain less stroma and
are rich in cancer cells [225], which may not reproduce the histological nature of a clinical
cancer. A recent study has compared B cell infiltration and activation in a genetic model
of murine PDAC (KPC mouse) as well as an injectable orthotopic model, to find that
significant B cell infiltration was only observed in KPC tumors and correlated with T
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cell infiltration, while orthotopic tumors showed a low infiltration rate of B cells [225].
Furthermore, KPC-derived B cells expressed GC entry, B cell memory, and plasma cell
differentiation markers accompanying significant intratumoral Ig deposition, a feature
detected less in orthotopic tumors.
I can therefore speculate that the absence of B cells is due to technical choices, cell
sorting and injection of syngeneic tumor cells, rather than a reflection of the underlying
true immunological mechanism. Neither of the two other mouse samples was enriched
for BCRs, hence, in this study, I did not further examine B cells.
(a) t-SNE projection (b) Feature plot
Fig. 4.50 Expression of PTPRC and TNFRSF17 in the patient1 sample presented in the
Chapter 2. Plots show that cells which express TNFRSF17 do not express PTPRC. (a) Blue
dots represent cells expressing TNFRSF17, orange dots PTPRC. (b) Correlating TNFRSF17
and PTPRC expression. Gene expression values are normalized and log2-transformed.
4.5.2 Co-expression of CD8 with CD4 and B cell genes IGHM
and IGKC
In all of our samples taken from the tumor of the AgRSR mice, I found cells displaying
co-expression of the surface markers CD8 and CD4. During positive selection which
takes place in the thymus, double-positive thymocytes differentiate into CD8+ or CD4+
single positive cells depending on whether they recognize the MHC class I or II molecule.
Therefore we should not be detecting DP CD8+CD4+ T cells in the tumor samples.
However CD8+CD4+ DP mature T cells have been reported in melanoma [55]. Addition-
ally, we see TCR bearing cells co-expressing IGHM/IGKC and CD8 even though these
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(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.51 The correlation between CD8 and CD4, IGHM, and IGKC. Note that these are
normalized log2-transformed gene expression levels.
(a) mouse_d15 (b) mouse_d19 (c) mouse_d25
Fig. 4.52 IGHV gene expressions of CD8+ cells. Expression levels are normalized and log2-
transformed.
genes are specific to B and T cells, respectively. See Figure 4.51 for the expression of
these genes. We could be observing a case of dual receptor-expressing lymphocytes as
presented in [7]. However, we did not perform BCR specific sequencing for these samples,
so we cannot determine whether these cells also express BCRs. The BCR recombinant
V, D, and J gene expression levels are too low to be picked up directly from the GEX
analysis. Figure 4.52 shows the co-expression of IGHM and CD8 along with BCR V
genes. I could not observe significant expression of Ig V segments. For this reason, it is
impossible to draw meaningful conclusion from this data regarding the nature of this
group of cells. Validation experiments would be required to investigate this population.
4.5.3 Dysfunctionality signatures
In all three tumor samples taken from the AgRSR mice, I detected different CD8+ T
cell clusters that correlate with different functional states. All tumor samples had cells
in the dysfunctional state, which was determined by the expression of PDCD1, LAG3,
TOX, HAVCR2, and CTLA-4. When I took the clonotype as the unit of identity, I was
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able to identify clonal dysfunctionality. It was most evident in mouse_d25 which was
the mouse kept alive the longest. Here I found clonotypes which differentially expressed
TOX, LAG3, and PDCD1, indicating dysfunctional clonotypes.
Furthermore, I detected the clonal expression of genes such as TCF7 and IL7R, which
have been shown to predict clinical response to immune checkpoint immunotherapy in
melanoma [197]. Another clonotype showed high expressions of GZMA and GZMK, as
well as high expressions of TIGIT, TOX, and EOMES. Similar exhaustion populations
have been described in chronic viral infections [173]. Considering we have different
clonotypes exhibiting dysfunction/exhaustion, it would be interesting to study further
what these different TCRs are binding.
4.5.4 The immune response is specific to each host
I compared all TCR chain clonotypes that were found in the tumor samples of each
mouse to see if they had any common clonotypes.
The two clonotypes that were common in all three tumor samples were single TRA
chains and present at rather small proportions: neither chain was observed in more
than 0.13% of the cells in any sample (Table 4.9). Considering that these were not
paired TRA-TRB chains and that they were represented with a low, and non-increasing
frequency of cells, it is likely that these clonotypes were not particularly active in the
ongoing intratumoral immune response.
Clonotype CDR3 mouse_d15 mouse_d19 mouse_d25
TRA:CAASASSGSWQLIF 0.00073 0.00042 0.00130
TRA:CAAEANYGNEKITF 0.00015 0.00021 0.00017
Table 4.9 Shared TCR clonotypes across all tumor samples.
I also compared the TCR chains found in the cells taken from the mouse spleens and
found no shared chain.
Our results do not show any evidence of shared immune response to melanoma in the
AgRSR mice. This may suggest that individuals subjected to similar antigenic challenges
might develop completely different TCR repertoires. This is even more striking if we
consider that the mice used in our experiments are almost genetically identical.
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4.5.5 The immune response is not localized
In Section 4.4.3 I showed that the tumor and spleen samples share multiple clonotypes.
Looking at their GEX profiles, we see that their clones are of different cell types. In
mouse_d15 and mouse_d19 the common clonotypes with the most cells in either the
spleen or the tumor samples are CD8+. However, in mouse_d25, the common clones
are Tregs expressing CD4 and FOXP3. With this dataset, we were able to show the
clonal expansion of Tregs. Additionally, in mouse_d25 the CD8+ dysfunctional T cells
were not represented in the spleen. However, we do see common clonotypes expressing
dysfunctionality signatures within the two other mouse samples.
4.5.6 Possible evidence of allelic inclusion
In all of the tumor samples combined, I detected one α and one β chain pairing in 74%
(9,171/12,454) of cells, two α and two β chain recombinants in 1.3% (156/12,454) of cells,
and solely two α chain recombinants in 0.56% (70/12,454). 510 cells had only one α
chain, and 246 had only one β. I detected two α and one β chain recombinants in 1666
cells out of 12,454 (13%) of cells, and one α and two β chain recombinants in 635 (5.1%)
cells. I considered only the clonotypes represented by at least 10 cells. All chains are
productive. Even though it is generally accepted that TCRs comprise one α and one β
chain, these observations are in line with the phenomenon of allelic inclusion described
in the literature [227], [30].
A more interesting case can be observed in the mouse_d25 tumor sample dataset.
Here we have three clonotypes, clonotype5, clonotype31, and clonotype44 which clustered
tightly based on their GEX profile (see Figure 4.53). Clonotype5 is represented by
246 cells which bear two α and one β chains: TRAV14-2, TRAV6-3, and TRBV13-2.
Clonotype31 has 30 cells with the chains TRAV6-3 and TRBV13-2, and clonotype44
has 14 cells which bear the chains TRAV14-2 and TRBV13-2. It is possible to see cells
with one α and one β chain, with additional captures of minor transcripts resulting in
multiple chains. In such cases, we would see one α chain with a high UMI count, one
β chain with a high UMI count, and all the other chains would have low UMI counts.
However, looking at Figure 4.54, it is clear that both α chains of clonotype5 have high
UMI counts. So here clonotype5 is expressing the same α and β chains as clonotype31
and clonotype44 and is expressing an α chain additional to the other two clonotypes.
Clonotype5 is more clonally expanded than both clonotype31 and clonotype44. Also,
observe that only clonotype5 has cell cycling clones (see the bottom panel of Figure 4.26c
which plots the cell cycling cluster). Although the simplest explanation could be that
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Fig. 4.53 UMAP of the mouse_d25 tumor sample CD8+ cells colored by clonotype membership.
all these clones, in fact, express the same double-α single-β chains on their surface but
cellranger vdj could not detect the additional α chains, it is possible that there is
a descendant relationship between clonotype5 and the other clonotypes. Additional
experiments would be required to investigate this further.
Fig. 4.54 The per cell UMI counts of the mouse_d25 tumor sample clonotypes. These are the
UMIs that were picked up with TCR enrichment.
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4.6 Discussion
Tumor infiltration by T cells is considered a proxy to immune response and has been
shown to reflect better prognosis in solid tumors [206], [163], [82], [264]. Currently,
immunotherapy studies are investigating ways to maintain this immune response, which
can, in time, be suppressed by the TME. Reactivating dysfunctional T cells can, in
some cases, lead to a sustained immune response [189]. Several recent studies have
coupled scRNA-seq and TCR repertoire information to characterize the tumor infiltration
in melanoma [235], [197], [140]. However, they provide limited insights as the TCR
repertoires they investigate are not particularly tumor-antigen specific. Recent work
provides evidence that some intratumoral T cells may be bystanders with no tumor
reactivity [219]. To detect T cell clones that are truly able to recognize cancer antigens,
we need to be able to identify the repertoire of tumor-reactive TCRs. This is of crucial
importance as developing new methods to overcome immune escape in cancer requires a
deeper understanding of cancer antigens and TCRs that actually drive the intratumoral
immune response.
In this study, I defined the clonal tumor infiltration of T cells in an unbiased manner
by linking single-cell RNA sequencing and TCR repertoire datasets which were obtained
by using a novel transgenic mouse model that allows for the in vivo identification of
activated T cells. In the cells of this animal, the injection of tamoxifen initiates the
expression of yellow fluorescent protein (EYFP) in TCR-activated clones. As a DNA
mediated event, the expression is inheritable, and the clonally expanded cells remain
EYFP+.
In collaboration with Dr. James Thaventhiran and Mr. Ty So, by performing FACS
and immune profiling of more than 30,000 EYFP+ cells present in the spleen and tumor,
we were able to identify tumor responding Treg, conventional CD4+, and CD8+ T cell
clones. Our findings show that tumoral CD8+ T cells comprise similar populations found
in human melanoma [140], [197]. By analyzing the GEX profile of tumor-reactive CD8+
T cells, I distinguished different clusters that correlate with different functional states.
By coupling the GEX profile with cell level TCR repertoire information, and taking
the clonotype as the unit of identity, I detected T cell clones which exhibit different
functional states. I was able to detect clonotypes with markers of dysfunctionality such
as PDCD1 (PD1 in humans), CTLA-4, TOX, EOMES, and LAG3.
With this mouse model, we fate mapped a clonally diverse population of T cells that
are TCR-activated towards melanoma tumors within an experimentally defined time
frame. The cells of the tumor sample taken from the mouse kept alive the longest showed
a decrease in the CD8+ T cell population. Furthermore, the CD8+ T cell clonotypes
4.6 Discussion 165
of this mouse showed expression of exhaustion and apparent clustering. Unless in a
cell cycling state, dysfunctional CD8+ T cells exclusively cluster separately indicating a
convergent differentiation state which may suggest that although multiple clonotypes
are proliferating within the tumor, their intratumoral differentiation state is dictated
by their TCR. This separation was not as evident in the two other earlier sacrificed
mice. For the immune response, a week might be a significant amount of time. By
analyzing the GEX profiles of mice cells harvested at different time points, I was also
able to suggest a preferable time of harvest in order to obtain and further study cells
exhibiting clear dysfunctionality markers. This would enable to improve the design of
further experiments.
With this study, we were able to match clonally expanded TCRs of the tumor with
those of the spleen. A majority of expanded T cell clones were shown to have clonally-
matched cells present in the secondary lymphoid tissues. Also, by analyzing the GEX
profile of the matching clonotypes, I was able to begin elucidating the gene expression
activity of different intratumoral T cell clones, and the interplay between local and
systemic response to cancer.
I was not able to study the clonality of intratumoral antigen-reactive plasma cells.
However, I could speculate that their absence in the tumor is due to cell sorting for
CD45+ which is expected to be low in plasma cells and plasmablasts [183]. Furthermore,
the injection of syngeneic tumor cells could have caused accelerated disease progression
which may have prevented the development of a natural immune response which would
have been expected in a tumor that occurred spontaneously [225].
I am aware that my findings are not conclusive since we only had single samples
with differing conditions taken at different time points. For this reason, it is necessary
to conduct further experiments using multiple samples, i.e., technical and biological
replicates while controlling for possible batch effects.
This study forms a first proof-of-principle effort for the comprehensive analysis of
combined scRNA-seq and TCR profiling of tumor-responsive T cells in-vivo in melanomas.
By performing larger scale experiments, it will now be possible to obtain better insights




Conclusions and future study
William B. Coley, a 19th-century surgeon, may have performed the first application of
immunotherapy in cancer when he administered patients with “Coley’s mixed bacterial
toxins” to treat their inoperable malignant tumors [49]. The field of anti-tumor immunity
has since seen numerous milestones: Paul Ehrlich’s cancer immunosurveillance hypothesis
[61], Ruth and John Graham’s cancer vaccine study of a 114 patient cohort [85], evidence
of tumor-specific antigens [121], the identification of immune cells including that of B and
T lymphocytes and their antigen specificity through receptor diversity [113], and Dunn
and Schreiber’s cancer immunoediting concept which replaced the immune surveillance
hypothesis [58], are amongst the numerous discoveries in the field. Most recently, the
independent discoveries of the checkpoint proteins CTLA-4 and PD-1 by James P. Allison
and Tasuku Honjo brought them the 2018 Nobel Prize in Physiology or Medicine, and
has led to tremendous scientific and clinical breakthroughs in anti-tumor immunity.
While ICB therapy has shown great success, its effects are not shared universally, and
the results are often not long-lasting [189], [52], [266]. It is necessary to associate the
mechanisms that limit durable positive response with ICB therapy in order to transform
immunotherapy into a more broadly applicable cancer treatment.
Through numerous genetic and epigenetic alterations, tumors might accumulate
neoantigens that can be recognized by the immune system [229]. The anti-tumor immune
response involves the innate and adaptive immune components which aim to control
tumor growth [153]. While a baseline immune response is well observed, it is not always
effective as tumors develop ways of resistance through immune suppression, tolerance,
and escape [205], [159]. With the studies on TILs, as well as TLSs, and their associations
with patient survival [26], [201], it has become clear that the TME needs to be analyzed
in-depth to expose the mechanisms that tumors adopt in order to counter an immune
response, and improve the benefits of ICB therapies.
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In Chapter 2, I characterized the TME of melanoma metastases. As expected, I found
significant infiltration of T lymphocytes, including Tc cells, Th cells, and Tregs. The role
of the effector T cells in anti-tumor immunity is well known, and the pre-existing mass of
antigen-experienced TILs in the TME has been associated with effective ICB therapies
[242], [214], [6], [26]. The role of B cells, on the other hand, remain uncertain [241],
[254]. By analyzing gene expression in 12,000+ intratumoral cells at single-cell level, I
confirmed the presence of TIL-Bs in melanomas, including CD19+, CD20+, and plasma
B cells, as well as proliferating B cells at various differentiation stages. With known
cell type biomarkers, I identified the presence of LTi and Tfh cells, and FRCs, which
indicated the formation of intratumoral TLS. The presence of TLS and the abundance of
TIL-Bs and TILs suggest a combined effort of B and T lymphocytes in generating an
anti-tumor response.
Furthermore, by coupling gene expression profiles with BCR immune repertoires, I
was able to detect clonally expanded plasma B cells. The fact that these plasma cells are
expressing class-switched antibodies suggests prolonged exposure to the target antigen.
The likely presence of TLS and clonally expanded plasma B cells expressing class-switched
antibodies at baseline may suggest an ongoing adaptive intratumoral immune response.
Having observed abundant plasma cells and highly clonal antibodies pre-immunotherapy
in melanoma metastases, I wanted to study B cell infiltration of tumors pre- and post-
therapy with AMD3100, and assess the difference in clonality in the receptor repertoires
of intratumoral lymphocytes. AMD3100 has been shown to re-accumulate effector T cells
amongst the cancer cells by blocking the CXCL12-CXCR4 axis [65]. I was interested in
the effects of this treatment on intratumoral B cells, and whether or not the cooperation
of B and T cells would be visible here as well. To this end, as presented in Chapter 3, I
reconstructed the B and T cell receptor repertoires of 37 samples taken before and after
treatment with AMD3100 from patients with CRC and PDAC. In all of the samples, the
number of unique BCR clonotypes was significantly higher than TCR clonotypes, showing
intratumoral antibody-secreting plasma cells. IgG and IgA were the most abundant
antibody isotypes, further showing that the majority of the detected Ig clonotypes were
expressed by B cells that have encountered an antigen and differentiated into plasma
and memory B cells. These findings strongly suggest B cell infiltration, and the presence
of plasma cells inside the CRC and PDAC tumors I studied.
Moreover, in some patients, the B cell infiltration increased after treatment, which
may be a result of the AMD3100 treatment. In a recent study, patients who did not show
a positive response to PD-1 inhibitor therapy had a greater increase in clonotype diversity
among B and T cells [266]. Based on these findings, I decided to identify patients with
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highly clonal BCRs. Although these patients were not administered with anti-PD-1
therapy, they may already have an ongoing anti-tumor immune response and may be
good candidates for an ICB therapy.
In both studies, I was able to show an intratumoral immune response involving both
B and T lymphocytes. However, we cannot conclude that these cells were necessarily
recognizing tumor-specific antigens. While high clonality may suggest tumor-reactive
antibodies and effector T cells, alternative explanations are also possible: the proliferation
of the actual tumor-reactive T cells may have been hindered by exhaustion [235], and the
antibodies may be in response to a non-tumor antigen. In addition, recent work provides
evidence of bystander T cells with no tumor reactivity [219]. In Chapter 4, I analyzed
30,000+ CD45+CD11B-EYFP+ cells harvested from the tumor and spleen of the AgRSR
mouse in order to unambiguously determine which specific B and T cells contribute to
anti-tumor immunity. In the cells of this mouse model, the injection of tamoxifen leads
to the expression of yellow fluorescent protein (EYFP) in activated B and T cells. As a
DNA mediated event, the clonally expanded daughter cells remain EYFP+. With this
mouse model, we were able to fate map a clonally diverse population of TCR-activated
T cells responding to melanoma tumors within an experimentally defined time frame. I
identified clonally expanded tumor-reactive Treg, CD4+, and CD8+ T cell clones and the
CD8+ T cells comprised similar populations found in human melanoma [140], [197]. By
analyzing the GEX profile of tumor-reactive CD8+ T cells, I distinguished clusters that
correspond to different functional states. Furthermore, by linking the GEX profile with
cell level TCR repertoire information, and taking the clonotype as the unit of identity,
I detected T cell clones which exhibit different functional states. I was able to detect
clones with markers of dysfunctionality.
Additionally, in this study, being able to profile gene expression simultaneously with
the TCR repertoire at a single cell level, I was able to match clonally expanded TCRs
of the tumor with those of the spleen and partially assess their activation status. This
allowed me to investigate the interplay between local and systemic response to cancer.
The immunosuppressive effects of the TME were evident in the dysfunctional intratumoral
T cell clones. Unfortunately, I was not able to study the clonality of intratumoral antigen-
reactive B cells. However, I can speculate that cell sorting for CD45+ may have discarded
plasma cells and that the injection of syngeneic tumor cells may have caused accelerated
disease progression limiting the development of a natural immune response as suggested
in [225].
scRNA-seq is an ideal method to study AgRs as it allows for the reconstruction
and pairing of receptor chains within a single cell. In Chapter 2, I recovered the AgR
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repertoires of melanoma metastases. The patient2 sample demonstrated a highly clonal
Ig repertoire in which the most dominant clonotype showed both class-switching and
possible SHMs. This intratumoral antibody may be generating an immune response
towards a possible melanoma tumor-antigen. With RNA-seq, it is not possible to pair
Ig heavy and light chains with full certainty. However, detecting a highly dominant
antibody in the melanoma tumor suggested the opportunity of finding such highly clonal
antibody heavy and light chains in the CRC and PDAC samples that where sequenced
using RNA-seq. Indeed, in patients 2, 11, and especially 25, I was able to detect heavy
and light Ig chains that were clonal enough to pair. All the reconstructed antibody
sequences are given in Appendix A. These sequences could allow one to have the specific
antibody expressed in mammalian cells. These antibodies could, in turn, be used to find
the tumor antigens they bind by using in-vitro screening methods.
In immunotherapy, it is crucial to determine which patients can gain the most benefit
from treatments, and what the best biomarkers are to guide treatment decisions. While
T cells have been studied in depth to reveal that response to ICB favors pre-existing
T cell infiltration in tumors [26], TIL-Bs have only recently incited interest [241], [254].
In Chapter 2 of this thesis, I characterized the TME of melanoma tumors prior to
immunotherapy. Using scRNA-seq coupled with targeted AgR enrichment allowed me to
determine clonally expanded, antigen-challenged immune components. Immediate future
work could be to study all the patients in the MelResist clinical trial [51] using the same
technique, with samples taken both pre- and post-immunotherapy. This could lead to
finding the effect of baseline TIL-Bs and TLSs, as well as detecting possible B cell related
biomarkers towards a positive patient response. Furthermore, we can determine the fate
of the clonally expanded antibodies post-immunotherapy and find candidate antibodies
for tumor-antigen detection.
In parallel, while in Chapter 3 I had access to pre- and post-treatment data from
a larger cohort, it would be beneficial to use a single-cell RNA-seq and targeted AgR
enrichment protocol to retrieve the gene expression profiles and VDJ sequences simulta-
neously from single B cells before and after treatment. By using this approach, we could
obtain the activation and differentiation status of each cell and thus potentially identify
the Igs which recognize highly immunogenic antigens in the tumor. These antibodies
would, in turn, allow for the identification of antigens that drive intratumoral adaptive
immune response. Either future work would benefit the field of cancer immunology
by further helping to interpret the mechanisms regulating the interactions between the
immune system and the TME, and possibly expand the benefits of immunotherapy to
more patients.
171
To conclude, this thesis aimed to investigate anti-tumor immunity by characterizing
the TME and the antigen receptor repertoires associated with intratumoral immune
responses. I hope that the findings presented in Chapters 2 and 3 will further ignite
interest in the role of B cells in anti-tumor immunity, while Chapter 4 establishes a solid
analytical groundwork for further experiments.
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T., and Olweus, J. (2014). High-throughput sequencing of TCR repertoires in multiple
sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. European
Journal of Immunology, 44(11):3439–3452.
[148] Lun, A. T. L., Bach, K., and Marioni, J. C. (2016a). Pooling across cells to
normalize single-cell RNA sequencing data with many zero counts. Genome Biology,
17(75).
[149] Lun, A. T. L., McCarthy, D. J., and Marioni, J. C. (2016b). A step-by-step workflow
for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Research,
5:2122.
[150] Lun, A. T. L., Riesenfeld, S., Andrews, T., Dao, T. P., Gomes, T., and Marioni,
J. C. (2019). EmptyDrops: Distinguishing cells from empty droplets in droplet-based
single-cell RNA sequencing data. Genome Biology, 20(63).
[151] Mahmoud, S. M. A., Lee, A. H. S., Paish, E. C., Macmillan, R. D., Ellis, I. O.,
and Green, A. R. (2012). The prognostic significance of B lymphocytes in invasive
carcinoma of the breast. Breast Cancer Research and Treatment, 132(2):545–553.
[152] Mak, T., Saunders, M., and Jett, B. (2014). Primer to the Immune Response.
Academic Cell.
[153] Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng,
W., Wang, L., Shifrin, N., and Raulet, D. H. (2014). Recognition of tumors by the
innate immune system and natural killer cells. In Advances in Immunology, pages
91–128. Elsevier.
[154] Martinez-Lostao, L., Anel, A., and Pardo, J. (2015). How do cytotoxic lymphocytes
kill cancer cells? Clinical Cancer Research, 21(22):5047–5056.
[155] McDade, T. W., Georgiev, A. V., and Kuzawa, C. W. (2016). Trade-offs between
acquired and innate immune defenses in humans. Evolution, Medicine, and Public
Health, 2016(1):1–16.
[156] McInnes, L., Healy, J., and Melville, J. (2018). UMAP: Uniform manifold approxi-
mation and projection for dimension reduction. Preprint at arxiv.org/abs/1802.03426.
[157] Melief, C. J., van Hall, T., Arens, R., Ossendorp, F., and van der Burg, S. H. (2015).
Therapeutic cancer vaccines. Journal of Clinical Investigation, 125(9):3401–3412.
[158] Messina, J. L., Fenstermacher, D. A., Eschrich, S., Qu, X., Berglund, A. E., Lloyd,
M. C., Schell, M. J., Sondak, V. K., Weber, J. S., and Mulé, J. J. (2012). 12-chemokine
gene signature identifies lymph node-like structures in melanoma: Potential for patient
selection for immunotherapy? Scientific Reports, 2(765).
186 References
[159] Mittal, D., Gubin, M. M., Schreiber, R. D., and Smyth, M. J. (2014). New insights
into cancer immunoediting and its three component phases—elimination, equilibrium
and escape. Current Opinion in Immunology, 27:16–25.
[160] Moncada, R., Wagner, F., Chiodin, M., Devlin, J. C., Baron, M., Hajdu, C. H.,
Simeone, D. M., and Yanai, I. (2019). Integrating single-cell RNA-Seq with spatial
transcriptomics in pancreatic ductal adenocarcinoma using multimodal intersection
analysis. bioRxiv.
[161] Mose, L. E., Selitsky, S. R., Bixby, L. M., Marron, D. L., Iglesia, M. D., Serody,
J. S., Perou, C. M., Vincent, B. G., and Parker, J. S. (2016). Assembly-based inference
of B-cell receptor repertoires from short read RNA sequencing data with V’DJer.
Bioinformatics, 32(24):3729–3734.
[162] Murphy, K. and Weaver, C. (2016). Janeway’s Immunobiology. Garland Science.
[163] Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., and Ohtani,
H. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in
human colorectal cancer. Cancer Research, 58(16):3491–3494.
[164] National Cancer Institute (2019a). The cancer genome atlas program. www.cancer.
gov/tcga. [Accessed 24/09/2019].
[165] National Cancer Institute (2019b). TCGA-SKCM. portal.gdc.cancer.gov/projects/
TCGA-SKCM. [Accessed 25/09/2019].
[166] Nguyen, Q. P., Deng, T. Z., Witherden, D. A., and Goldrath, A. W. (2019). Origins
of CD4+ circulating and tissue-resident memory T-cells. Immunology, 157(1):3–12.
[167] Nielsen, J. S., Sahota, R. A., Milne, K., Kost, S. E., Nesslinger, N. J., Watson,
P. H., and Nelson, B. H. (2012). CD20+ tumor-infiltrating lymphocytes have an
atypical CD27- memory phenotype and together with CD8+ T cells promote favorable
prognosis in ovarian cancer. Clinical Cancer Research, 18(12):3281–3292.
[168] Nurieva, R. I., Chung, Y., Martinez, G. J., Yang, X. O., Tanaka, S., Matskevitch,
T. D., Wang, Y. H., and Dong, C. (2009). Bcl6 mediates the development of T follicular
helper cells. Science, 325(5943):1001–1005.
[169] O’Donnell, J. S., Teng, M. W. L., and Smyth, M. J. (2018). Cancer immunoediting
and resistance to T cell-based immunotherapy. Nature Reviews Clinical Oncology,
16(3):151–167.
[170] Oliveira, A. F., Bretes, L., and Furtado, I. (2019). Review of PD-1/PD-L1 inhibitors
in metastatic dMMR/MSI-h colorectal cancer. Frontiers in Oncology, 9.
[171] Overgaard, N. H., Jung, J.-W., Steptoe, R. J., and Wells, J. W. (2015). CD4+/CD8+
double-positive T cells: More than just a developmental stage? Journal of Leukocyte
Biology, 97(1):31–38.
[172] Padera, T. P., Meijer, E. F., and Munn, L. L. (2016). The lymphatic system in
disease processes and cancer progression. Annual Review of Biomedical Engineering,
18(1):125–158.
References 187
[173] Paley, M. A., Kroy, D. C., Odorizzi, P. M., Johnnidis, J. B., Dolfi, D. V., Barnett,
B. E., Bikoff, E. K., Robertson, E. J., Lauer, G. M., Reiner, S. L., and Wherry, E. J.
(2012). Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic
viral infection. Science, 338(6111):1220–1225.
[174] Parham, P. (2009). The Immune System, 3rd Edition. Garland Science.
[175] Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto,
H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., Louis, D. N., Rozenblatt-
Rosen, O., Suvà, M. L., Regev, A., and Bernstein, B. E. (2014). Single-cell RNA-seq
highlights intratumoral heterogeneity in primary glioblastoma. Science, 344(6190):1396–
1401.
[176] Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., and Kingsford, C. (2017). Salmon
provides fast and bias-aware quantification of transcript expression. Nature Methods,
14(4):417–419.
[177] Perfetto, S. P., Chattopadhyay, P. K., and Roederer, M. (2004). Seventeen-colour
flow cytometry: unravelling the immune system. Nature Reviews Immunology, 4(8):648–
655.
[178] Pesce, S., Greppi, M., Grossi, F., Zotto, G. D., Moretta, L., Sivori, S., Genova, C.,
and Marcenaro, E. (2019). PD/1-PD-Ls checkpoint: Insight on the potential role of
NK cells. Frontiers in Immunology, 10.
[179] Petersen-Mahrt, S. K., Harris, R. S., and Neuberger, M. S. (2002). AID mutates e.
coli suggesting a DNA deamination mechanism for antibody diversification. Nature,
418(6893):99–104.
[180] Pevzner, P. A., Tang, H., and Waterman, M. S. (2001). An Eulerian path ap-
proach to DNA fragment assembly. Proceedings of the National Academy of Sciences,
98(17):9748–9753.
[181] Philip, M. and Schietinger, A. (2019). Heterogeneity and fate choice: T cell
exhaustion in cancer and chronic infections. Current Opinion in Immunology, 58:98–
103.
[182] Pons, P. and Latapy, M. (2005). Computing communities in large networks using
random walks. In Computer and Information Sciences - ISCIS 2005, pages 284–293.
Springer Berlin Heidelberg.
[183] Protein Atlas (2019). Dictionary - Expression: PTPRC - The Human Protein Atlas.
www.proteinatlas.org/learn/dictionary/expression/PTPRC. [Accessed 14/07/2019].
[184] Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S.,
Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., Deschler, D. G., Varvares, M. A.,
Mylvaganam, R., Rozenblatt-Rosen, O., Rocco, J. W., Faquin, W. C., Lin, D. T.,
Regev, A., and Bernstein, B. E. (2017). Single-cell transcriptomic analysis of primary
and metastatic tumor ecosystems in head and neck cancer. Cell, 171(7):1611–1624.e24.
188 References
[185] Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov,
S. B., and Bar-Sagi, D. (2016). IL35-producing B cells promote the development of
pancreatic neoplasia. Cancer Discovery, 6(3):247–255.
[186] Quinlan, A. R. and Hall, I. M. (2010). BEDTools: A flexible suite of utilities for
comparing genomic features. Bioinformatics, 26(6):841–842.
[187] Rawla, P., Sunkara, T., and Gaduputi, V. (2019). Epidemiology of pancreatic
cancer: Global trends, etiology and risk factors. World Journal of Oncology, 10(1):10–
27.
[188] Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi,
F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., Bhatia, S., Hwu, W.-J.,
Gajewski, T. F., Slingluff, C. L., Chowell, D., Kendall, S. M., Chang, H., Shah, R.,
Kuo, F., Morris, L. G., Sidhom, J.-W., Schneck, J. P., Horak, C. E., Weinhold, N., and
Chan, T. A. (2017). Tumor and microenvironment evolution during immunotherapy
with nivolumab. Cell, 171(4):934–949.e16.
[189] Ribas, A. and Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint
blockade. Science, 359(6382):1350–1355.
[190] Rizzetto, S., Koppstein, D. N. P., Samir, J., Singh, M., Reed, J. H., Cai, C. H.,
Lloyd, A. R., Eltahla, A. A., Goodnow, C. C., and Luciani, F. (2018). B-cell receptor
reconstruction from single-cell RNA-seq with VDJPuzzle. Bioinformatics, 34(16):2846–
2847.
[191] Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud,
A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank,
C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N.,
Ebbinghaus, S., and Ribas, A. (2015). Pembrolizumab versus ipilimumab in advanced
melanoma. New England Journal of Medicine, 372(26):2521–2532.
[192] Robins, H. S., Campregher, P. V., Srivastava, S. K., Wacher, A., Turtle, C. J.,
Kahsai, O., Riddell, S. R., Warren, E. H., and Carlson, C. S. (2009). Comprehensive
assessment of T-cell receptor β-chain diversity in αβ T cells. Blood, 114(19):4099–4107.
[193] Rosati, E., Dowds, C. M., Liaskou, E., Henriksen, E. K. K., Karlsen, T. H., and
Franke, A. (2017). Overview of methodologies for T-cell receptor repertoire analysis.
BMC Biotechnology, 17(1):61.
[194] Rosvall, M. and Bergstrom, C. T. (2007). An information-theoretic framework
for resolving community structure in complex networks. Proceedings of the National
Academy of Sciences, 104(18):7327–7331.
[195] Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S.,
Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., and Rosenberg, S. A. (2010). Phase
2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic
pancreatic adenocarcinoma. Journal of Immunotherapy, 33(8):828–833.
[196] Rudensky, A. Y. (2011). Regulatory T cells and FOXP3. Immunological Reviews,
241(1):260–268.
References 189
[197] Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins,
R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., Freeman, S. S.,
Reuben, A., Hoover, P. J., Villani, A.-C., Ivanova, E., Portell, A., Lizotte, P. H.,
Aref, A. R., Eliane, J.-P., Hammond, M. R., Vitzthum, H., Blackmon, S. M., Li, B.,
Gopalakrishnan, V., Reddy, S. M., Cooper, Z. A., Paweletz, C. P., Barbie, D. A.,
Stemmer-Rachamimov, A., Flaherty, K. T., Wargo, J. A., Boland, G. M., Sullivan,
R. J., Getz, G., and Hacohen, N. (2018). Defining T cell states associated with response
to checkpoint immunotherapy in melanoma. Cell, 175(4):998–1013.e20.
[198] Saeys, Y., Gassen, S. V., and Lambrecht, B. N. (2016). Computational flow
cytometry: Helping to make sense of high-dimensional immunology data. Nature
Reviews Immunology, 16(7):449–462.
[199] Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., and
Anderson, A. C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell
exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine,
207(10):2187–2194.
[200] Sant’Angelo, D. B., Lucas, B., Waterbury, P. G., Cohen, B., Brabb, T., Goverman,
J., Germain, R. N., and Janeway, C. A. (1998). A molecular map of T cell development.
Immunity, 9(2):179–186.
[201] Sautès-Fridman, C., Petitprez, F., Calderaro, J., and Fridman, W. H. (2019).
Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews
Cancer, 19(6):307–325.
[202] Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R.,
Byrne, D. J., Teo, Z. L., Dushyanthen, S., Byrne, A., Wein, L., Luen, S. J., Poliness,
C., Nightingale, S. S., Skandarajah, A. S., Gyorki, D. E., Thornton, C. M., Beavis,
P. A., Fox, S. B., Darcy, P. K., Speed, T. P., MacKay, L. K., Neeson, P. J., and Loi, S.
(2018). Single-cell profiling of breast cancer T cells reveals a tissue-resident memory
subset associated with improved prognosis. Nature Medicine, 24(7):986–993.
[203] Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O.,
Patt, D., Chen, T.-T., Berman, D. M., and Wolchok, J. D. (2015). Pooled analysis of
long-term survival data from phase II and phase III trials of ipilimumab in unresectable
or metastatic melanoma. Journal of Clinical Oncology, 33(17):1889–1894.
[204] Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom,
R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., Schell,
T. D., Garbi, N., and Greenberg, P. D. (2016). Tumor-specific T cell dysfunction is a
dynamic antigen-driven differentiation program initiated early during tumorigenesis.
Immunity, 45(2):389–401.
[205] Schreiber, R. D., Old, L. J., and Smyth, M. J. (2011). Cancer immunoedit-
ing: Integrating immunity's roles in cancer suppression and promotion. Science,
331(6024):1565–1570.
[206] Schumacher, K., Haensch, W., Röefzaad, C., and Schlag, P. M. (2001). Prognostic
significance of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Cancer Research, 61(10):3932–3936.
190 References
[207] Scialdone, A., Natarajan, K. N., Saraiva, L. R., Proserpio, V., Teichmann, S. A.,
Stegle, O., Marioni, J. C., and Buettner, F. (2015). Computational assignment of
cell-cycle stage from single-cell transcriptome data. Methods, 85:54–61.
[208] Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M.,
Trivedi, P., Menocal, L., Appleby, H., Camara, S., Zamarin, D., Walther, T., Snyder,
A., Femia, M. R., Comen, E. A., Wen, H. Y., Hellmann, M. D., Anandasabapathy,
N., Liu, Y., Altorki, N. K., Lauer, P., Levy, O., Glickman, M. S., Kaye, J., Betel, D.,
Philip, M., and Schietinger, A. (2019). TOX is a critical regulator of tumour-specific
T cell differentiation. Nature, 571(7764):270–274.
[209] See, P., Lum, J., Chen, J., and Ginhoux, F. (2018). A single-cell sequencing guide
for immunologists. Frontiers in Immunology, 9:2425.
[210] Seidel, J. A., Otsuka, A., and Kabashima, K. (2018). Anti-PD-1 and anti-CTLA-4
therapies in cancer: Mechanisms of action, efficacy, and limitations. Frontiers in
Oncology, 8:86.
[211] Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang,
Y. H., López-Moyado, I. F., Georges, R. O., Zhang, W., Onodera, A., Wu, C.-J., Lu,
L.-F., Hogan, P. G., Bhandoola, A., and Rao, A. (2019). TOX and TOX2 transcription
factors cooperate with NR4a transcription factors to impose CD8+ T cell exhaustion.
Proceedings of the National Academy of Sciences, 116(25):12410–12415.
[212] Shah, D. K. and Zúñiga-Pflücker, J. C. (2014). An overview of the intrathymic
intricacies of T cell development. The Journal of Immunology, 192(9):4017–4023.
[213] Shalapour, S., Font-Burgada, J., Di Caro, G., Zhong, Z., Sanchez-Lopez, E.,
Dhar, D., Willimsky, G., Ammirante, M., Strasner, A., Hansel, D. E., Jamieson, C.,
Kane, C. J., Klatte, T., Birner, P., Kenner, L., and Karin, M. (2015). Immunosup-
pressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature,
521(7550):94–98.
[214] Sharma, P., Hu-Lieskovan, S., Wargo, J. A., and Ribas, A. (2017). Primary,
adaptive, and acquired resistance to cancer immunotherapy. Cell, 168(4):707–723.
[215] Shcherbo, D., Murphy, C. S., Ermakova, G. V., Solovieva, E. A., Chepurnykh,
T. V., Shcheglov, A. S., Verkhusha, V. V., Pletnev, V. Z., Hazelwood, K. L., Roche,
P. M., Lukyanov, S., Zaraisky, A. G., Davidson, M. W., and Chudakov, D. M. (2009).
Far-red fluorescent tags for protein imaging in living tissues. Biochemical Journal,
418(3):567–574.
[216] Shimabukuro-Vornhagen, A., Schlößer, H. A., Gryschok, L., Malcher, J., Wennhold,
K., Garcia-Marquez, M., Herbold, T., Neuhaus, L. S., Becker, H. J., Fiedler, A.,
Scherwitz, P., Koslowsky, T., Hake, R., Stippel, D. L., Hölscher, A. H., Eidt, S.,
Hallek, M., Theurich, S., and von Bergwelt-Baildon, M. S. (2014). Characterization
of tumor-associated B-cell subsets in patients with colorectal cancer. Oncotarget,
5(13):4651–4664.
[217] Shin, H., Blackburn, S. D., Intlekofer, A. M., Kao, C., Angelosanto, J. M., Reiner,
S. L., and Wherry, E. J. (2009). A role for the transcriptional repressor Blimp-1 in
CD8+ T cell exhaustion during chronic viral infection. Immunity, 31(2):309–320.
References 191
[218] Shitaoka, K., Hamana, H., Kishi, H., Hayakawa, Y., Kobayashi, E., Sukegawa, K.,
Piao, X., Lyu, F., Nagata, T., Sugiyama, D., Nishikawa, H., Tanemura, A., Katayama,
I., Murahashi, M., Takamatsu, Y., Tani, K., Ozawa, T., and Muraguchi, A. (2018).
Identification of tumoricidal TCRs from tumor-infiltrating lymphocytes by single-cell
analysis. Cancer Immunology Research, 6(4):378–388.
[219] Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong,
J. P. S., Nahar, R., Zhang, T., Kared, H., Duan, K., Ang, N., Poidinger, M., Lee,
Y. Y., Larbi, A., Khng, A. J., Tan, E., Fu, C., Mathew, R., Teo, M., Lim, W. T., Toh,
C. K., Ong, B.-H., Koh, T., Hillmer, A. M., Takano, A., Lim, T. K. H., Tan, E. H.,
Zhai, W., Tan, D. S. W., Tan, I. B., and Newell, E. W. (2018). Bystander CD8+ T
cells are abundant and phenotypically distinct in human tumour infiltrates. Nature,
557(7706):575–579.
[220] Singer, A., Adoro, S., and Park, J.-H. (2008). Lineage fate and intense debate:
myths, models and mechanisms of CD4- versus CD8-lineage choice. Nature Reviews
Immunology, 8(10):788–801.
[221] Singer, M., Wang, C., Cong, L., Marjanovic, N. D., Kowalczyk, M. S., Zhang,
H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., Xia, J., Kwon, J. Y., Nevin,
J., Herbst, R. H., Yanai, I., Rozenblatt-Rosen, O., Kuchroo, V. K., Regev, A., and
Anderson, A. C. (2016). A distinct gene module for dysfunction uncoupled from
activation in tumor-infiltrating T cells. Cell, 166(6):1500–1511.e9.
[222] Six, A., Mariotti-Ferrandiz, M. E., Chaara, W., Magadan, S., Pham, H. P., Lefranc,
M. P., Mora, T., Thomas-Vaslin, V., Walczak, A. M., and Boudinot, P. (2013). The
past, present, and future of immune repertoire biology - the rise of next-generation
repertoire analysis. Frontiers in Immunology, 4:413.
[223] Slaney, C. Y., Kershaw, M. H., and Darcy, P. K. (2014). Trafficking of T cells into
tumors. Cancer Research, 74(24):7168–7174.
[224] Smith, T. and Waterman, M. (1981). Identification of common molecular subse-
quences. Journal of Molecular Biology, 147(1):195–197.
[225] Spear, S., Candido, J. B., McDermott, J. R., Ghirelli, C., Maniati, E., Beers, S. A.,
Balkwill, F. R., Kocher, H. M., and Capasso, M. (2019). Discrepancies in the tumor
microenvironment of spontaneous and orthotopic murine models of pancreatic cancer
uncover a new immunostimulatory phenotype for B cells. Frontiers in Immunology,
10:542.
[226] Stegle, O., Teichmann, S. A., and Marioni, J. C. (2015). Computational and
analytical challenges in single-cell transcriptomics. Nature Reviews Genetics, 16(3):133–
145.
[227] Stubbington, M. J. T., Lönnberg, T., Proserpio, V., Clare, S., Speak, A. O., Dougan,
G., and Teichmann, S. A. (2016). T cell fate and clonality inference from single-cell
transcriptomes. Nature Methods, 13(4):329–332.
[228] Sun, C., Mezzadra, R., and Schumacher, T. N. (2018). Regulation and function of
the PD-L1 checkpoint. Immunity, 48(3):434–452.
192 References
[229] Swann, J. B. and Smyth, M. J. (2007). Immune surveillance of tumors. Journal of
Clinical Investigation, 117(5):1137–1146.
[230] Takagi, M., Absalon, M. J., McLure, K. G., and Kastan, M. B. (2005). Regulation
of p53 translation and induction after DNA damage by ribosomal protein L26 and
nucleolin. Cell, 123(1):49–63.
[231] Teillaud, J.-L. and Dieu-Nosjean, M.-C. (2017). Tertiary lymphoid structures: An
anti-tumor school for adaptive immune cells and an antibody factory to fight cancer?
Frontiers in Immunology, 8:830.
[232] Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S.,
Xerri, L., Chetaille, B., and Olive, D. (2012). PD-1 is a novel regulator of human
B-cell activation. International Immunology, 25(2):129–137.
[233] Thommen, D. S. and Schumacher, T. N. (2018). T cell dysfunction in cancer.
Cancer Cell, 33(4):547–562.
[234] Thompson, E. D., Enriquez, H. L., Fu, Y.-X., and Engelhard, V. H. (2010). Tumor
masses support naive T cell infiltration, activation, and differentiation into effectors.
The Journal of Experimental Medicine, 207(8):1791–1804.
[235] Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta,
J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., Fallahi-Sichani, M., Dutton-
Regester, K., Lin, J.-R., Cohen, O., Shah, P., Lu, D., Genshaft, A. S., Hughes, T. K.,
Ziegler, C. G. K., Kazer, S. W., Gaillard, A., Kolb, K. E., Villani, A.-C., Johannessen,
C. M., Andreev, A. Y., Allen, E. M. V., Bertagnolli, M., Sorger, P. K., Sullivan, R. J.,
Flaherty, K. T., Frederick, D. T., Jane-Valbuena, J., Yoon, C. H., Rozenblatt-Rosen,
O., Shalek, A. K., Regev, A., and Garraway, L. A. (2016). Dissecting the multicellular
ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 352(6282):189–196.
[236] Topalian, S. L., Drake, C. G., and Pardoll, D. M. (2015). Immune checkpoint
blockade: A common denominator approach to cancer therapy. Cancer Cell, 27(4):450–
461.
[237] Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C.,
McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B.,
Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M.,
Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H.,
Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A.,
Wigginton, J. M., and Sznol, M. (2012). Safety, activity, and immune correlates of
anti-PD-1 antibody in cancer. New England Journal of Medicine, 366(26):2443–2454.
[238] Topham, N. J. and Hewitt, E. W. (2009). Natural killer cell cytotoxicity: How do
they pull the trigger? Immunology, 128(1):7–15.
[239] Toubal, A., Nel, I., Lotersztajn, S., and Lehuen, A. (2019). Mucosal-associated
invariant T cells and disease. Nature Reviews Immunology, 19(10):643–657.
References 193
[240] Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B.,
Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., Routy, J.-P., Haddad,
E. K., and Sekaly, R.-P. (2006). Upregulation of PD-1 expression on HIV-specific CD8+
T cells leads to reversible immune dysfunction. Nature Medicine, 12(10):1198–1202.
[241] Tsou, P., Katayama, H., Ostrin, E. J., and Hanash, S. M. (2016). The emerging
role of B cells in tumor immunity. Cancer Research, 76(19):5597–5601.
[242] Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert,
L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M.,
Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic,
G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert,
C., and Ribas, A. (2014). PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature, 515(7528):568–571.
[243] Upadhyay, A. A., Kauffman, R. C., Wolabaugh, A. N., Cho, A., Patel, N. B., Reiss,
S. M., Havenar-Daughton, C., Dawoud, R. A., Tharp, G. K., Sanz, I., Pulendran,
B., Crotty, S., Lee, F. E.-H., Wrammert, J., and Bosinger, S. E. (2018). BALDR: a
computational pipeline for paired heavy and light chain immunoglobulin reconstruction
in single-cell RNA-seq data. Genome Medicine, 10(1):20.
[244] Vallejos, C. A., Risso, D., Scialdone, A., Dudoit, S., and Marioni, J. C. (2017).
Normalizing single-cell RNA sequencing data: Challenges and opportunities. Nature
Methods, 14(6):565–571.
[245] van der Maaten, L. and Hinton, G. (2008). Visualizing Data using t-SNE. Journal
of Machine Learning Research, 9(Nov):2579–2605.
[246] Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J.,
Griesbeck, M., Butler, A., Zheng, S., Lazo, S., Jardine, L., Dixon, D., Stephenson,
E., Nilsson, E., Grundberg, I., McDonald, D., Filby, A., Li, W., De Jager, P. L.,
Rozenblatt-Rosen, O., Lane, A. A., Haniffa, M., Regev, A., and Hacohen, N. (2017).
Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and
progenitors. Science, 356(6335).
[247] Wang, C., Sanders, C. M., Yang, Q., Schroeder, H. W., Wang, E., Babrzadeh,
F., Gharizadeh, B., Myers, R. M., Hudson, J. R., Davis, R. W., and Han, J. (2010).
High throughput sequencing reveals a complex pattern of dynamic interrelationships
among human T cell subsets. Proceedings of the National Academy of Sciences,
107(4):1518–1523.
[248] Weinstein, J. A., Jiang, N., White, R. A., Fisher, D. S., and Quake, S. R.
(2009). High-throughput sequencing of the zebrafish antibody repertoire. Science,
324(5928):807–810.
[249] Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V.,
Subramaniam, S., Blattman, J. N., Barber, D. L., and Ahmed, R. (2007). Molecular
signature of CD8+ T cell exhaustion during chronic viral infection. Immunity, 27(4):670–
684.
194 References
[250] WHO (2019). WHO Fact Sheet - Cancer 2019. www.who.int/news-room/
fact-sheets/detail/cancer. [Accessed 02/09/2019].
[251] Wittrup, K. D. (2017). Antitumor antibodies can drive therapeutic T cell responses.
Trends in Cancer, 3(9):615–620.
[252] Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J.,
Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., Smylie, M.,
Dummer, R., Hill, A., Hogg, D., Haanen, J., Carlino, M. S., Bechter, O., Maio, M.,
Marquez-Rodas, I., Guidoboni, M., McArthur, G., Lebbé, C., Ascierto, P. A., Long,
G. V., Cebon, J., Sosman, J., Postow, M. A., Callahan, M. K., Walker, D., Rollin,
L., Bhore, R., Hodi, F. S., and Larkin, J. (2017). Overall survival with combined
nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine,
377(14):1345–1356.
[253] Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin,
A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., Burke, M. M., Caldwell,
A., Kronenberg, S. A., Agunwamba, B. U., Zhang, X., Lowy, I., Inzunza, H. D., Feely,
W., Horak, C. E., Hong, Q., Korman, A. J., Wigginton, J. M., Gupta, A., and Sznol,
M. (2013). Nivolumab plus ipilimumab in advanced melanoma. New England Journal
of Medicine, 369(2):122–133.
[254] Wouters, M. C. and Nelson, B. H. (2018). Prognostic significance of tumor-
infiltrating B cells and plasma cells in human cancer. Clinical Cancer Research,
24(24):6125–6135.
[255] Xu, C. and Su, Z. (2015). Identification of cell types from single-cell transcriptomes
using a novel clustering method. Bioinformatics, 31(12):1974–1980.
[256] Yang, Z., Algesheimer, R., and Tessone, C. J. (2016). A comparative analysis of
community detection algorithms on artificial networks. Scientific Reports, 6(1):30750.
[257] Yao, C., Sun, H.-W., Lacey, N. E., Ji, Y., Moseman, E. A., Shih, H.-Y., Heuston,
E. F., Kirby, M., Anderson, S., Cheng, J., Khan, O., Handon, R., Reilley, J., Fioravanti,
J., Hu, J., Gossa, S., Wherry, E. J., Gattinoni, L., McGavern, D. B., O’Shea, J. J.,
Schwartzberg, P. L., and Wu, T. (2019). Single-cell RNA-seq reveals TOX as a
key regulator of CD8+ T cell persistence in chronic infection. Nature Immunology,
20(7):890–901.
[258] Yates, A. J. (2014). Theories and quantification of thymic selection. Frontiers in
Immunology, 5.
[259] Ye, J., Ma, N., Madden, T. L., and Ostell, J. M. (2013). IgBLAST: an immunoglobu-
lin variable domain sequence analysis tool. Nucleic Acids Research, 41(W1):W34–W40.
[260] Yuen, G. J., Demissie, E., and Pillai, S. (2016). B lymphocytes and cancer: A
love–hate relationship. Trends in Cancer, 2(12):747–757.
[261] Yuseff, M.-I., Pierobon, P., Reversat, A., and Lennon-Duménil, A.-M. (2013). How
B cells capture, process and present antigens: a crucial role for cell polarity. Nature
Reviews Immunology, 13(7):475–486.
References 195
[262] Zajac, A. J., Blattman, J. N., Murali-Krishna, K., Sourdive, D. J., Suresh, M.,
Altman, J. D., and Ahmed, R. (1998). Viral immune evasion due to persistence
of activated T cells without effector function. Journal of Experimental Medicine,
188(12):2205–2213.
[263] Zamora, A. E., Crawford, J. C., and Thomas, P. G. (2018). Hitting the target:
How T cells detect and eliminate tumors. The Journal of Immunology, 200(2):392–399.
[264] Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M.,
Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin,
S. C., and Coukos, G. (2003). Intratumoral T cells, recurrence, and survival in epithelial
ovarian cancer. New England Journal of Medicine, 348(3):203–213.
[265] Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B.,
Zhang, Q., Huang, J. Y., Konno, H., Guo, X., Ye, Y., Gao, S., Wang, S., Hu, X., Ren,
X., Shen, Z., Ouyang, W., and Zhang, Z. (2018). Lineage tracking reveals dynamic
relationships of T cells in colorectal cancer. Nature, 564(7735):268–272.
[266] Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T.,
Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., Filip, I., Orenbuch, R., Goetz,
M., Yamaguchi, J. T., Cloney, M., Horbinski, C., Lukas, R. V., Raizer, J., Rae, A. I.,
Yuan, J., Canoll, P., Bruce, J. N., Saenger, Y. M., Sims, P., Iwamoto, F. M., Sonabend,
A. M., and Rabadan, R. (2019). Immune and genomic correlates of response to
anti-PD-1 immunotherapy in glioblastoma. Nature Medicine, 25(3):462–469.
[267] Zhao, L., Zhao, H., and Yan, H. (2018). Gene expression profiling of 1200 pancreatic
ductal adenocarcinoma reveals novel subtypes. BMC Cancer, 18(603).
[268] Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R.,
Huang, J. Y., Zhang, Q., Liu, Z., Dong, M., Hu, X., Ouyang, W., Peng, J., and Zhang,
Z. (2017a). Landscape of infiltrating T cells in liver cancer revealed by single-cell
sequencing. Cell, 169(7):1342–1356.e16.
[269] Zheng, G. X. Y., Terry, J. M., Belgrader, P., Ryvkin, P., Bent, Z. W., Wilson, R.,
Ziraldo, S. B., Wheeler, T. D., McDermott, G. P., Zhu, J., Gregory, M. T., Shuga,
J., Montesclaros, L., Underwood, J. G., Masquelier, D. A., Nishimura, S. Y., Schnall-
Levin, M., Wyatt, P. W., Hindson, C. M., Bharadwaj, R., Wong, A., Ness, K. D.,
Beppu, L. W., Deeg, H. J., McFarland, C., Loeb, K. R., Valente, W. J., Ericson,
N. G., Stevens, E. A., Radich, J. P., Mikkelsen, T. S., Hindson, B. J., and Bielas,





A.1 Chapter 2 - Melanoma

























Listing A.1 Sequences of tumor-antigen specific antibody candidate
198 Reconstructed clonotype sequences
A.2 Chapter 3 - CRC








9 > Pat02.L{IGKV1 -39: IGKJ1:IGKC}
10 TGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGAGTTACAGTACCTGGTGGACGTTCGGCCAAGG
11 GACCAAGGTGGAAATCAAA
Listing A.2 Sequences of tumor-antigen specific antibody candidate reconstructed from patient
2
1 > Pat11.H{IGHV3 -30: IGHD1 -7: IGHJ4:IGHA2}
2 CACGCTGTATCTGCAAATGAACAGTCTGAGAGGTGAGGACTCGGCTGTGTATTACTGTGCGAAAGAAGAA
3 CTACGACGAGGGCCCCATGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG
4 > Pat11.L{IGKV1 -39: IGKJ1:IGKC}
5 TCTGCAACCTGAAGATTTTGCAACTTACTTCTGTCAACAGAGTTACATTACCCCTCGGACGTTCGGCCAA
6 GGGACCAAGGTGGAAATCAAA
Listing A.3 Sequences of tumor-antigen specific antibody candidate reconstructed from patient
11
A.3 Chapter 3 - PDAC


















Fig. B.1 (a) plots the percentage of UMI originating from mitochondrial genes against the
library size and (b) against the detected gene counts of the patient1 and patient2 samples.
Each point represents a cell. Color denotes whether an AgR was detected in a cell or not.
200 Supplementary Figures
(a) Communities detected with WalkTrap
(b) Communities detected with Louvain
Fig. B.2 The patient2 sample projected onto 2D space with UMAP where each point corre-
sponds to a cell. Clusters are colored by membership as detected by the (a) WalkTrap and (b)
Louvain algorithms. There are 27 distinct clusters in (a), and 15 in (b).
201
Fig. B.3 Screenshot of the Loupe VDJ browser opened with the BCR repertoire of the patient2
sample.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. B.5 Clonotype projection of the patient1 sample. UMAP embedded data is colored by


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. B.6 Clonotype projection of the patient2 sample. UMAP embedded data is colored by











Fig. B.7 Overlays of cell cycle phase on the UMAP of the patient2 sample before and after





























Fig. B.8 Overlays of each metadata on the UMAP of the patient2 sample after cell cycle







Fig. B.9 Overlays of selected gene expressions, colored from low (gray) to high (red), on the









Fig. B.11 Most highly expressed genes in the cells with high (> 0.5) IGLV and IGHV expression.
Gene expressions are normalized and log2-transformed.
209
Fig. B.12 I remove cells with mitochondrial content greater than 3 MADs and with total genes
detected less than 600, 600, and 500, in samples mouse_d15, mouse_d19, and mouse_d25
respectively.
210 Supplementary Figures
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Fig. B.16 Cluster biomarkers of mouse_d25.
214 Supplementary Figures
Fig. B.17 CD8 expression in the clusters of tumor samples. In mouse_d15, I subsetted on
clusters 1,2,3,4,5,6,9,10,11 (top panel), in mouse_d19 on clusters 1,5,7,8,10,12,13,14 (middle
panel), and in mouse_d25 on 1,3,4,6 (bottom panel). From each cluster, I only took the cells
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Fig. B.19 Clonotype biomarkers of mouse_d15 calculated using the Wilcoxon rank sum test
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Fig. B.21 Clonotype biomarkers of mouse_d19 calculated using the Wilcoxon rank sum test

















































































































































































Fig. B.23 Clonotype biomarkers of mouse_d25 calculated using the Wilcoxon rank sum test
















































































Fig. B.24 Clonotype proportions within cell cycle phases.
222 Supplementary Figures
Fig. B.25 mouse_d15 biomarkers.
